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Summary 
Mast cells are long-lived, tissue-resident cells of the innate immune system. Since the 
identification of mechanisms that regulate mast cell proliferation, survival and overall 
homeostasis in the tissues may have important implications for the treatment of mast cell-related 
diseases such as asthma, allergy and mastocytosis, we investigated novel molecular mechanisms 
at the basis of mast cell biology, and in particular the role of two activation-induced miRNAs, 
miR-221 and miR-146a. We found that miR-221 has important roles in regulating multiple 
processes in differentiated primary mast cells, such as degranulation, adhesion, migration and 
cytokine production. Since miR-221 is expressed at basal level in mast cells but it is also 
inducible upon stimulation, we proposed a model in which miR-221 has a dual role in these 
cells: at resting state, it contributes to the regulation of the cell cycle and cytoskeleton, an effect 
probably common also to other cell types that express basal levels of this miRNA. However, in 
response to stimulation through IgE-antigen complexes, miR-221 effects are mast cell-specific 
and activation-dependent, contributing to the regulation of degranulation, cytokine production 
and cell adherence (Chapter 1). 
Mice that lack the p50 subunit of NF-kB (p50KO) are unable to mount airway 
eosinophilic inflammation due to the inability to produce IL-4, IL-5 and IL-13, which play 
distinct roles in asthma pathogenesis, and to a defect in the polarization of Th2 lymphocytes. 
Since mast cells are master effector cells in allergic responses, we evaluated whether the 
asthma-resistant phenotype observed in p50KO mice could be partially due to a defect in mast 
cell development or function. While our data indicate that p50KO mast cells may only 
marginally contribute to the airway inflammation defect of p50KO mice through a slight 
impairment in cytokine production, p50KO mast cells showed a marked increase in their ability 
to survive in response to withdrawal of essential cytokines, which likely correlated with a strong 
increase in the percentage of mast cells that was observed in the tissues of p50KO animals. Such 
improved survival of mast cells lacking p50 was due to altered expression of several molecules 
involved in regulating cell survival and cell death, such as Bcl2, A1 and BAX. Importantly, we 
also found that miR-146a, a miRNA known to regulate NF-kB signalling, was not expressed in 
IgE- or LPS-stimulated p50KO mast cells, and that in the context of mast cell survival, miR-
146a acted as a pro-apoptotic factor, identifying therefore a new molecular network that 
regulates mast cell survival in response to a variety of signals (Chapter 2).  
Previous work from our lab also pointed toward a role for miR-146a in the differentiation 
and/or activation of murine CD4 T lymphocytes. We therefore continued investigating a 
possible role for this miRNA not only in regulating mast cell survival, but also in the 
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differentiation and function of T cells. We found that miR-146a is expressed at high levels in 
the effector and effector-memory T cell compartment in both mouse and human, and we provide 
evidences that miR-146a may regulate T cell expansion upon activation and possibly also 
memory formation (Chapter 3). A review on the role of miR-146a in immunity and disease is 
provided in Chapter 4. 
Overall our work demonstrates that miR-221 and miR-146a play a key role in regulating 
mast cell activation, function and survival, and that miR-146a also contributes to the extent of T 
lymphocyte activation. Finally, we provide novel insights on the role of miRNAs in regulating 
various functions of mast cells and T lymphocytes in the immune response, contributing to the 
groundwork for a further understanding of the molecular mechanisms that may lead to immune-
related diseases such as asthma, allergy, altered inflammatory responses, and mastocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11	
  	
  
	
  
 
 
 
 
 
 
 
 
 
 
 
 
Mast Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12	
  	
  
	
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13	
  	
  
	
  
Introduction 
Paul Ehrlich identified mast cells (MCs) in 1878 (reviewed in Ref.1). These are cells 
of the immune system that are present in most tissues of the body and especially near the 
boundaries between the outside world and the internal milieu, such as the mucosa of the 
lungs, digestive tract, skin, mouth, and nose2. For many years, it was believed that MCs 
were the same cellular type as basophils, present in the connecting tissues rather than in the 
blood. It was then discovered that MCs exhibit specific markers and respond to factors 
differently from basophils2. Mature MCs have a limited proliferative ability, which is 
increased during infection. These cells are round with a diameter of 20-30 µm. MCs are 
present in the connecting tissue and stretch to concentrate themselves particularly along the 
blood vessels; they are also abundant in the peritoneum. MCs can be divided in two types, 
mucosal MCs (MCM) and connective tissue-type (MCCT).  
-> MCM are found in mucosal epithelial surfaces of the intestine and respiratory 
tract. They are typically associated with Th2 responses. The phenotype of these cells 
is dynamic and defined by inflammatory perturbations at a tissue site, allowing them 
to play roles in the induction/amplification phase and the resolution/healing phase of 
the response3. The development of MCM is dependent on T-cell derived factors, such 
as IL-3 and IL-4. 
-> MCCT are found in the sub-mucosal connective tissues of the intestine, and 
throughout the body in association with other connective tissues. Their maturation is 
T cell-independent, because normal numbers are seen in lymphocyte-deficient mice4. 
Compared to MCM, their numbers do not increase as significantly in acute reactions 
in the lung following Th2-mediated inflammation or atopic diseases3. 
 
MCs take part in allergic reactions and anaphylactic hypersensitivities (anaphylactic 
shock). When MCs become activated they quickly release the content of their cytoplasmic 
granules. Such granules (diameter of 0.3-0.8µm) contain pre-stored mediators including 
proteases, histamine and heparin. The most abundant proteins stored in MC secretory 
granules are endopeptidases, which are released by exocytosis. The major enzymes are 
tryptic and chymotryptic peptidases called tryptases and chymases, respectively. The types, 
amounts and properties of these serine peptidases vary by MC subtype, tissue, and mammal 
of origin. Because MCs can express certain of the peptidases at a very high level, 
immunohistochemistry and immunoassay approaches using antibodies directed against these 
enzymes are useful experimentally as well as clinically in assessing MC numbers, locations, 
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activation, and disease-association. Tryptases and chymases also can oppose inflammation 
by inactivating allergens and neuropeptides causing inflammation and bronchoconstriction. 
Thus, like MCs themselves, MC serine peptidases play multiple roles in host defence. 
-> Tryptase is the most abundant protease in human MCs, comprising up to 
20% of the cell protein content5. It has a variety of effects including inducing 
chemotactic activity in eosinophils6, inactivation of fibrinogen, activation of 
tissue matrix metalloproteinase, stimulation of fibroblast proliferation. 
-> Chymases, like serine endopeptidase and cathepsin-G, are synthesized by 
MCs, neutrophils and eosinophils. It has a variety of effects including the 
activation of angiotensin I, which is a vasoconstriction peptide7. 
Other pre-formed mediators of the cytoplasmic granules include histamine and 
heparin. Histamine is a vaso-active mediator that increases vascular permeability, while 
heparin is a glycosaminoglycan sulphate, with a strong negative electric charge that has 
powerful anticoagulation properties.  
Apart from the abovementioned pre-formed mediators stored in the cytoplasmic 
granules, MCs can produce a broad panel of de-novo synthesized mediators, including 
cytokines (e.g IL-6, IL-13, IL-4, IL-5, TGFβ) and chemokines (e.g MIP-1α, MIP-1β, 
RANTES), as well as nitrogen oxide and leukotrienes. 
 
 
Figure 1: An image of a MC. This image appeared on the cover of the Oct 2007 issue of Laboratory 
Investigation. 
 
 
 
 
 
 
Mast Cell Differentiation, Activation and Migration 
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The progenitors of the MCs are found in the bone marrow and migrate through the 
blood stream in an immature state to reach the target tissue8. Two models of murine MCs 
differentiation have been described. The first was published in 2005 by Chen et al. in which, 
based on the expression of a number of surface markers, the MC progenitors (MCPs) were 
described as Lin– Kit+ Sca-1– Ly6c– FcεRIα– CD27– β7+ - T1/ST2+ 6. These cells gave rise 
only to MCs in culture and reconstituted the MC compartment when transferred into kit 
mutant MC-deficient mice6. A second model was described (also in 2005) by Arinobu et 
al.9, in which they found that Lin– Kit+ FcγRII/III+ β7+ cells were bipotent progenitors 
because they could give rise to both basophils and MCs (BMCPs). They concluded that 
BMCPs could be generated mainly from bone marrow granulocyte/macrophage progenitors 
(GMPs). Finally, somewhat reconciling all these different models, Franco et al in 2010 
described two subsets of myeloid progenitors: Sca-1lo common myeloid progenitors (SL-
CMPs, Sca-1lo Lin– Kit+ CD27+ Flk-2–), and Sca-1lo granulocyte/macrophage progenitors 
(SL-GMPs, Sca-1lo Lin– Kit+ CD27+ Flk-2+ CD150-/lo) 10. They found that MCP potential was 
present in the SL-CMP fraction but not in the more differentiated SL-GMP population. In 
conclusion, during hematopoiesis the MC lineage appears to be specified earlier than and 
independently from other granulocytes10. 
 
                  
Figure 2: MC hematopoiesis and the change of lineage models. (A) In the old view, the presence of MCPs was 
not clear, but mast cells were considered to be the progeny of CMPs. (B) In the new view proposed by Chen et 
al.8 the presence of MCPs is clear. The thick line shows the main differentiation pathway from MPP to mast 
cell. CLP (common lymphoid progenitor); CMP (common myeloid progenitor); GMP (granulocyte 
macrophage progenitor); MCP (mast cell-committed progenitor); MEP (megakaryocyte erythrocyte progenitor) 
11-12. 
Upon final differentiation in the tissues where they will ultimately reside, MCs can 
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be activated through a variety of receptors present on their surface. Some are activating 
receptors and others play an inhibitory role. Activating receptors include: the high affinity 
IgE receptor (FcεRI)13/14, Kit (stem cell factor receptor)15-18, the IL-3 receptor19-21, IgG 
receptors, complement receptors and Toll-like receptors (TLRs).  
During MC activation, such as in allergic reactions, MCs remain inactive until an 
antigen (or an allergen) is recognized by specific IgE antibodies already associated to the 
FcεRI on the MC surface, leading to MC degranulation, production of cytokines and other 
mediators, and to a cascade of responses which may eventually lead to eradication of the 
infections agent or to allergic responses. Allergic hypersensitivity is associated with both 
IgE and type-2 (Th2) T cell responses to environmental allergens. As shown in Figure 3, in 
allergic individuals initiation of type-2 responses to an allergen leads to the production of 
cytokines, such as IL-13 and IL-4, which favour allergen-specific IgE production from B-
lymphocytes. Once such MC-bound allergen-specific antibodies are cross-linked by an 
allergen, the release of MC mediators determines the subsequent physiological responses to 
the allergen.  
                      
Figure 3:  MCs activation and related activity. Upon stimulation via the allergen-induced IgεR, MCs were 
activated and released mediators that could lead to a variety of physiological effects.13 
 
Migration is essential at several stages of the MC differentiation and activation, 
including:  i) progenitor movement towards the sinusoids in the bone marrow; 
ii) migration through the sinusoidal endothelium; 
iii) recruitment via venules into tissues; 
iv) migration during maturation towards their final location within the tissue. 
 
Mechanisms operate under basal conditions to maintain MC numbers in the target tissues. A 
local MC hyperplasia is likely to involve increased progenitor recruitment in addition to 
17	
  	
  
	
  
increased local MC proliferation22. MCs are thought to use the same basic migration 
mechanisms as other granule-containing inflammatory cells, in which chemo-attractant 
molecules generated in inflamed tissues recruit granulocytes by acting on surface 
receptors23. 
 
Interactions with other immune cell types  
Not only MCs are key effector cells in allergic and asthmatic responses, but also they 
are capable of modulating other innate and adaptive immune responses24-26. They assist the 
defence against pathogens by releasing the contents of their granules. These molecules are 
key for the early defence and recruitment of other effector cells to sites of infection27-29. For 
example, the very broad panel of cytokines and chemokines produced by MCs upon 
activation can influence the differentiation, recruitment and activation of other innate 
immune cells as well as of T lymphocytes. Moreover, the release of histamine can have 
multiple effects on other cells of the immune system, such as activation of IFN-γ-producing 
Th1 lymphocytes via H1 receptors, or suppression of immune responses through H2 
receptors30.  
A role for MCs as antigen-presenting cells was hypothesized based on the fact that 
expression of MHC class II molecules can be induced on these cells upon activation with 
LPS, INF-γ and TNF-α31, however, the in vivo role of MHCII expression on these cells 
remains debated. 
In the past few years a number of studies also focused on the interaction between 
MCs and others cells of the immune system32/33. It was found (Pucillo’s group 2008) that T 
regulatory (Treg) cells directly inhibited the FcεRI-dependent MC degranulation through 
cell-cell contact involving interactions between OX40 on Treg cells and OX40L on MCs. 
Moreover, it was shown that in the presence of activated MCs, MC-derived IL-6 and Th2 
cytokines (IL-4, IL-13) skewed Tregs and effector T cell into IL-17–producing T cells 
(Th17)32 . 
 
Mast cell-related pathologies 
The release of mediators from MC granules is a common pathological event during 
allergic responses. Consequently, MC stabilization has become the main treatment for 
patients with allergic symptoms. Activated MCs contribute to allergic and vascular diseases, 
but also to rheumatoid arthritis, cancer, atherosclerotic lesions33-37, and probably many other 
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untested diseases38. Moreover, a dysregulated MC proliferation and activation leads also to 
mastocytosis44. 
 
Specifically: 
- Allergy: it is a hypersensitivity disorder of the immune system39/40. Allergic reactions 
occur when a person's immune system reacts to normally harmless substances in the 
environment. In some people, severe allergies to environmental, dietary allergens or to 
medication may result in life-threatening reactions called anaphylaxis41. Food allergies and 
reactions to the venom of stinging insects, such as wasps and bees, are often associated with 
these severe reactions. Treatment for allergies includes anti-histamines that specifically 
prevent allergic reactions, steroids that modify the immune system in general, and 
medications such as decongestants that reduce the symptoms. Immunotherapy uses injected 
allergens to desensitize the body's response. 
 
- Asthma: it is the common chronic inflammatory disease of the airways characterized by 
variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Asthma 
is becoming more common each year, especially in children.42 
 
- Mastocytosis: it is a tumor characterized by the abnormal proliferation and accumulation 
of aberrant MCs in tissues. Its clinical course is variable ranging from an asymptomatic state 
for years to a highly aggressive and devastating one. When mastocytosis develops into an 
aggressive form, its course is very rapid and often fatal43. 
->Genetic of mastocytosis: A point mutation in the tyrosine kinase receptor gene KIT is the 
most common genetic abnormality found in mastocytosis patients.  This mutation results in 
a substitution of valine for aspartate at codon 816 of exon 1744. 
->Therapy for mastocytosis: patients with mastocytosis are treated symptomatically and no 
curative therapies for the aggressive disease types are currently available. Some success in 
reducing the mast cells burden has been reported with alpha-interferon45/46. 
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Introduction 
 Adaptive or specific immunity recognizes non-self and can eliminate foreign 
antigens. Unlike innate immunity, adaptive responses display antigen specificity, a big 
diversity and immunological memory. Moreover, self/ non–self-discrimination is regulated 
by more sophisticated mechanisms than is the case of innate immunity. The adaptive 
immune system is capable of distinguishing subtle differences and associating them with a 
cellular context. It can recognize billions of antigen variants and exhibits a memory for the 
encountered foreign antigens. An effective adaptive immune response requires the 
presentation of an antigen by a professional antigen-presenting cell (APC) to a specific 
lymphocyte. There are two major populations of lymphocytes: 
-> B lymphocytes  
-> T lymphocytes 
 
B lymphocytes  
B lymphocytes mature within the bone marrow47. When B cells leave the bone 
marrow, they already express a unique antigen-binding receptor at the surface. This B cell 
receptor (BCR) is constituted by a membrane bound immunoglobulin (Ig) molecule. When 
this molecule encounters a matching antigen, binding induces the proliferation of the B cell 
bearing it48. Its progeny can then differentiate into memory B cells and effector plasma cells. 
B cell development occurs through several stages, each stage representing a change in the 
genome content at the antibody loci.  
An antibody is composed of two identical light (L) and two identical heavy (H) 
chains. In each chain the variable (V) region is unique and is specific for an antigen, while 
the constant (C) region specifies the physiological effect of an antibody once it recognizes 
its antigen49. The C region can change in a process called class switching: this leads to the 
generation of an antibody that retains the same specificity (specified by the variable 
domains), but different constant domains. The H chain is the larger of the two types of 
chains that comprise a normal immunoglobulin or antibody molecule. The H chain portion 
of an antibody contains 2 regions; the Fab (Antigen-binding portion) and Fc (Constant 
region; confers biological activity such as phagocytosis of microorganisms) (Figure 4).  
For example, naïve (antigen-inexperienced) mature B cells produce both IgM and 
IgD, which are the first two heavy chain segments in the immunoglobulin locus. After 
encounter with an antigen, activated B cells undergo antibody class switching to produce 
22	
  	
  
	
  
IgG, IgA or IgE antibodies. IgE antibodies are the ones that are mainly involved in allergy 
and are bound to the FcεRI on the MCs surface. 
 
Figure 4: Schematic representation of an immunoglobulin. VL= Variable domain on the light chain, VH= 
Variable domain on the heavy chain , CH= Constant domain in the heavy chain, Fab= Fragment Antigen 
Binding, Fc= fragment crystallizable, position of the carbohydrate =green and interchain disulfide bonds =red. 
Poljsk R, “Production and structure of diapodies”, Structure 1994, Vol 2, Issue 12, 1121-1123 
 
Upon encounter with an antigen, B cells differentiate to plasma cells, which are 
short-lived and dedicated to secrete very high amounts of antibodies, or to memory B cells, 
which are long-lived and provide faster responses following a second exposure to the same 
antigen. 
 
T lymphocytes  
 T cells derive from progenitors in the bone marrow, but unlike B cells, they 
terminate their maturation in the thymus. Mature T cells express a specific T cell receptor 
(TCR) at their cell surface, a receptor responsible for recognizing antigens bound to major 
histocompatibility complex (MHC) molecules.  
 T cells can only recognize an antigen in the context of MHC molecules, meaning that 
the antigen must be ‘presented’ to the T cell from the surface of another cell. There are two 
types of MHC molecules: 
-> Class I = present on nearly all nucleated cells 
-> Class II = only expressed on professional APCs such as dendritic cells, activated 
   macrophages and B cells.  
MHC class I molecules present degradation products derived from intracellular 
(endogenous) proteins in the cytosol. For example, protein products deriving from an 
intracellular pathogen such as a virus will be presented by the infected cell on its surface in 
the context of MHCI molecules. These will be recognized by specific cytotoxic T cells that 
will kill the infected cell leading to eradication of the infection. 
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MHC class II molecules present fragments derived from extracellular (exogenous) 
proteins that are located in an extracellular compartment. These are expressed by 
professional APCs, which will be recognized by helper T cells (Th) that will be activated 
and than can help to trigger an appropriate immune response, which may include localized 
inflammation and swelling due to recruitment of phagocytes, or may lead to a full-force 
antibody immune response due to activation of B cells. 
T lymphocytes fall into different groups based on their response to pathogens: 
 
-> T cytotoxic cells (CTL) kill cells that are infected with viruses or other intracellular 
pathogens, or are otherwise damaged or dysfunctional (such as tumor cells). They produce 
toxic granules containing enzymes that induce the death of pathogen-infected cells. CTL 
express TCRs that can recognize a specific antigenic peptide bound to MHCI molecule, 
which in turn is recognized by the surface protein CD8, that is a trans-membrane 
glycoprotein that serves as a co-receptor for the TCR. 
 
-> T helper cells (Th) have no direct cytotoxic or phagocytic activity, but rather, they 
activate and direct other immune cells through a combination of cell-to-cell interactions 
(such as CD40/CD40L) and through cytokine production. They are characterized by the 
expression of the CD4 receptor that interacts directly with MHC class II molecules on the 
surface of the APC. 
 
CD4+ T cells priming 
Dendritic cells (DCs) can be considered the first actors to enter the game in the 
process of T cell activation as they capture peptide antigens and present them in complex 
with MHC for T cell recognition. DCs act as real APCs, as they are able to deliver all 
signals required to fully activate a T cell. 
During an immune response DCs travels from the infection site to the lymph nodes, 
where they present antigens that are bound to MHCII. The antigen recognition by the TCR 
is known as Signal 1 for T cell activation. However, to become fully activated, a T cell 
needs to receive other co-stimulatory signals, known as Signal 2. This is a protective 
measure to ensure that a T cell is responding to a foreign antigen. The second signal 
involves co-stimulatory molecules such as, for example CD28 that is expressed by T cells, 
which interacts with CD80 and CD86 on the membrane of DCs. Based on the cytokine 
produced by DCs (Signal 3), naïve T cells can differentiate to different phenotypes.  
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For example, IL-12 favours differentiation of naive CD4 T cells towards a Th1 
phenotype, characterized by the ability to produce high levels of IFN-γ.  
Upon encounter with an antigen in the presence of all co-stimulating signals, a naïve 
T cell can differentiate into an effector phenotype, characterized by high expression of 
effector cytokines (such as IFN- γ, IL-2 and IL-4). This population will normally contract 
and return to basal levels upon eradication of the pathogen, however some antigen-
experienced T cells will remain and form the memory compartment. In the case of 
successive infection, memory cells will be able to quickly induce a more rapid and robust 
secondary immune reaction.  
 
 
Figure 5: Priming model for Th1/Th2 cells. Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill 
Livingstone. ISBN 0-443-07145-4. Page 223 
 
Memory T cells (Tm)  
Memory cells are characterized by the ability to quickly expand and respond upon 
secondary exposure to their cognate antigen. Two phenotypic subpopulations of Tm cells 
have been identified based on the expression of different surface markers and predominant 
immunological characteristics such as their tissue homing properties: central memory T cells 
(TCM cells) and effector memory T cells (TEM cells)50. 
 
TCM => they are characterized by the expression of the following combination of surface 
markers: high expression of CD62L, CCR7, CD44, CD127, and low expression of CD45RA 
and CD25. Due to their high expression of CD62L and CCR7 (see below), they have been 
shown to migrate efficiently to peripheral lymph nodes. 
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TEM => compared to TCM, they express lower levels of CD62L and CCR7, which make 
these cells poorly able to migrate to the lymph nodes, and are rather preferentially found in 
other sites, such as the liver and lungs, where they have immediate effector functions upon 
encountering antigen. 
 
Specifically: 
CD62L (L-selectin) => CD62L acts as a "homing receptor" for leukocytes to enter 
secondary lymphoid tissues via high endothelial venules. This receptor is commonly found 
on the cell surfaces of naive T-lymphocytes, which have not yet encountered their specific 
antigen. Antigen-experienced TCM, also express CD62L to localize in secondary lymphoid 
organs.  
CD44  => This protein participates in a wide variety of cellular functions 
including lymphocyte activation, recirculation and homing51. It is commonly considered a 
marker of T cell activation. 
CD45RA => The protein encoded by this gene is a member of the protein tyrosine 
phosphatase (PTP) family. This gene is specifically expressed in hematopoietic cells and it 
has been shown to be an essential regulator of T- and B-cell antigen receptor signalling. 
Various isoforms of CD45 exist: CD45RA, CD45RB, CD45RC, CD45RAB, CD45RAC, 
CD45RBC, CD45R0, CD45R (ABC), each characterized by expression on specific T cell 
subsets. Naive T cells express the large CD45 isoform, CD45RA, while the shortest isoform 
(lacking RA, RB and Rc exons), CD45R0, characterizes memory T cells.  
CCR7  => It has been shown to control the migration of naïve and memory T 
cells to secondary lymphoid organs, such as lymph nodes, as well as to stimulate dendritic 
cell maturation52. CCR7 deficiency results in massive accumulation of CD4+ and CD8+ T 
cells in the peritoneal and pleural cavities53. 
 
CD4+ lymphocytes differentiation  
 CD4 T helper (Th) cells can be divided into different subsets characterized as 
follows by the cytokines they produced and by the expression of ‘master’ transcription 
factor essential for their differentiation54: 
Th1 => - signature cytokine   : IFN- γ  
  - master transcription factor : T-bet 
  - function   : promote protective immunity against 
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intracellular pathogens. By secreting 
IFN-γ, they induce activation of 
macrophages and upregulation of iCOS 
leading to the killing of pathogens.  
Th2 => - signature cytokines   : IL-4, IL-5, IL-13  
  - master transcription factor : GATA3 
  - function   : promote humoral immune responses 
and host defense against extracellular 
parasites. However, they can also 
potentiate allergic responses and 
asthma. Their development and 
maintenance is regulated by IL-4, IL-25 
and IL-33 
Th9 => - cytokines production : IL-9, IL-10  
  - transcription factor  : PU.I 
  - function   : as opposed to the others, this is not yet 
considered a separate linage. These 
cells are involved in host defense 
against extracellular parasites, primarily 
nematodes.  
Despite their production of anti-
inflammatory IL-10, they promote 
allergic inflammation. Their role in 
other inflammatory diseases remains 
still unclear. 
Th17 => - signature cytokines  : IL-17, IL-22 
  - master transcription factor : RORγt 
  - function   : promote protective immunity against 
       extracellular bacteria  and fungi. Also 
promote autoimmune and inflammatory 
diseases. Th17 cells are generated in the 
presence of TGF-β and IL-6 and/or IL-
21 and are maintained by IL-23 and IL-
1β. 
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Th22 => - signature cytokine  : IL-22 
  - master transcription factor : AHR 
  - function    : Identified in inflammatory skin 
diseases. Their role in host defense 
remains unclear as this subset only 
recently been characterized.  
Tfh => - cytokines production : IL-21 
  - transcription factor  : BCL6 
  - function   : These cells are involved in the  
       promotion of germinal center responses 
and provide help for B cell class 
switching. 
Tregs => - signature cytokine  : IL-10 
  - master transcription factor : Foxp3 
  - function   : are crucial in the maintenance of 
immunological tolerance, as their major 
role is  to shut down T cell-mediated 
immunity toward the end of an immune 
reaction and to suppress auto-reactive T 
cells that escaped the process of 
negative selection. They are 
characterized by the expression of high 
levels of CD25 on the surface. 
 
While the subsets shown above are important to define the different classes of Th 
cells with their different functions, it is important to also underlie that these cells are not 
only heterogeneous in their phenotype, but they also show considerable plasticity. In other 
words, even within ‘pure’ populations, some cells retain the ability to switch to another 
subset or to a mixed phenotype55/56. The cytokines produced by the different subsets of T 
cells influence isotype switching to different classes of antibodies. Most relevant to MCs 
and MC-related diseases, Th2-derived IL-4 induces B cells to produce IgE in both mouse 
(table 1) and human (table 2) 
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Table 1: Mouse 
T cells Cytokines 
Immunoglobulin classes 
IgG1 IgG2a IgG2b IgG3 IgA IgE 
Th2 
IL-4 ↑ ↓ ↓ ↓ ↓ ↑ 
IL-5         ↑   
Th1 IFNγ ↓ ↑ ↓ ↓ ↓ ↓ 
Treg TGFβ     ↑ ↓ ↑   
 
 
Table 2: Human 
 
T cells Cytokines 
Immunoglobulin classes 
IgG1 IgG2 IgG3 IgG4 IgA IgE 
Th2 
IL-4       ↑   ↑ 
IL-5         ↑   
Th1 IFNγ             
Treg TGFβ         ↑   
 
Table 1 and 2: Ig class switching in mouse (table 1) and in the human (table 2) for Th1, Th2 and Treg 
cells55/56. The red arrows meaning the up-regulation of the correspondent immunoglobulin in the presence of 
the indicated cytokine, while the black  the down-regulation.  
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Introduction  
MicroRNAs (miRNAs) are small (20-25 nucleotides (nt)), non-coding RNA molecules 
involved in posttranscriptional gene regulation57. They are representative features of all 
cells, as they regulate large fractions of a cell’s transcriptome. In vertebrates, miRNAs 
constitute about 1% of all genes, with 1048 miRNAs found in humans and 672 in mice 
(miRBase database, www.mirbase.org)58. In 1993, during developmental studies on C. 
elegans, Victor Ambros and colleagues discovered that the gene lin-4 encoded for 2 small 
RNAs: the first measured 22nt in length, while the second was long 61nt59/60. Moreover, the 
lin-4 mRNA sequence showed antisense complementarity for different sites in the 3’ 
untranslated region (3’UTR) of the gene lin-14. Briefly, lin-4 regulated lin-14, reducing the 
amount of transcribed protein without changing the level of the messenger. Since that 
seminal discovery, the 22nt RNA lin-4 has been recognized as a prototype for a wide class 
of regulatory RNA called miRNAs. In 2000, another gene was found in C.elegans: let7, 
encoding for a second miRNA involved in the transition from the larval to the adult stage60; 
since then miRNAs have been discovered in most organisms and they have been shown to 
regulate a large proportion of biological processes. MiRNAs perform their function by 
binding to the RNA-induced silencing complex (RISC) 61, which constitutes the machinery 
that modulates target mRNA expression in this endogenous regulatory RNA pathway. 
Indeed, the RISC complex recognizes complementary mRNA molecules and blocks their 
translation (and/ or induces mRNA degradation in case of perfect complementary with the 
miRNA sequence) resulting in substantially decreased levels of protein translation and 
effectively turning off the gene. Apart from miRNAs, other classes of small RNAs include 
short interfering RNA (siRNAs, mainly found in plants), piwi RNA (piRNA), trans-acting 
RNA (transiRNA), small scan RNA (scnRNA) and repeat associated siRNA (rasiRNA)62. 
 
MiRNA biogenesis 
Mature miRNAs derive from long double-stranded (ds) primary transcripts (pri-
miRNA), characterized by the presence of a stem-loop secondary structure, called pre-
miRNA. The pri-mRNA is usually dependent for its transcription on the RNA polymerase 
II62. From the pri-miRNA, the process to yield mature miRNAs involves two steps and 
requires the RNase-III enzymes Drosha and Dicer, as well as companion dsRNA-binding 
proteins (Figure 6). In the nucleus, Drosha processes the newly transcribed pri-miRNA into 
the pre-miRNA hairpin precursor of approximately 70nt. Pre-miRNAs are exported into the 
cytoplasm through exportin 5, a protein localized on the nuclear membrane57. The 
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cytoplasmic enzyme Dicer further processes the pre-miRNA into a 19-25nt miRNA 
duplex63-65. The less stable of the two strands in the duplex is incorporated into the RISC 
complex 63, which regulates protein expression. The RISC complex has as catalytic center in 
the Argonauts protein (Ago) characterized by two domains: a PAZ domain, that can bind the 
single stranded 3’ end of the mature miRNA, and a PIWI domain that structurally resembles 
ribonuclease-H and functions to interact with the 5’ end of the guide strand. The precise 
molecular mechanisms that underlie posttranscriptional repression by miRNAs still remain 
to be fully elucidated.  
 
Figure 6: canonical microRNA biogenesis pathway. Adapted from T.Asselah et al, 2008 66 
 
Post-transcriptional gene silencing by microRNAs 
In human there are four Ago proteins (Ago1- 4). However Ago-267 is the only one 
with a so-called ‘slicer’ activity, as it is the only Ago family member able to degrade target 
mRNAs, and it is therefore required for RNA-mediated gene silencing (RNA interference or 
RNAi) mediated by the RISC. The 'minimal RISC' appears to include EIF2C2/Ago-2 bound 
to a short guide RNA such as a miRNA or siRNA. These guide RNAs direct RISC to 
complementary mRNAs that are targets for RISC-mediated gene silencing. The precise 
mechanism of gene silencing depends on the degree of complementarity between the 
miRNA or siRNA and its target. Binding of RISC to a perfectly complementary mRNA 
generally results in silencing due to the cleavage of the mRNA specifically by Ago-2. Such 
mechanism is usually the one at play with siRNAs in plants and in RNAi experiments. 
Binding of RISC to a partially complementary mRNA results in silencing through inhibition 
of translation, which represents instead the most common form of miRNA-mediated 
regulation for example in mammals and is independent of endonuclease activity. 
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Figure 7: a. Plant miRNAs recognize fully or nearly complementary binding sites, b. Animal 
miRNAs recognize partially complementary binding sites, which are generally located in 3′ UTRs. 
Adapted from E Huntzinger at all, Nature, 2011 
As mentioned above, in plants the complex constituted from RISC and miRNA is 
perfectly complementary to the mRNA target, causing the cut of the mRNA61/68/69. Similar to 
the mechanism employed in RNAi, the cleavage of a single phosphodiester bond on the 
target mRNA occurs between bases 11 and 1070. In animals, conversely, the complex 
constituted from RISC and miRNA is an imperfect match to the 3' UTR of the mRNA target. 
This association causes a block in mRNA translation with or without destabilization and 
secondary degradation of the mRNA target. Importantly, miRNAs act in a combinatorial 
manner, as the same transcript may be regulated by multiple miRNAs, while one individual 
miRNA may target many different transcripts. 
MiRNAs regulate the expression of hundreds of gene71. However, identifying the 
target genes has proven difficult because their effect is often small72 and they bind to target 
mRNAs by partial complementarity over a short sequence. Indeed, the part of a miRNA 
essential for target recognition is the so-called ‘seed’ sequence, which comprises nucleotides 
2-to-7 in the miRNA most 5’ portion73. However, a number of algorithms to predict miRNA 
targets have been developed over the years, and although they may contain some false 
positive and false negative and always need to be related to the specific cellular context, 
they have been instrumental to identify relevant miRNA targets. Some of the most utilized 
target prediction databases include TargetScan73/74,PicTar 75/76 and miRanda 77/78. 
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Figure 8: Post-transcriptional gene silencing by a miRNA. miRNAs also bind to targets with imperfect 
complementarity and block translation. M.Vella et al, 2005 79 
 
MicroRNAs and the immune system  
In the past few years it became clear that miRNAs play pivotal roles in regulating both 
adaptive and innate immunity80. Chen et al identified miR-181 as a miRNA specifically 
expressed in hematopoietic cells81. It was also demonstrated that miRNAs are involved in 
the immune system in studies showing selective expression of miR-223 in the bone marrow 
and the involvement of this miRNA, with miR-155 and miR-146a, in the differentiation of 
myeloid cells82. 
After these works, many studies identified miRNAs as crucial components of the 
molecular circuitry that controls differentiation and function of cells of the immune system, 
including the control of the differentiation of various immune cell subsets as well as their 
immunological functions. 
 
MiR-146a 
During the past several years some miRNA functions in the immune system have been 
unveiled, among which one miRNA has shown important regulatory functions: miR-146. 
The murine and the human genome contain two miR-146 genes: miR-146a and miR-146b58. 
MiR-146a and miR-146b are both conserved in all vertebrates and are involved in the 
regulation of inflammation and other processes in innate as well as adaptive immunity. 
Some miRNAs, like these two miR-146 molecules, are expressed as a family that share the 
same seed sequence, but are encoded by different loci in the genome. MiR-146a and miR-
146b are located on murine chromosome 5 and 10, respectively, and their products differ 
only by 2nt in the 3’ region, while the ‘seed’ sequence, that is a conserved heptamer situated 
in the miRNA 5´-end and important for target recognition, is identical, implicating that both 
miR-146a and miR-146b should recognize the same targets. 
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mmu-miR-146a  UGAGAACUGAAUUCCAUGGGUU 
mmu-miR-146b  UGAGAACUGAAUUCCAUAGGCU 
Figure 9: Mature form of miR-146a and miR-146b. The regions highlighted in red display the differences in 
sequence. Shaded in grey is the seed sequence, important for target recognition and identical in both miRNAs. 
 
Most studies examined primarily miR-146a rather than miR-146b, as these two 
miRNAs not only should recognize the same targets, but miR-146a is often more abundantly 
expressed in the immune system. As for a role of miR-146a in innate immunity, it was 
shown that in human monocytes, miR-146a is a primary inflammatory response gene 
induced by IL-1β and TNFα and transcriptionally regulated by NF-kB83. Its targets were 
shown to be TRAF6 (TNF receptor-associated factor 6) and IRAK1 (IL1-receptor associated 
kinase)83, which are adaptor molecules implicated in the NF-kB activation pathway. In the 
context of human monocytes activated with LPS, miR-146a was shown to act as a negative 
regulator of NF-kB activation, and specifically to work in a feedback system in which a 
stimulus induces NF-kB activation through a MyD88-dependent pathway, resulting in the 
expression of inflammatory genes, but also in the up-regulation of the miR-146a, which in 
turn down-regulates levels of IRAK1 and TRAF6 expression, reducing the activity of the 
pathway83.  
As for a role for miR-146a in adaptive immunity, recently it has been found that NF-
kB and c-ETS binding sites are essential for the induction of miR-146a transcription upon 
TCR stimulation in T cells83, while in a Jurkat T cell line miR-146a was shown to regulate 
activation-induced cell death (AICD) through modulation of FADD expression84. In this 
model, miR-146a overexpression also led to impaired AP1 activity and as a consequence, 
reduced IL-2 expression84. 
Importantly, recent studies have revealed important physiological roles of miRNAs 
in many aspects of mammalian immune cell function and their altered expression has been 
associated to pathological conditions on the immune system, such as autoimmunity and 
cancer85. Chronic inflammation contributes to cancer initiation and progression. Among the 
many mechanisms linking inflammation to cancer, NF-kB has been identified as a key 
mediator of inflammation-induced carcinogenesis86. As a negative regulator of NF-kB 
activation, miR-146a has been shown to be involved in progressive myeloproliferative 
disorders87. Specifically, it was shown that miR-146a KO mice develop, with the age, a 
chronic inflammatory and carcinogenesis phenotype meaning that miR-146a plays an 
important role as a tumor suppressor miRNA in hematopoietic lineages87.  
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In human T cells, miR-146a is expressed at low levels in naïve T lymphocytes while 
it is abundantly expressed in memory T cells88 as well as in Treg89 and it is induced upon 
TCR stimulation, consistent with its expression being dependent on NF-kB induction86/89. In 
Treg cells, miR-146a mediated down-regulation of Stat1 (a key transcription factor required 
for Th1 effector cell differentiation), and was shown to be necessary for their ability to 
suppress Th1 responses89.  
Overall, these data showed an important role for miR-146a in regulating both innate 
and adaptive immunity, and a dysregulation of miR-146a expression may lead to a number 
of diseases, including cancer, making this miRNA also a putative novel attractive target for 
therapy.	
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Introduction 
The choice between life and death is a crucial event in the regulation of the immune 
system. A major regulator of this decision is the transcription factor NF-κB. NF-κB was first 
discovered by Nobel Prize (1975) laureate David Baltimore via its interaction with an 11-
base pair sequence in the immunoglobulin light-chain enhancer in B cells90. NF-κB is like a 
master switch because it turns on (or off) the genes that code for mediators of inflammation. 
In nature, a variety of mechanisms exist that modulate NF-κB activity. Indeed, NF-
κB is a transcription factor involved in the regulation of many aspects of the biological 
processes such as inflammation and innate immune responses91-93. A deficit of NF-κB can 
lead to an immune dysfunction as well as to autoimmune diseases and cancer92/93. NF-κB 
binds DNA as a dimer that recognizes a discrete nucleotide sequence (5’- GGGRNYYYCC 
- 3’, in which R=purine and Y=pyrimidine) in the upstream region of a variety of cellular 
and viral response genes. In mammalian cells, the NF-κB/Rel family contains five members: 
Rel A (p65), c-Rel, Rel-B, NF-κB1 (p50; p105) and NF-κB2 (p52; p100) 94. P100 and p105 
are the precursors for p52 and p50 respectively. These proteins share a conserved 300 amino 
acid sequence in the N-terminal region, known as the Rel homology domain (RHD).  
The RHD is the common DBD (DNA binding domain) ant it is found in a family of 
eukaryotic transcription factors, which includes NF-κB, Dorsal, NFAT, among others. Some 
of these transcription factors appear to form multi-protein DNA-bound complexes95. RHD 
acts as regulator of some of these transcription factors, modulating the expression of their 
target genes96. NF-κB proteins bind the DNA as homo- and heterodimers. The most 
common NF-κB heterodimer is p65-p50; in unstimulated cells, it is sequestered in the 
cytoplasm through interaction with IκB inhibitory proteins. Upon stimulation, the IκB kinase 
phosphorylates the IκB. When phosphorylated, the IκB inhibitor molecules are modified by 
ubiquitination, which then leads them to be degraded by proteasome. With the degradation 
of IκB, the NF-κB complex is then free to enter the nucleus where it can 'turn on' the 
expression of specific genes that have DNA-binding sites for NF-κB nearby. 
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Figure 10: Schematic diagram of NF-κB protein structure with RHD (Rel homology domain) and TAD (trans-
activator domain)97 
 
P50 can bind DNA as a heterodimer with other NF-κB family members as well as a 
p50:p50 homodimer ((p50)2). Importantly, since p50 (as well as p52) does not contain the 
COOH-terminal transactivation domain, it can form inhibitory homodimers, able to function 
as transcriptional repressors. A physiological role as negative regulators implies that their 
biogenesis must be highly controlled. Such a regulatory step could involve the release of the 
inactive precursor (p105). If proteolysis of p105 is triggered and there is not enough p65 
available as partner for heterodimerization, (p50)2 should form.  
The overexpression of p50 acts to suppress the transactivating effectors of p65 at 
some NF-kB sites98, and this mechanism has been implicated in the down-regulation of 
major histocompatibility complex expression99 leading to a high malignancy and low 
immunogenicity of certain murine tumors, such as breast cancer and Hodgkin’s lymphoma. 
The explanation for this down-regulation effect, is that (p50)2 reduces transcriptional 
activation by competing for binding with p65-p50, since p65, but not p50, carries a 
transactivating domains. Another explanation could be that (p50)2 interacts with a 
transcriptional repressor, as suggested by the observation that some proteins (e.g Drosophila 
dorsal switch protein 1) converts NF-κB from a transcriptional activator to a repressor only 
in presence of p50100. 
 
NF-kB activation pathway 
  In an inactive state, NF-κB is located in the cytosol in complex with the inhibitory 
protein IκBα. NF-κB can be activated through 2 different pathways: a classical and an 
alternative pathway. 
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-> CLASSICAL PATHWAY: 
A variety of extracellular signals can activate the enzyme IκB kinase (IKK). IKK, in 
turn, phosphorylates the IκBα protein, which results in ubiquitination, dissociation of IκBα 
from NF-κB, and eventual degradation of IκBα by the proteosome. Through this cascade of 
phosphorylation events, NF-κB becomes therefore able to enter the nucleus, where it binds 
to response elements in the DNA, inducing gene expression and ultimately resulting in 
activation of transcription101-103. Specifically, this pathway leads to the increased 
transcription of target genes encoding chemokines, cytokines, and adhesion molecules, 
perpetuating inflammatory responses and promoting cell survival. The classical pathway is 
typically triggered by ligand binding to the TCR, BCR, TLR, TNF receptor and interleukin-
1 receptor (IL1-R) superfamily members. 
 
-> ALTERNATIVE PATHWAY: 
In the alternative pathway, p52/p100 is phosphorylated at two C-terminal sites by the 
IKKα homodimer and ubiquitinated. This modification targets the inhibitory C-terminus for 
proteasomal degradation, producing p52. Although they are often activated concurrently, the 
classical and alternative NF-κB activation pathways have distinct regulatory functions 101/104-
105. The alternative pathway is triggered by the activation of certain TNF receptor family 
members, including CD40, CD30, LTβR (lymphotoxin β receptor) and B-cell-activating 
factor belonging to the TNF family receptor (BAFF-R). Activation of the alternative 
pathway regulates the development of lymphoid organs and the adaptive immune system106. 
                      
Figure 11:  This schema shows the classical and the alternative NF-κB activation pathways. In the classical 
pathway, IKK frees NF-κB from the inhibitor that holds it in the cytoplasm – so that it may enter the nucleus. 
Once inside the nucleus, NF-κB is able to bind gene promoters and ‘turn on’ inflammation106.  
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NF-κB and apoptosis 
Apoptosis is the process of programmed cell death that may occur in multicellular 
organisms104. Two pathways of initiation of apoptosis are known in mammals105/106. 
 
- "Extrinsic or death receptor pathway": following activation of "death receptors" 
(molecules in the TNF receptor superfamily, including TNF-R1, CD95 (Fas)), caspase-8 is 
recruited into the DISC complex (death-inducing signaling complex) through FADD (Fas-
associated death domain)107 and activated. This cascade then activates caspase-3 and 
eventually induces apoptosis108. 
- Intrinsic or mitochondrial pathway": various signals may converge at the mitochondrial 
level to induce a translocation of mitochondrial cytochrome c (cyt c) into the cytosol. 
Proteins in the Bcl-2 (B-cell leukemia/lymphoma 2) family represent the primary regulators 
in this pathway: anti-apoptotic members (Bcl-2, Bcl-XL, Bcl-W, Bfl-1 and Mcl-1) act as 
inhibitors while pro-apoptotic members (Bax, Bak, Bad, Bcl-XS, Bid, Bik, Bim and Hrk) 
serve as promoters109/110 by blocking or enhancing, respectively, the release of cyt c into the 
cytosol.  
 
NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell 
proliferation and cell survival. As such, many different types of human tumors have 
dysregulated NF-κB expression and/or activation111-113. Active NF-κB turns on the 
expression of genes that keep the cell proliferating and protect the cell from conditions that 
would otherwise cause it to die via apoptosis. Defects in NF-κB results in increased 
susceptibility to apoptosis leading to increased cell death111-113.  
In tumor condition, such as in Hodgkin's lymphoma or breast cancer, NF-κB is active 
either due to mutations in genes encoding the NF-κB transcription factors themselves or in 
genes that control NF-κB activity (such as IκB genes) leading to a down-regulation of NF-
κB targeted genes. Blocking NF-κB can lead, in these tumors, to a reduced proliferation, 
increased cell death, or to increased sensitivity to the action of anti-tumor agents113. 
Since NF-κB is a key player in the inflammatory response and its suppression can 
limit the proliferation of cancer cells, methods to inhibit NF-κB signalling have potential 
therapeutic applications in cancer and inflammatory diseases111-113. NF-κB is therefore the 
subject of active research among pharmaceutical companies as a target for anti-cancer 
therapy113. Thus, combined therapy that inhibits NF-κB function in the presence of apoptotic 
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stimuli may lower the anti-apoptotic threshold of tumors to provide a more effective 
treatment against resistant forms of cancer.  
 
NF-κB p50 KO mice 
Contrary to mice deleted for other NF-κB family members, such as p65, which is 
embryonically lethal114, mice lacking the NF-κB p50 subunit show no developmental 
abnormalities but exhibit multifocal defects in immune responses involving B-lymphocytes, 
including non-specific responses to infection115 as well as defective proliferative responses 
to LPS116. These mice also show a tumor-resistant phenotype characterized by the presence 
of M1-like tumor-infiltrating macrophages117/118. M1 macrophages are considered potent 
effector cells that kill intracellular organisms and tumors cells, and are characterized by the 
ability to produce high levels of pro-inflammatory cytokines such IL-12, IFN-γ and TNF-α. 
Another important phenotype of p50KO mice is their inability to mount airway eosinophilic 
inflammation (figure 12) in response to challenge with aerosolized OVA119. Such reduced 
eosinophilic inflammation was correlated to the inability of T lymphocytes to polarize to 
Th2 and as a consequence to a failure to induce production of IL-4, IL-5 and IL-13, all 
cytokines with important roles in asthma pathogenesis119. However, the possibility of a 
defect in MC differentiation and function in these mice was never investigated. 
                   
Figure 12: Immunohistochemical slides of a lung section from a WT (a) and p50KO (b) mouse sensitized with 
OVA . Here we can see the total absence of the airway inflammation in p50KO mice119. 
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Aim of this work 
Mast cell-related diseases heavily affect a high percentage of the world population. 
For example more than 3% of the population in US and 9.4% in UK suffer from asthma, 
while more than 40% is affected by some kind of allergy120. Moreover, mastocytosis is a 
mast cell tumor that ,although rare and often mild, has no cure, and when becomes 
aggressive it also becomes very rapidly devastating and fatal. A better understanding of how 
mast cell differentiation and function are regulated within normal immune responses as well 
as disease can lead us to better treatments of diseases such as asthma, allergy and 
mastocytosis. Importantly, miRNAs have emerged as important regulators of many aspects 
of cell differentiation, proliferation and interaction with the environment and effector 
functions. 
They are also quickly becoming useful biomarkers and possible targets for 
manipulation for therapeutic purposes. However, the role of miRNAs in the regulation of 
mast cell differentiation, proliferation and effector functions is almost completely 
unexplored, and it is exactly the Aim of this study.  
Importantly, we found that some of our newly identified mechanisms of mast cell 
regulation are also at play during the acute activation of T lymphocytes, indicating that they 
may represent more general mechanisms of regulation of the immune response.  
The identification of new molecular networks that regulate T lymphocytes and mast 
cell biology and homeostasis could lead us to the identification of novel points of entry for 
diagnosis and possibly therapy of mast cell-related diseases.  
 
This thesis is divided into 4 chapters:  
 
Chapter 1) MiR-221 is an activation-induced miRNA in MCs, that our lab identified as 
important in regulating mast cell proliferation121. Following up on that work, 
we found that miR-221 has important roles in regulating multiple processes 
in differentiated MCs, such as degranulation, adhesion and migration. Since 
miR-221 is expressed at basal level in MCs but it is also inducible upon 
stimulation, we proposed a model in which miR-221 has a dual role in these 
cells: at resting state, it contributes to the regulation of the cell cycle and 
cytoskeleton. However, in response to stimulation through IgE-antigen 
complexes, miR-221 effects are MC-specific and activation-dependent, 
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contributing to the regulation of degranulation, cytokine production and cell 
adherence.  
This part of the work was published in PLoS ONE (2011); 6:1-13: “MiR-
221 Influences Effector Functions and Actin Cytoskeleton in Mast 
Cells”. 
 
Chapter 2)  The specific aim of this part of the work was to investigate the role of NF-kB 
p50 in regulating MC function. Indeed, mice lacking NF-kB p50 (and p105) 
show reduced eosinophilia and airway inflammation upon challenge, but 
differentiation and functionality of MCs in these mice were never evaluated. Our 
data show that p50KO MCs differentiated normally in vitro and expressed 
reduced cytokine levels in response to different stimuli, such as IgE-crosslinking 
or LPS, indicating that although the airway inflammation defect originally 
observed in p50KO mice might be predominantly Th2-dependent, reduced 
cytokine production from MCs may also contribute to this phenotype. 
Importantly, we found that p50KO MCs showed a marked increase in their 
ability to survive in response to withdrawal of essential cytokines, which likely 
correlated with a strong increase in the percentage of MCs that were observed in 
the tissues of p50KO animals. Since the identification of novel mechanisms that 
regulate MC proliferation, survival and overall homeostasis in the tissues may 
have important implications for the treatment of MC-related diseases such as 
asthma, allergy and mastocytosis, we investigated the molecular mechanisms at 
the basis of such enhanced survival. 
This part of the work was published in Mol Cell Biol. (2012) 
Nov;32(21):4432-44: “miR-146a and NF-κB1 Regulate Mast Cell 
Survival and T Lymphocyte Differentiation. 
 
 
Chapter 3) Despite intense investigation, the requirements for the acquisition and 
maintenance of the human T memory phenotype have yet to be completely 
elucidated. MiR-146a is a well-known regulator of the immune system: it has 
an established role in regulating NF-kB activation and tolerance in innate 
immunity, it acts as an onco-suppressor, and it modulates T regulatory (Treg) 
cell functions. However, the role of miR-146a (and miRNAs in general) in 
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the establishment of immunological memory remains unexplored. Here, we 
found that miR-146a was expressed at high levels in the memory T cell 
compartment from both human and mouse. Although expression of miR-146a 
in primary human T cells determined no significant effect on cytokine 
production and Fas-mediated cell death, miR-146a expression lead to 
increased expansion in response to TCR stimulation pointing towards a role 
for this miRNA in human T cell activation and possibly memory formation.  
This part of the work was published in Mol Cell Biol. (2012) 
Nov;32(21):4432-44: “miR-146a and NF-κB1 Regulate Mast Cell 
Survival and T Lymphocyte Differentiation. 
 
 
Chapter 4) MiRNAs are regulatory molecules able to influence all aspects of the biology 
of a cell, in particular is important as a modulator of differentiation and 
function of cells of the immune system. Here we summarize the most recent 
progress in understanding the role of a specific miRNA, miR-146a, in innate 
and adaptive immune responses, as well as in disease. 
This part of the work was published in Mol. Biol. Int. 
(2011);2011:437301 “miR-146a in Immunity and Diseases”. 
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“MiR-221 Influences Effector Functions and Actin Cytoskeleton in Mast 
Cells” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MiR-221 Influences Effector Functions and Actin
Cytoskeleton in Mast Cells
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Abstract
Mast cells have essential effector and immunoregulatory functions in IgE-associated allergic disorders and certain innate
and adaptive immune responses, but the role of miRNAs in regulating mast cell functions is almost completely unexplored.
To examine the role of the activation-induced miRNA miR-221 in mouse mast cells, we developed robust lentiviral systems
for miRNA overexpression and depletion. While miR-221 favored mast cell adhesion and migration towards SCF or antigen
in trans-well migration assays, as well as cytokine production and degranulation in response to IgE-antigen complexes,
neither miR-221 overexpression, nor its ablation, interfered with mast cell differentiation. Transcriptional profiling of miR-
221-overexpressing mast cells revealed modulation of many transcripts, including several associated with the cytoskeleton;
indeed, miR-221 overexpression was associated with reproducible increases in cortical actin in mast cells, and with altered
cellular shape and cell cycle in murine fibroblasts. Our bioinformatics analysis showed that this effect was likely mediated by
the composite effect of miR-221 on many primary and secondary targets in resting cells. Indeed, miR-221-induced cellular
alterations could not be recapitulated by knockdown of one of the major targets of miR-221. We propose a model in which
miR-221 has two different roles in mast cells: in resting cells, basal levels of miR-221 contribute to the regulation of the cell
cycle and cytoskeleton, a general mechanism probably common to other miR-221-expressing cell types, such as fibroblasts.
Vice versa, upon induction in response to mast cell stimulation, miR-221 effects are mast cell-specific and activation-
dependent, contributing to the regulation of degranulation, cytokine production and cell adherence. Our studies provide
new insights into the roles of miR-221 in mast cell biology, and identify novel mechanisms that may contribute to mast cell-
related pathological conditions, such as asthma, allergy and mastocytosis.
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Introduction
Mast cells are cells of the innate immune system that reside in
most tissues and are characterized by cytoplasmic granules
containing active mediators such as histamine and proteases,
which can be rapidly released upon activation. A broad panel of
cytokines and chemokines is also rapidly synthesized upon acute
stimulation, although some cytokines (such as TNFa) can be pre-
stored in the granules [1,2]. On the surface, mast cells are
characterized by the expression of KIT and FceRI (high-affinity
IgE receptor). KIT, the receptor for the stem cell factor (SCF), is a
critical regulator of mast cell differentiation, proliferation,
activation and survival. Although mast cells have been considered
for a long time detrimental to the host, mainly because of their
major role as master effector cells in allergic responses, it is now
becoming clear that depending on the context, mast cells can
either positively or negatively regulate innate or adaptive immune
responses to pathogens or allergens (for a recent review see [3]).
MicroRNAs (miRNAs) are small, non-coding RNAs that are
emerging as major players in the regulation of endogenous gene
expression in immune homeostasis [4]. Specifically, miRNAs
regulate the expression of target genes by interacting with sites in
the 39 untranslated region (39UTR) of their target mRNAs.
MiRNAs regulate all aspects of a cell, including differentiation,
function, proliferation, survival, metabolism, and responses to
environmental changes. A single miRNA can potentially modulate
the expression of hundreds of transcripts in a cell, both by direct
and indirect effects, and as many as 90% of human genes may be
regulated by miRNAs [5]. MiRNAs are implicated in various
pathologic conditions as well as in tumorigenesis [4,6], and within
the immune system, deletion or overexpression of specific miRNAs
can impair innate or adaptive immune responses [7].
While the importance of miRNAs in various types of normal
and diseased cellular processes is by now well established, very
little is known about the role of miRNAs in mast cell development,
function and disease. Our lab identified miR-221/-222 as a family
of miRNAs that is transcriptionally induced upon mast cell
activation, and we showed that expression of miR-221 and/or
miR-222 to levels similar to the endogenous of activated mast cells,
led to reduced mast cell proliferation [8]. MiR-221 and miR-222
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derive from the same primary transcript and share the same seed
sequence, implying that they should recognize the same targets
[9]. Following up on our previous studies, we investigated the role
of miR-221 in mast cell differentiation and function. Specifically,
we found that although miR-221 does not seem to affect mast cell
differentiation, it has important roles in regulating multiple
processes in differentiated mast cells, such as degranulation,
adhesion and migration, some of which may be linked to a
dysregulation in the actin cytoskeleton. Indeed, we found that
alteration of miR-221 expression in mast cells and fibroblasts led
not only to a reduction in cell proliferation similar to what we
previously described using a different expression system, but also
to an alteration of actin content and overall cellular shape in both
cell types. Transcriptional profiling and bioinformatics analysis
using the Sylamer algorithm [10], indicated that miR-221 effects
in mast cells were mediated by the alterations of the level of
expression of many primary and secondary targets. Importantly,
such miR-221-mediated alterations of the cell phenotype could not
be recapitulated by knockdown of one of the most prominent
target for miR-221, suggesting that the observed effect of miR-221
in resting mast cells and fibroblasts is likely to be composite, due to
the alteration of many genes. Moreover, we also observed mast
cell-specific, activation-dependent effects of miR-221. Since miR-
221 is expressed at basal level in mast cells, but it is also inducible
upon stimulation, we propose a model in which miR-221 has a
dual roles in these cells: at resting state, it contributes to the
regulation of the cell cycle and cytoskeleton, a housekeeping effect
that can be observed also in different cell types expressing this
miRNA. However, in response to stimulation through IgE-antigen
complexes, miR-221 effects are mast cell-specific and activation-
dependent, contributing to the regulation of degranulation,
cytokine production and cell adherence. Overall, our studies
provide insights on the role of miRNAs in mast cells, and lay the
groundwork for understanding some of the mechanisms underly-
ing pathological conditions caused by mast cells, such as allergy
and mastocytosis.
Materials and Methods
Ethics statement
All animal studies were performed in accordance with the Swiss
Federal Veterinary Office guidelines and were approved by the
Dipartimento della Sanita’ e della Socialita’, authorization number
18/2010.
Plasmids
About 400bp of the mouse miR-221 or miR-222 genomic
sequences were cloned into the pAPM lentiviral vector [11]. Point
mutations in the seed sequence of miR-221 were introduced using
the Quick Change Site-Directed Mutagenesis kit (Stratagene) and
the following primers (mutations underlined): miR-221mFW: 59-
GTTTGTTAGGCAACATCGCGATTGTCTGCTGGGTTTC-
AGG; miR-221mRV: 59- CCTGAAACCCAGCAGACAATCGC-
GATGTTGCCTAACAAAC. The control vector pAPM-shLuc,
expressing a miR-30-based shRNA against luciferase, was obtained
from Thomas Pertel and Jeremy Luban and contained the following
sequence: 59- CACAAACGCTCTCATCGACAAG. The miRNA
target (miRT) vectors containing four sequences fully complemen-
tary to miR-221 and/or miR-222, were provided by Bernhard
Gentner and Luigi Naldini [12].
Cell cultures
For bone marrow-derived mast cells (BMMCs) differentiation,
bone marrow cells from C57Bl/6 mice (6-8 weeks old) were
differentiated and maintained in IMDM with 10% FBS, 2 mM L-
glutamine, 0.1 mM non essential amino acids, 50 mMb-mercap-
toethanol, antibiotics and 50% WEHI-3 conditioned supernatant
as a source of IL-3 [13,14]. The IL-3-dependent mast cell line
MC/9 (ATCC) was cultured as for primary BMMCs. 3T3 cells
were cultured in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 0.1 mM non-essential amino acids, 50 mMb-mercap-
toethanol and antibiotics.
Transductions and transfections
Lentiviral transductions of mast cells were performed exactly as
described [8,13]. 3T3 cells were transduced with concentrated
lentiviruses prepared exactly as described [8,13] and selected with
2 mg/mL puromycin for several days before performing experi-
ments. For transient transfections with oligonucleotides, 3T3 cells
were transfected with Lipofectamine-2000 (Invitrogen) and 20pmol
of siRNAs against p27Kip1 (siGENOME Cdkn1b) or control siRNAs
(siGENOME non-targeting siRNA #2 and/or siGLO) (all from
Thermo Scientific) following manufacturer’s instructions. Cells were
analyzed 48–72 h after transfection. Efficiency of transfection was
assessed in each experiment by transfecting a fluorescent oligonu-
cleotide (siGLO) and analyzing the percentage of siGLO+ cells by
FACS, which usually ranged between 50 and 70%. The efficiency of
protein knockdown was assessed by Western blot.
RNA extraction and RT-PCR
Total RNA was extracted using TRIzol (Invitrogen) according
to manufacturer’s instructions. To analyze miRNA expression,
qRT-PCR was performed using a miRNA reverse transcription kit
and TaqMan miRNA assays from Applied Biosystems, following
exactly manufacturer’s instructions.
Immunostainings and microscopy
Anti-KIT-APC, anti-FceRIa-PE and anti-CD25-PE were
purchased from eBioscience. For microscopy, 105 BMMCs were
labeled with CFSE (Invitrogen) and added to a monolayer of 3T3
cells on coverslips. After 12 hours, coverslips were washed to
eliminate non-adherent cells, and cells were fixed with 3.7% p-
formaldehyde, permeabilized with 0.1% Triton-X100 and stained
with 160nM phalloidin-AlexaFluor-594 (Invitrogen). Glass slides
were mounted using Gelvatol (20% polyvinyl alcohol, 100mM
Tris-HCl pH 8.5, 2.5% DABCO). The same protocol was used to
stain 3T3 cells grown directly on coverslips. Bright field images
were captured with a Nikon Eclipse E800 and analyzed with the
Openlab software (Improvision). For FACS-based quantification
of F-Actin, 3?105 cells were fixed 15–30 min in 4–5% p-
formaldehyde, permeabilized 2min with 0.1% Triton-X100, and
stained with phalloidin at a 1:100 dilution.
Degranulation, adhesion and migration assays
For degranulation assay, BMMCs (5?104) were resuspended in
50 mL OptiMEM, 1% FBS and stimulated for 1 h with 1.5 mg/mL
IgE-anti-DNP (clone SPE-7, Sigma) and 0.2 mg/mL DNP-HSA
(Sigma). After stimulation, cell pellets were lysed in 50 mL of 0.5%
Triton-X100 in OptiMEM, 1% FBS, and 50 mL of a 3.8 mM
solution of the b-hexosaminidase substrate 4-nitrophenyl N-acetyl-
b-D-glucosaminide (Sigma) were added to both cell lysates and
supernatants. After incubation for 2 h at 37uC, the reaction was
stopped with 90 mL glycine 0.2 M, pH 10.7, and absorbance was
read at 405 nm. The percentage of degranulation was calculated as
the ratio between the absorbance of supernatants and the total
absorbance of supernatants and cell lysates [15]. Alternatively,
degranulation was assessed using the same annexin V-PE kit used to
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detect apoptosis (BD-Pharmingen) [16,17]. Briefly, cells were
stimulated for 30 min with 1.5 mg/mL IgE-anti-DNP and 0.2 mg/
mL DNP-HSA, in the presence or absence of 20 ng/mL SCF
(Peprotech). Cells were then washed and stained with annexin V-PE
following manufacturer’s instructions. For adhesion experiments,
105 BMMCs were added to a monolayer of 3T3 cells in 24-well
plates. Floating cells were harvested 8h later, and adherent cells
were detached using 10mMEDTA. In order to distinguish BMMCs
from fibroblasts, cells were stained for KIT, and numbers of KIT+
cells were evaluated by FACS. The percentage of adherent cells was
calculated as the ratio between adherent cells versus total. Cell
migration was assayed using 24-well transwell chambers (Corning)
with 8.0 mm pores in polycarbonate membranes. 2?105 BMMCs
were seeded in the upper chambers and allowed to migrate for 2 h.
In some experiments, 20 ng/mL of SCF was used as chemoat-
tractant, while in others BMMCs were first sensitized with 300 ng/
mL IgE-anti-DNP for 12 h and then allowed to migrate towards
0.2 mg/mL DNP-HSA. The percentage of migrated cells was
calculated as the ratio between the number of cells in the lower
chamber versus total.
Cell-cycle analysis and Western blots
For propidium iodide staining and DNA content analysis, non-
confluent 3T3 cells were fixed in 70% ethanol for 45 min on ice,
followed by incubation for 30 min at 37uC with 100 mg/mL
RNaseA and 40 mg/ml propidium iodide. Cells were analyzed by
FACS immediately afterwards. Total protein extracts for Western
blot were prepared by cell lysis in Laemmli sample buffer. Samples
were run on 12% SDS-polyacrylamide gels and immunodetection
was performed with p27 C-19 and b-tubulin H-235 antibodies
(Santa Cruz Biotechnologies).
Microarrays and Sylamer analysis
Gene arrays were performed at Miltenyi Biotec using Agilent
dual-color whole-genome oligo arrays and total RNA from three
independent biological replicas. Genes found to be commonly
regulated were functionally annotated. Sylamer analysis was
performed through a Sylarray web server [18,19]. Specifically, the
Agilent probes were mapped to the 39zUTRs of genes stored in the
Sylarray database. The sequences were previously masked from low
complexity regions and redundant UTR sequences with DUST
algorithm and RSAT purge-sequence interface to Vmatch [20,21].
As a control we also analyzed the mutant seed sequence to check for
any evidence of its influence in the experiment and no significant
association was found. Array data are MIAME compliant and are
deposited in the MIAME compliant database Gene Expression
Omnibus (GEO) with accession number GSE24462.
Statistical analysis
Results are expressed as mean 6 standard deviation. Compar-
isons were made using the Student’s unpaired t-test and the
GraphPad Prism Software.
Supporting Information
Additional information can be found in the Supplementary
Methods S1.
Results
A robust lentiviral system for manipulating microRNA
expression in mast cells
As we previously described for acute stimulation of mast cells
[8], BMMCs stimulated with IgE-antigen complexes upregulated
miR-221 expression (Figure 1A). While stimulation-dependent
upregulation of this miRNA could be favored by SCF co-
stimulation, SCF alone had no effect on miR-221 expression (not
shown). To investigate the role of miR-221 in regulating primary
mast cell functions, we developed a lentiviral system to manipulate
miRNA expression in primary BMMC and used it to alter miR-
221 expression. The pAPM/pAGM vectors were used to
overexpress miR-221 or miR-222; as control, we used a mutant
version of miR-221 (miR-221m), containing mutations in the seed
region to abrogate target recognition, as well as a vector expressing
an irrelevant hairpin (shLuc) (Figure 1B). The miR-221m mature
sequence had no predicted targets as assessed by TargetScan [9].
The ‘miRNA target’ (miRT) vectors contain four miRNA binding
sites (miR-bs) cloned downstream a GFP reporter gene, and they
were used to functionally ablate miR-221/-222 [12]. Transcrip-
tion from such vectors results in accumulation of decoy mRNAs
that divert miRNAs from their physiological targets [22].
To assess expression from these vectors, BMMCs were
transduced with the indicated vectors, and miRNA expression
was assessed by qRT-PCR (Figures 1C and 1D). Compared to
untransduced, unstimulated cells (expression set to 1 in Figures 1C
and 1D), transduction of primary mast cells with pAGM/pAPM-
miR-221 increased miR-221 expression by ,60-fold, whereas
transduction with miRT-221 decreased expression by ,10-fold
(Figure 1D). Transduction with the mutant miR-221m had no
effect (Figure 1C). Initial experiments were performed using a
vector (Tween) that induced only modest overexpression (,4-fold),
similar to the levels of endogenous miR-221 observed upon cell
stimulation (Figure 1A) [8]. However, both types of vectors
(weaker and stronger expression) gave similar results qualitatively,
although the stronger vector provided bigger quantitative
differences, and was therefore used in most of the subsequent
experiments. To assess the functional effects of miRNA overex-
pression/ablation, the mast cell line MC/9 was transduced to
overexpress miR-221 or the mutant miR-221m. Transduced cells
were selected with puromycin, subjected to a second round of
transduction with the miRT vectors, and monitored for GFP
expression (Figure 1E). As a result of binding of the overexpressed
miRNAs to their cognate sites in the 39 UTR of the GFP reporter
mRNA expressed from the miRT, GFP expression was strongly
reduced specifically in cells expressing miR-221 but not the
mutant miR-221m. We therefore used both validated systems
(overexpression and ablation) to study mast cell differentiation in
the presence or absence of miR-221.
MiR-221/-222 as well as the transcriptional repressor PLZF are
both known important regulators of hematopoietic cell differen-
tiation [23,24,25]. We previously showed that binding sites for
PLZF were enriched in mast cell-specific DNaseI hypersensitive
sites found upstream of the miR-221-222 genomic sequence [8].
To address the possible relation between PLZF and miR-221, we
analyzed expression of both Plzf mRNA and miR-221 during mast
cell differentiation (Supplementary Figure S1). We observed an
inverse relation between Plzf and miR-221 expression during mast
cell differentiation, and ectopic expression of PLZF in mast cells
diminished miR-221 expression in response to acute stimulation,
suggesting that PLZF is able to repress miR-221-222 induction
either directly or indirectly, and possibly through PLZF-binding
regulatory elements in the miR-221-222 locus [8]. However,
ectopic expression of PLZF in differentiated mast cells had no
effect on the basal levels of endogenous miR-221, indicating that
other factors regulate basal expression of this miRNA in mast cells.
To assess whether miR-221/-222 may have a direct role in
regulating the differentiation process in mast cells, we transduced
bone marrow-derived hematopoietic progenitors with lentiviruses
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to either overexpress (pAPM) or ablate (miRT) miR-221 and/or
miR-222 early during mast cell differentiation (Supplementary
Figure S1). Differentiation was monitored over a period of at least
three weeks by assessing the percentage of FceRIa+ KIT+ cells.
Interestingly, the percentage of BMMCs increased steadily over
time in all samples, and mast cell differentiation was not
significantly affected by either overexpression or ablation of
miRNAs. Moreover, there was no obvious alteration in cell
granularity or in the content of the granules (data not shown).
MiR-221 regulates degranulation, migration and
adherence in differentiated BMMCs
Since there was no effect of miR-221 in mast cell differentiation,
we set out to investigate its role in mast cell functions, especially
the ones connected to signaling through the FceRI, given that
miR-221 expression is inducible upon stimulation. Differentiated
BMMCs were lentivirally transduced to force expression of miR-
221, followed by analysis of the effects on mast cell degranulation,
migration and adherence (Figure 2). Upon activation, mast cells
release an array of enzymes that are pre-stored in cytoplasmic
granules. We analyzed the ability of miR-overexpressing BMMCs
to degranulate upon stimulation using b-hexosaminidase activity
in the supernatant of activated cells as a measure of degranulation
(Figure 2A). In resting conditions, cells did not degranulate,
regardless of miRNA expression (Figure 2A, top panel) but, upon
stimulation with IgE and antigen, BMMCs overexpressing miR-
221 degranulated more compared to the controls (Figure 2A, lower
panel), although they also showed a slightly reduced content of b-
hexosaminidase in the granules to begin with (Figure 2A, top panel).
To further confirm these results and to assess the effect of different
conditions of stimulation (namely IgE crosslinking with or without
SCF co-stimulation), we assessed degranulation of cells overex-
pressing miR-221 or controls by using a staining with annexin V.
This staining takes advantage of the fact that mast cells do not die
upon stimulation (which is instead a survival factor [26]) and that
during the membrane fusion process of degranulation, annexin V
binding occurs at sites of secretory granule exposure to the cell
surface [16,17]. In general, BMMCs stimulated with a combina-
tion of IgE-antigen and SCF degranulated more strongly
compared to cells stimulated without SCF (Figure 2B). However,
Figure 1. MiR-221 is upregulated upon mast cell activation and its expression levels can be altered using lentivirus-based systems.
A) Differentiated BMMCs were either left resting or were stimulated with 1.5 mg/mL IgE anti-DNP, 0.2 mg/mL DNP-HSA and 20ng/mL SCF prior analysis of
miR-221 expression by TaqMan qRT-PCR. SnoRNA202 was used as endogenous control. B) Schematic representation of the lentiviral vectors used to
stably overexpress or functionally ablate miR-221 and miR-222 in BMMCs. Reporter genes were either puromycin or ZsGreen in the pAPM or pAGM
vectors, respectively. Sequences corresponding to the mature murine miR-221, miR-222 and miR-221m are also shown. The miRT vectors contain 4
sequences fully complementary to miR-221 and/or miR-222 cloned downstream the reporter gene. SFFVp: spleen focus-forming virus promoter;
d4EGFP: destabilized GFP; bs: binding sites. C) BMMCs were transduced with the control vector shLuc, miR-221 or miR-221-mutant. After selection with
2 mg/mL puromycin for 48h, miR-221 expression levels were assessed by TaqMan qRT-PCR. Expression levels are referred to the ones of the shLuc-
transduced cells, which are set to one. D) BMMCs were transduced with miRT-221 (depleting) or miR-221 (overexpressing) vectors, and miR-221
expression levels were assessed by TaqMan qRT-PCR. Cells transduced with miR-221 were selected with 2 mg/mL puromycin for 48h prior analysis, while
cells transduced with miRT-221 were sorted to .90% GFP+ prior RNA extraction. Untransduced cells were either left unstimulated or were stimulated
with PMA and ionomycin for 24 h prior RNA extraction. Expression levels are referred to the untransduced and unstimulated cells, which are set to one.
E) MC/9 cells were transduced with miR-221 (upper panels) or miR-221m (lower panels) and selected with 1 mg/mL puromycin prior a second
transduction with the indicatedmiRT vectors (miRT-empty or miRT-221). GFP levels were determined by FACS. Transduction efficiency and levels of miR-
221 expression or depletion are representative of tens of experiments, including all the experiments shown hereafter.
doi:10.1371/journal.pone.0026133.g001
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compared to the controls (shLuc and miR-221m) miR-221
overexpression increased degranulation in response to IgE, as
shown already by b-hexosaminidase assay, but miR-221-overex-
pressing cells did not further degranulate in response to the
combination of both SCF and IgE crosslinking (middle panel).
This could be due to the fact that the SCF receptor KIT is
expressed at lower levels on these cells (see below), or to the fact
that in the presence of miR-221 cells are activated more strongly
upon IgE crosslinking, and cannot be further activated by the
combination of IgE and SCF.
Next, we investigated the capability of BMMCs to migrate in a
transwell system (Figure 2C). We found that cells overexpressing
miR-221 migrated significantly less towards SCF as compared to
the controls (Figure 2C, right panel). KIT is a target for miR-221
[24], therefore, to understand whether the reduced migration was
due to an intrinsic feature of cells overexpressing miR-221, or to a
reduced ability to ‘sense’ SCF in the environment due to lowered
expression of KIT, we repeated the same experiment sensitizing
BMMCs with IgE-anti-DNP prior inducing migration towards
DNP-HSA (Figure 2C, left panel). The discernible, albeit modest,
migration of control-transduced cells towards the antigen was
significantly impaired if miR-221 was overexpressed, indicating
that the reduced migration was due to effects of miR-221 on
targets other than KIT.
Another process promoted by the stimulation through the
FceRI is adherence of mast cells to the substrate. Since mature
mast cells do not normally circulate in vivo, but reside in tissues, we
explored whether miR-221 had any role in regulating cell
adherence and migration, as these are essential processes not only
under normal homeostatic conditions, but also during inflamma-
tion and tumorigenesis. As in vitro-differentiated mast cells grow in
suspension, we assessed the ability of BMMCs to adhere to a
feeder layer of fibroblasts in a co-culture system (Figure 2D).
Increased adherence is a normal process observed upon
stimulation of mast cells with IgE and antigen, however, BMMCs
expressing miR-221 adhered at a higher percentage compared to
the controls even in resting, unstimulated conditions. Vice versa,
upon stimulation all cells were able to adhere to the feeder layer of
fibroblasts at comparable levels, regardless of miRNA expression.
Since miR-221 overexpression was sufficient by itself to increase
adherence, our data indicate that endogenous miR-221/-222
upregulation upon cell activation may contribute to the increased
adherence of mast cells observed upon stimulation.
These results may point towards a role for miR-221 in
regulating the signaling cascade originating from the FceRI. In
this context, it is important to highlight that miR-221 overexpres-
sion did not alter surface expression of FceRI (see below). To
evaluate whether signaling from the FceRI could be affected in
presence of miR-221, we assessed the levels of ERK phosphor-
ylation in response to IgE crosslinking (Supplementary Figure S2).
In all conditions and time-points tested, there was no significant
difference in ERK phosphorylation in cells overexpressing miR-
Figure 2. Degranulation, migration and adherence of cells overexpressing miR-221. A) Transduced BMMCs were either left unstimulated
(upper panel; n = 5 experiments, each performed in triplicate) or were stimulated with IgE anti-DNP and DNP-HSA for 1h (lower panel; n = 2
experiments, each performed in triplicate) prior measurement of b-N-acetylhexosaminidase release to assess degranulation. B) Transduced BMMCs
were either left unstimulated or were stimulated for 30min with IgE-antigen complexes alone or in combination with 20ng/mL of SCF. Cells were then
stained with annexin V-PE to assess the extent of degranulation (representative of 2 independent experiments). The red shading in the figure
indicates the difference between IgE versus IgE+SCF stimulation in control cell, which is reduced in miR-221-expressing cells). C) Right panel: BMMCs
transduced with indicated vectors were seeded in the upper well of a transwell chamber and then allowed to migrate towards the lower chamber
containing no chemoattractant (empty circles) or SCF (black circles). Each circle represents one independent experiment. Left panel: same as above,
except that cells were sensitized with anti-DNP IgE overnight, and allowed to migrate towards the antigen (DNP-HSA). D) BMMCs transduced with the
indicated vectors were seeded on a monolayer of 3T3 cells, and were either left resting or were stimulated for 8h with IgE-antigen complexes and
SCF. Cells were then detached by treatment with 10mM EDTA, and the percentage of adherent cells versus total was assessed by surface staining for
KIT and FACS analysis. Shown is one experiment out of at least six.
doi:10.1371/journal.pone.0026133.g002
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221 compared to the controls, suggesting that miR-221 might not
affect directly the signaling cascade from the FceRI. However, in
miR-221-expressing cells, in addition to increased degranulation
(Figure 2, panels A and B), we also observed increased cytokine
production (IL-6 and TNFa) in response to IgE crosslinking, but
not to LPS (Supplementary Figure S2 and data not shown). This
observation may indicate that miR-221 expression favors mast cell
activation in response to IgE-antigen complexes, however in a way
that doesn’t seem to grossly affect ERK phosphorylation.
Microarray analysis identified genes affected by miR-221
To gain insight into the mechanisms underlying such pleiotropic
effects of miR-221 in mast cells, we performed a microarray
analysis of BMMCs overexpressing miR-221 or miR-221m, as it
has been reported that indeed the impact of a miRNA on protein
production can be closely approximated using mRNA arrays [27].
Out of ,42.000 transcripts analyzed, we found 397 significantly
upregulated genes in miR-221-expressing BMMCs, as well as 343
significantly downregulated genes as compared to cells transduced
with miR-221m (Figure 3A). Importantly, the known miR-221
targets Cdkn1b (p27Kip1) and Kit were found to be downregulated
with a mean fold-change repression of -3.2 and -2.0, respectively.
While the upregulated genes presumably reflect secondary
changes due to changes in the expression of primary targets, the
downregulated gene subset may contain both primary targets as
well as secondary effects.
Of note, when we compared the list of our downregulated genes
with the targets predicted by TargetScan [9] and microCosm [28],
we found very few overlapping genes, which could indicate either
that only few downregulated genes are the real primary targets, or
that many targets are relevant only in the specific mast cell context
(Figure 3B). To better understand how miR-221 could regulate
gene expression specifically in mast cells, we therefore performed a
Sylamer analysis [19] on the complete gene list from the arrays,
which was ranked from most downregulated to most upregulated
(left to right in the graph in Figure 3C). Sylamer is an algorithm for
determining whether specific 6, 7 or 8nt motifs corresponding to
miRNA seed sequences are enriched or depleted in a ranked gene
list [19]. The Sylamer plots can be used to analyze influence of a
miRNA on an expression set profile. Sylamer calculates enrich-
ment of seed words in 39UTRs of a sorted gene list, providing a p-
value for genes left of each rank versus the genes on the right. In
this case, the upper left portion of the plot represents an influence
of miRNAs on downregulated genes (Figure 3C), indicating a
specific influence of miR-221 on a subset of downregulated genes.
Any point of a line provides a p-value that a word is enriched in
the UTRs left of it on the X-axis. Although in some cases most of
the effect of a given miRNA in a particular cellular context goes
Figure 3. Identification of genes dysregulated upon miR-221 overexpression in BMMCs. A) Double-log scatter plot comparing the
differential expression of mRNAs in BMMCs transduced with the miR-221 and miR-221m. Red diagonal lines define the areas of 2-fold differential
signal intensities. Blue cross: unchanged genes. Red cross: significantly upregulated genes (p-value ,0.01). Green cross: significantly downregulated
genes (p-value ,0.01). B) Comparison between significantly downregulated genes and genes predicted to be miR-221 targets by microCosm and
Targetscan. C) Sylamer plot analysis for the Seed Complementary Region (SCR) words corresponding to the seed of miR-221 (red) and its one-
nucleotide shifted sequence (orange). Log10- transformed and sign-adjusted enrichment P values for each SCR word, relative to P values of all other
words, are plotted on the Y-axis, against the ranked gene list on the X-axis (left, downregulated genes; right, upregulated genes). The dashed green
line defines the Bonferroni corrected p-value cutoff for significance of 0.05.
doi:10.1371/journal.pone.0026133.g003
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primarily through one or few molecular targets, in other cases this
does not provide the complete picture of miRNA effect on the
transcriptome and proteome of a cell [27,29,30]. Our array
analysis showed that the transcriptomes of miR-221-overexpress-
ing cells differed by the expression of 740 genes compared to the
controls, and the Sylamer analysis indicated that many of the
downregulated genes in mast cells were likely to be directly
affected by miR-221 expression, suggesting that the effect of this
miRNA goes through the fine modulation of a multitude of targets.
Some of the targets that were up- or downregulated were also
confirmed at protein level; among others, we selected two of the
already known targets for miR-221, Kit and Cdkn1b [8,24,31], as
well as one upregulated gene (Il2Ra) that is particularly relevant in
mast cell biology as a marker for systemic mastocytosis [32,33]. As
assessed by surface staining, levels of KIT, but not of FceRI, were
significantly diminished (,2-fold) in BMMCs overexpressing miR-
221 (Figure 4A). In contrast, as we previously described [8], levels
of p27Kip1 protein were especially decreased in stimulated cells
(Figure 4B, compare lane 4 with lanes 2 and 6). While CD25
(Il2Ra) is normally not expressed by human mast cells in non-
pathogenic conditions [32,33], it is normally expressed by a subset
of in vitro-differentiated murine BMMCs (Figure 4C) as well as by a
subset of peritoneal and tissue mast cells in the mouse (Deho’ and
Monticelli, unpublished observation). The mean fold increase for
Il2Ra from the arrays was 2.1, which strongly correlated with the
increased surface expression of this marker in cells overexpressing
miR-221 (Figure 4C).
Although some of the targets for miR-221 were individually
confirmed, our arrays experiments and Sylamer analysis indicated
that miR-221 determines the downregulation of more than 200
primary targets and the subsequent secondary alterations of many
genes in the transcriptome. Therefore, to gain insights into the
function of the genes that showed altered expression in the presence
of miR-221, we performed functional grouping and gene ontology
Figure 4. MiR-221 primary and secondary targets are altered also at protein level. A) Differentiated BMMCs were either left untransduced
or were transduced with the indicated vectors. After selection with puromycin, surface expression of KIT (left) and FceRI (right) was assessed by FACS.
The mean fluorescence intensity (MFI) for KIT expression in miR-221- (red) and shLuc- (black) expressing cells is also indicated. B) Differentiated
BMMCs as in A) were either left untreated or were stimulated with 20nM PMA and 1 mM ionomycin for 24h prior lysis and Western blot analysis of
p27Kip1 expression. b-tubulin was used as loading control. C) BMMCs as in A) were stained and FACS-analyzed to assess surface expression of KIT and
CD25. The horizontal dotted line was added as a reference to appreciate the expected KIT dowregulation in miR-221 expressing cells.
doi:10.1371/journal.pone.0026133.g004
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(GO) analysis, and found that many basic biological processes were
affected (Table 1). Among the downregulated genes, the categories
that were statistically significant were surprisingly few, and
belonging for the most part to very general metabolic pathways,
such as protein folding, transcription, lipid metabolism and cell
differentiation. This finding may suggest that in resting, unstimu-
lated cells, miR-221/-222 regulate basic metabolic processes that
are common to many different cell types and/or species, and
correlates with the fact that these miRNAs belong to a family very
conserved in evolution, down to at least zebrafish [8]. Although they
are most likely due to secondary changes in the transcriptome, the
GO categories of the upregulated genes included several pathways
that we also observed altered experimentally, such as cell
proliferation, cell adhesion and cell migration. Among these latter
GO categories, we focused our attention on one of the most
statistically significant one, namely the cytoskeleton (which was also
present in the GO list of terms for the downregulated genes,
although with a p-value of 0.1), as we hypothesized that an
alteration in the ability of the cells to properly regulate the
cytoskeleton could to some extent explain why these miRNAs affect
many different biological processes, at least in unstimulated cells.
MiR-221-dependent alterations of the cytoskeleton and
actin content in mast cells and 3T3 cells
To assess whether miR-221 expression could affect the
cytoskeleton, we stained transduced BMMCs with phalloidin
(Figure 5A). We used the same co-culture system with fibroblasts
used in Figure 2D to assess cell adherence, and to distinguish mast
cells from the underlying layer of feeder cells (also stained by
phalloidin), BMMCs were first labeled with CFSE. Strikingly, not
only miR-221-overexpressing cells showed increased numbers of
adherent cells (as shown also in Figure 2D), but while the actin ring
underneath the plasma membrane was barely visible in control
cells, cells overexpressing miR-221 (or miR-222, not shown)
showed the presence of a much thicker ring (Figure 5A).
Moreover, when we quantified the overall cellular amount of F-
actin in cells depleted for miR-221 (using the miRT-depleting
vectors), we observed a small but reproducible decrease in the
amount of F-actin present in these cells (Figure 5B), further
indicating that these miRNAs might be important regulators of the
actin organization in mast cells.
To independently confirm these results, and to investigate
whether the observed effect was a general feature of this miRNA
or a cell type-specific effect due to alterations of targets relevant
only in the mast cell context, we transduced 3T3 fibroblasts with
the same lentiviral vectors used on mast cells. 3T3 cells expressed
low levels of endogenous miR-221 that were increased ,20-folds
upon transduction with a miR-221 expressing vector (Figure 6A).
MiR-221 overexpression in 3T3 cells led to a strong downregu-
lation of endogenous p27Kip1, even more remarkable than the one
observed in mast cells (Figure 6B). Despite such strong
downregulation of the cell-cycle inhibitor p27Kip1, 3T3 cells
overexpressing miR-221 showed the same reduced proliferation
that we previously described for mast cells (Figure 6C) [8].
Moreover, 3T3 cells overexpressing miR-221 showed overall
altered morphology, with odd, elongated and/or irregular shapes
(Figure 6D), as well as a slightly increased content of F-actin
(Figure 6E), indicating that the miR-221-dependent effects on the
cytoskeleton and cell cycle observed in resting mast cells are likely
to be due to the dysregulation of targets that are ubiquitously
expressed and are therefore cell type-independent. However,
FceRI stimulation led to mast cell-specific (or at least not present in
fibroblasts) effects of miR-221, with increased degranulation and
cytokine production.
Analyzing the data from our transcriptome profiling, we found
that in the ‘cytoskeleton’ group of downregulated genes, the top
candidate, most downregulated gene was Cdkn1b (p27Kip1), and
specifically the one splice variant that can be regulated by miR-
221/-222 (as we previously described in [8]). While p27Kip1 is a
cell cycle inhibitor with a well established role in cell cycle
progression at the G1-S transition, it has also been shown that
cytoplasmic p27Kip1 plays an important role in cell motility and
migration, and that p27Kip1-deficient fibroblasts fail to form long
cellular protrusions, assume an overall rounded shape [34] and
show reduced migration [35]. To assess whether miR-221-
dependent down-regulation of p27Kip1 may have a role in
regulating 3T3 and mast cells shape and cytoskeleton, we therefore
performed a knockdown of p27Kip1 in 3T3 cells using siRNAs
(Figure 7). Efficiency of transfection and p27Kip1 knockdown were
evaluated by transfection and FACS analysis of a fluorescent ds-
oligo (siGLO) and by Western blot, respectively (data not shown
and Figure 7A). It has to be noted that the efficiency of transfection
was at the most ,70%, so that the residual protein observed in
Western blot may in part be due to the fact that some cells still
expressed significant levels of p27Kip1. However, the knockdown of
p27Kip1 did not alter the overall cell-cycle profile of 3T3 cells
(Figure 7B), and the cells did not show any particularly altered
shape, apart from a slight increase in the percentage of cells that
were smaller and more rounded (Figure 7, panels C and D).
Although this effect was fairly modest (even in the experiments
Table 1. Gene Ontology (GO) frequency distribution for
downregulated and upregulated genes.
DOWNREGULATED –
Categories Times Observed Probability
Cell migration 15 5.30E-05
Protein folding/modification 30 1.80E-04
Transcription 38 5.70E-04
Lipid metabolism 17 2.30E-03
Cell differentiation 28 3.20E-03
Other metabolism 29 8.00E-03
UPREGULATED – Categories Times Observed Probability
Receptor signaling 73 9.40E-09
Cell proliferation 26 4.60E-08
Cytoskeleton 35 4.70E-08
Cell cycle 27 6.40E-08
Cell adhesion 26 3.30E-07
Cell differentiation 37 1.10E-05
Kinase/Phosphatase signaling 23 1.30E-05
Other metabolism 39 1.90E-05
Protein folding/modification 35 2.50E-05
Development 46 2.90E-05
G-protein signaling 43 8.80E-05
Cell migration 15 3.10E-04
Nucleotide metabolism 26 3.70E-04
Inflammation 11 1.00E-03
Intracellular trafficking 20 5.08E-03
Gene ontology (Bonferroni corrected) of mRNAs that were downregulated or
upregulated in the microarrays. A cutoff of P = 0.01 was used for the categories
to be considered statistically significant.
doi:10.1371/journal.pone.0026133.t001
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with the strongest downregulation of p27Kip1 only ,15% of the
cells were counted as ‘small and round’, compared to the controls),
it was in line with what was previously reported for Cdkn1b-deleted
fibroblasts. Indeed, p27Kip1 KO fibroblasts were shown to have a
rounded shape with no alterations in the cell cycle [34]. Most
importantly, the knockdown of p27Kip1 did not recapitulate the
phenotype we observed in miR-221 overexpressing 3T3 cells, as
cell cycle and cellular shape were either unaltered or completely
different from what we observed in miR-221-transduced cells,
suggesting (as indeed indicated by our Sylamer analysis), that the
effect of this miRNA is composite and goes through the down-
modulation of multiple targets.
Although the mechanisms underlying the role of miR-221
specifically in mast cells in both resting and stimulated conditions
will require further investigation and will be the subject of future
work, our data show that the effect of this miRNA goes through
the alteration of the levels of many targets in the mast cell
transcriptome, that it has important roles in regulating mast cell
physiology, and finally that at least some of its biologic effects in
resting cells may be explained by alterations in the actin
cytoskeleton of mast cells.
Discussion
Although mast cells have a long lifespan, accumulation of a
large mast cell burden in vivo is usually not observed. Thus, a
homeostatic mechanism must exist to limit differentiation and
accumulation of mast cells in peripheral tissues, both during basal
maintenance, and during mast cell hyperplasia in inflammatory
processes [36]. MiR-221 is a likely candidate as a regulator of mast
cell functions: we previously showed that it is transcriptionally
induced upon mast cell activation, and that it contributes to the
modulation of proliferation in unstimulated mast cells [8]. We now
showed that miR-221 may have more ubiquitous effects to fine-
Figure 5. MiR-221 influences BMMCs actin cytoskeleton. A) Transduced BMMCs were loaded with CFSE (green) and allowed to adhere to a
monolayer of 3T3 cells. After washing to remove non-adherent cells, F-actin was stained with phalloidin-AlexaFluor-594 (red) prior imaging with a
fluorescence microscope. Shown is one representative experiment out of three. B) BMMCs were transduced with the indicated miRT vectors, and
overall F-Actin content was assessed by FACS staining with phalloidin. Shown is one representative experiment out of three.
doi:10.1371/journal.pone.0026133.g005
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tune proliferation and actin cytoskeleton in cells as different as
resting mast cells and fibroblasts. On the other hand, miR-221 also
influenced many other features of differentiated mast cells,
including cytokine production, migration, adhesion and survival
upon withdrawal of essential cytokines (Supplementary Figure S3),
all mechanisms that may be involved in regulating tissue
accumulation and resolution of hyperplasia upon eradication of
inflammation in vivo.
While we were able to show that at least some of these effects
may be linked to a miR-221-dependent regulation of the actin
cytoskeleton in mast cells, this miRNA may have both ‘house-
keeping’ functions, active in different cell types, like the regulation
of the cytoskeleton and cell cycle, but also cell-specific effects on
targets such as KIT and CD25 that are expressed by mast cells but
not fibroblasts. As for targets, our arrays data and bioinformatics
analysis showed that expression of miR-221 led to the downreg-
ulation of 343 genes, many of which are likely to be primary
targets, containing the miR-221 seed-complementary sequence in
their 39UTR. For this reason, we think that the effect of miR-221
in resting mast cells may be composite and due to small alterations
of many genes in the transcriptome. However, since we did not
perform knockdown of every individual potential target, the
possibility remains that the effect of miR-221 in mast cells and
fibroblasts might be mediated by the downregulation of one or few
predominant genes that we were so far unable to identify. Yet,
although levels of p27Kip1 in miR-221 overexpressing fibroblasts
were very low, the individual knockdown of this protein led to a
phenotype that somewhat resembled the phenotype of p27Kip1-
deleted fibroblasts, but did not resemble in any way the phenotype
of miR-221 overexpressing cells, suggesting that miR-221 target
regulation is more complex then the downregulation of one
predominant target.
While it is clear that miRNAs regulate many different cellular
processes, understanding the details of the functions of individual
miRNAs remains challenging. Indeed, as in the case of miR-221
and -222, miRNAs are frequently present as families of redundant
genes. MiR-221 and -222 share the same seed sequence (Figure 1B),
and should recognize the same targets [9]; although most of the
experiments shown here were performed primarily with miR-221,
we also performed experiments using miR-222-expressing vectors,
which always gave results similar to miR-221, both in mast cells and
in fibroblasts (not shown). Another difficult aspect of dealing with
miRNAs is that each miRNA has many potential targets with
disparate functions, with no means to decide a priori which is the
most meaningful and therefore worthy of experimental validation.
Finally, the degree of target downregulation is typically less than
50% [29,37], and understanding which fraction of the miRNA:-
target interaction is actually relevant for a biological response
remains a challenging task. In our hands, p27Kip1 was a striking
example of this phenomenon, as while it was downregulated very
strongly upon miR-221 expression, its knockdown did not
recapitulate the complex effect of miR-221 expression.
Figure 6. MiR-221 affects cell proliferation and actin cytoskeleton in fibroblasts. A) 3T3 cells were transduced with lentiviral vectors to
express either miR-221 or controls shLuc and miR-221m. After selection with 2 mg/mL for at least 2 days, total RNA was extracted and levels of miR-
221 expression were assessed by TaqMan qRT-PCR. SnoRNA202 was used as endogenous control; for comparison, levels of miR-221 expression in the
shLuc-transduced sample were set to one. Representative of two independent experiments. B) 3T3 cells as in A) were lysed in Laemmli sample buffer
and p27Kip1 expression was analyzed by Western blot. Expression of b-tubulin was used for normalization in the quantification of bands intensity
(numbers below the blot). One representative experiment out of 3 is shown. C) Cells as in A) were collected during exponential-phase growth and the
DNA content was assessed with propidium iodide staining as a measure of the number of cells in each stage of the cell cycle. For simplicity, only the
percentage of G1 cells (left in each plot) versus the percentage of dividing cells (S+G2+M) are shown. One out of three independent experiments is
shown. D) Cells as in A) were seeded on a coverslip and allowed to adhere overnight, after which they were fixed in 4% paraformaldehyde and
stained with phalloidin-AlexaFluor-594 prior imaging with a fluorescent microscope. Shown is one representative experiment out of two. E) Cells as in
A) were trypsinized to single cell suspension, fixed and stained as in B) and analyzed by FACS. The left plot shows (on a log scale) the unstained
control compared to stained samples, while on the left the scale was changed to linear to better show the differences among samples. The MFI for
each sample is also provided. Depending on the experiment, control cells were either untransduced cells, cells transduced with shLuc- or the miR-
221m-expressing vector, or all of the above. Shown is one representative experiment out of four.
doi:10.1371/journal.pone.0026133.g006
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Although clearly able to regulate some general cellular features,
such as cell cycle and cytoskeleton in resting mast cell, we
speculate that miR-221/-222 may also be part of a mechanism
that contribute to mediate many of the changes that occur in mast
cells upon stimulation. Specifically, miR-221 may have a
‘housekeeping’ function in resting mast cells, where it is expressed
at low, basal levels, and contributes to the regulation of the cell
cycle and cytoskeleton. Vice versa, miR-221 is also transcription-
ally activated upon stimulation, and in this case it would contribute
to the regulation of cell-type specific, FceRI-dependent mecha-
nisms, such as cytokine production, degranulation and cell
adhesion. In this perspective, it is important to highlight that
although transcription of pri-miR-221-222 starts early upon IgE
stimulation, mature miR-221 accumulation occurs with a ‘slow’
kinetic (the peak of mature miRNA expression is reached at ,24h
after initial stimulation) [8]. We therefore speculate that the slow
kinetic of accumulation of the mature form of miR-221 may
actually contribute to a resting, but ‘activation-ready’ cellular state,
that favors increased degranulation, adherence and cytokine
production upon challenge (Supplementary Figure S4).
Indeed, mast cell stimulation normally leads to increased
adherence and increased survival of the cells, which can be
further activated by a secondary challenge [26,38]. Upon
secondary encounter with the antigen mast cells respond with
increased degranulation and cytokine production (reviewed in
[38]). Although such higher levels of degranulation and cytokine
production are usually considered to be the result of increased
levels of FceRI, the fact that miR-221-expressing cells showed no
perturbation of FceRI expression and at the same time increased
adherence (even in the absence of stimulation), increased
degranulation as well as cytokine production suggests that miR-
221 may contribute to such intensified cellular response upon
secondary challenge. The processes mediated by this miRNA may
also have a role in regulating mast cell homeostasis in tissues and
possibly also in pathologic conditions. It will be therefore
interesting to assess what is the role of miR-221/-222 in vivo in
mouse models, both in terms of cell homeostasis at steady-state or
upon sensitization and challenge with an antigen or with a
pathogen, and this will be the subject of future work.
Along the line of a possible role of these miRNAs in mast cell-
related diseases, we showed that miR-221 and miR-222 regulate
levels of KIT expression in mast cells. Of note, KIT levels are
often abnormally low in patients with indolent systemic mastocy-
tosis, although the D816V gain-of-function mutation in KIT is
Figure 7. Knockdown of the miR-221 target p27Kip1 does not recapitulate the composite effects of miR-221 expression. A) 3T3 cells
were transfected with siRNA oligonucleotides against p27Kip1 (si p27) or with a non-targeting control (si CTRL). 48–72 h later cells were collected and
lysed for Western blot analysis. Shown is the quantification (against b-tubulin, used as loading control) of one representative blot; the actual blot for
p27Kip1 is shown in the inset. Efficiency of transfection ranged between 50–70% depending on the experiment, with a downregulation of protein
expression as assessed by Western blot that ranged widely between 0.05–80% of the levels of control, with the latter case (highest expression,
minimal knockdown) showing no phenotypic effect. B) 3T3 cells as in A) were trypsinized to single-cell suspension, fixed in ethanol and stained with
propidium iodide for cell-cycle analysis. C) Cells as in A) were seeded on coverslips and allowed to adhere overnight prior fixation with 4%
paraformaldehyde and staining with phalloidin-AlexaFluor-594. Nuclei were counterstained with DAPI (blue). D) Quantification of the percentage of
‘small, round’ cells observed in an experiment as in C). For each sample, 8 random fields were counted, at a magnification of 10x.
doi:10.1371/journal.pone.0026133.g007
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present in most of these patients and is sufficient to cause indolent
mastocytosis [39]. This downregulation of KIT expression is even
more pronounced in poor prognosis systemic mastocytosis (i.e.
systemic mastocytosis associated with a clonal hematopoietic
disease, aggressive systemic mastocytosis and mast cell leukemia)
[39], suggesting that multiple layers of regulation of this receptor
may be acting in diseased cells. In this context, it will be interesting
to assess whether miR-221/-222 could be part of a molecular
mechanism involved in KIT regulation specifically in mastocytosis.
Indeed, although the D816V mutation may be sufficient to cause
indolent mastocytosis, other additional defects, that remain to be
identified, are required to induce aggressive mast cell disorders,
and may very well include dysregulated miRNA expression
[40,41,42]. This is even more intriguing considering that CD25,
which is so far the best available diagnostic marker for systemic
mastocytosis with bone marrow involvement [32,33], is also
regulated by these miRNAs. While miR-221/-222 were already
implicated in various human cancers for their effect on
proliferation, we show here for the first time that these miRNAs
also regulate mast cell adhesion, migration, and survival, all
processes that may have implications in mastocytosis.
In summary, although miR-221 doesn’t seem to affect mast cell
differentiation, it influences many features of the biology of
differentiated cells. Specifically, at basal levels, in resting
conditions, these effects are likely to be linked, at least in part,
to the regulation of the actin cytoskeleton and cell cycle, two
features that are regulated by miR-221 independently of the cell
type. However, upon mast cell stimulation, miR-221 may have
some more cell type-specific, activation-dependent effects, influ-
encing the extent of degranulation, adherence and cytokine
production in response to IgE-antigen complexes. Although still
speculative, we propose a model in which miR-221 would have
two different roles in mast cells: in resting cells, it contributes to
normal cell homeostasis through the regulation of the cell cycle
and cytoskeleton, while upon induction following acute stimula-
tion, it contributes to increase the strength of the response to
antigenic challenge. Overall, our work provides new insights into
previously unknown effects of miR-221 in mast cell biology, and
may have important implications for our understanding of the
molecular mechanisms underlying normal and pathologic mast
cell conditions.
Supporting Information
Figure S1 MiR-221 expression can be regulated by the
transcriptional repressor PLZF, but it has no role in
BMMC differentiation. A) Lineage depleted (Lin–, lacking
surface expression of CD5, CD45R, CD11b, Gr-1, 7-4 and Ter-
119) and Lin+ bone marrow cells were either immediately used for
RNA extraction or differentiated to mast cells in IL-3 containing
medium [43]. Total RNA from Lin– derived mast cells was used to
assess Plzf mRNA expression (upper panel) and miR-221 (lower panel).
B) Differentiated BMMCs were lentivirally transduced to
ectopically express PLZF. After puromycin selection for 48h, cells
were either left untreated or were stimulated with 20nM PMA and
1 mM ionomycin for 24h, prior RNA extraction and analysis of
Plzf and miR-221 expression. C) Lin– cells were transduced with
the indicated vectors to either force (pAPM) or ablate (miRT)
miR-221 expression, and were cultured for three weeks in the
presence of IL-3 to allow mast cell differentiation. Cultures were
analyzed weekly for the presence of mast cells (FceRIa+ KIT+) by
surface staining. Each point represents one independent experi-
ment. Cells transduced with shLuc, miR-221 and miR-221m
vectors were selected with 2 mg/mL puromycin, while cells
transduced with the miRT vectors (empty, T-221 and T-221-
222) were FACS-sorted for GFP expression. D) Total RNA was
extracted from cells treated as in C) at the end of the
differentiation period (percentage of FceRIa+ KIT+ cells was
greater than 90%), and expression of miR-221 was assessed by
TaqMan qRT-PCR. SnoRNA202 was used as endogenous
control, with levels of miR-221 expression set to one in the
shLuc-transduced sample. Cells transduced with shLuc and miR-
221 vectors were selected with 2 mg/mL puromycin, while cells
transduced with the miRT vectors (empty, T-221 and T-221-222)
were FACS-sorted for GFP expression.
(TIF)
Figure S2 MiR-221 expression does not significantly
alter ERK phosphorylation in mast cells, but favors
cytokine production. A) Differentiated BMMCs transduced
with the indicated vectors were sensitized with 1.5 mg/mL of IgE-
anti-DNP for 15min on ice. After washing to remove unbound
IgE, 200ng/mL of DNP-HSA were added, and the cells were
immediately moved to a 37uC water bath for 5, 15 and 45min.
Cells were subsequently fixed, permeabilized and stained with
biotinylated anti-phospho-p44/42 MAPK (Erk1/2). The mean
fluorescence intensity for each sample is indicated on the left. B)
Cells as in A) were either left untreated or were stimulated for
5min with 1 mM ionomycin and 20nM PMA at 37uC, after which
cells were fixed, permeabilized and stained with an anti-Erk1/2
antibody. The mean fluorescence intensity for each sample is
indicated next to the histograms. Shown is one experiment out of
two. C) BMMCs as in A) were stimulated with 1.5 mg/mL IgE-
anti-DNP and 200ng/mL DNP-HSA for 3.5h at 37uC. To block
export from the Golgi, brefeldin A (10 mg/mL) was added in the
last two hours of stimulation. Cells were subsequently fixed,
permeabilized and stained with anti-IL-6-PE and anti-TNF-a-PE-
Cy7. One representative experiment out of three is shown.
(TIF)
Figure S3 MiR-221 expression favors mast cell survival
in response to withdrawal of essential cytokines. BMMCs
were transduced with the indicated vectors and differentiated in
the presence of IL-3 only (top panel) or IL-3 + 10ng/mL SCF (bottom
panel) for three weeks, after which all cytokines were washed out of
the culture medium for at least 24h prior evaluation of early cell
death with annexin V and 7AAD staining. Shown is the
percentage of cells in early apoptosis (annexin V+ 7AAD–).
(TIF)
Figure S4 A ‘dual’ role for miR-221 in mast cells.
Speculative model of the possible roles of miR-221 in mast cells.
At resting state, basal levels of miR-221 expression would regulate
homeostatic mechanisms such as the cell cycle and cytoskeleton.
These effects are not necessarily cell type-specific, as they can be
active also in fibroblasts, which also express miR-221. Upon mast
cell activation, ‘early’ effects include the release of preformed
mediators from the cytoplasmic granules and the de novo synthesis
of other mediators, including a broad panel of cytokines. The peak
of accumulation of mature miR-221 is instead a ‘late’ event upon
cell stimulation, and we speculate that it may contribute to the
strength of the response upon secondary challenge, with increased
degranulation, cytokine production and cell adherence.
(TIF)
Methods S1
(DOC)
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SUPPORTING INFORMATION 
 
 
SUPPLEMENTARY METHODS 
Plasmids. Murine Plzf was provided by Wilfried Ellmeier [1], and it was subcloned 
into the scALPS vector [2] using standard cloning techniques. 
Cell cultures. Lineage-negative (Lin–) cells [3] were enriched from bone marrow 
using a lineage-depletion kit (Miltenyi Biotec) and cultured for 48h in serum-free media 
(StemCell Technologies) containing 100ng/mL SCF, 100ng/mL Flt3L, 50ng/mL TPO, 
20ng/mL IL-3 (all from Peprotech), antibiotics; media was then changed to regular BMMC 
media. 
RT-PCR. For semi-quantitative RT-PCR, total RNA (1µg) was reverse transcribed 
using the iScript kit (Bio-Rad), before PCR amplification using the following primers: 
PlzfFW: 5’- CCTTTGTGTGTGATCAATGCGGTG; PlzfRV: 5’- 
TGGTGCTTGAGGCTGAACTTCTTG; β-actinFW: 5’- GCAGCTCCTTCGTTGCCGGT; β-
actinRV: 5’- GGCTTTGCACATGCCGGAGC. 
Apoptosis detection. Apoptosis was evaluated using the annexin V-PE apoptosis 
detection kit (BD-Pharmingen) following exactly manufacturer’s instructions. 
Intracellular staining. For intracellular cytokine staining, cells were stimulated with 
1.5µg/mL IgE anti-DNP and 200ng/mL DNP-HSA in complete media for 3,5h at 37°C. 
Brefeldin-A (10µg/mL, Sigma) was added in the last 2h of stimulation. Cells were then fixed 
in 4% paraformaldehyde for 10min at RT, and permeabilized with 0.5% saponin, 1% BSA in 
PBS, prior staining with fluorochrome-conjugated anti-cytokines antibodies (anti-IL-6, anti-
TNF-α, both from eBioscience) for 30min at RT. For intracellular staining of phospho-ERK, 
cells were sensitized with 1.5µg/mL of IgE-anti-DNP for 15min on ice. After washing to 
remove unbound IgE, 200ng/mL of DNP-HSA were added, and the cells were immediately 
moved to a 37°C water bath for an incubation time of 5, 15 and 45min. Alternatively, cells 
were stimulated with 1µM ionomycin and 20nM PMA at 37°C. Cells were subsequently fixed 
in 4% paraformaldehyde, permeabilized with 0.5% saponin, 1% BSA in PBS and stained 
intracellularly with biotinylated anti-phospho-p44/42 MAPK (Erk1/2) (Cell Signaling). 
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Chapter 2 
 
“NF-kBp50 regulates mouse mast cell survival in part through 
upregulation of miR146a“ 
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Summary 
 Mice that lack the p50 subunit of NF-kB (p50KO) are unable to mount airway 
eosinophilia inflammation due to the inability to produce IL-4, IL-5 and IL-13, and to 
a defect in the polarization of Th2 lymphocytes. Since MCs are master effector cells 
in asthmatic and allergic responses, we evaluated whether the asthma-resistant 
phenotype observed in p50KO mice could be partially due to a defect in MCs 
development or function. Our data showed that p50KO MCs differentiated normally 
in vitro and produced reduced cytokines levels in response to different stimuli such 
IgE-crosslinking or LPS, indicating that although the airway inflammation defect 
observed in p50KO mice might be predominantly Th2-dependent, reduced cytokine 
production by MCs could also contribute to this phenotype.  
Interestingly, we also found that p50KO MCs showed a marked increase in their 
ability to survive in response to withdrawal of essential cytokines, which likely 
correlated with a strong increase in the percentage of MCs that was observed in the 
tissues of p50KO animals. Since the identification of novel mechanisms that regulate 
MC proliferation, survival and overall homeostasis in the tissues may have important 
implications for the treatment of MC related diseases such as asthma, allergy and 
mastocytosis, we investigated the molecular mechanisms at the basis of such 
enhanced survival. Compared to normal controls, we found that MCs lacking p50 
showed altered expression of several molecules involved in cell survival and cell 
death. Specifically, expression of the anti-apoptotic molecules Bcl2 and A1 was 
increased, while levels of the pro-apoptotic factor BAX were decreased.  
Importantly, we also found that miR-146a, a miRNA known to regulate NF-kB 
signalling, was not expressed in IgE- or LPS-stimulated p50KO MCs, and that in the 
context of MC survival, miR-146a acted as a pro-apoptotic factor.  
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Introduction 
 MCs are derived from hematopoietic progenitor cells that enter nearly all 
vascularized tissues, where they complete their maturation. MCs are regarded as key 
effector cells in immediate hypersensitivity reactions and allergic disorders such 
cutaneous/mucosal allergy, asthma and mastocytosis. Asthma is a chronic 
inflammatory disease of the airways characterized by variable and recurring 
symptoms, reversible airflow obstruction, and bronchospasm39-42. When activated, 
MCs secrete mediators such as cytokines, histamine, chemokines, proteases and 
leukotrienes. These cells can be activated through a variety of stimuli, including direct 
injury, cross-linking of IgE or IgG receptors, TLRs or by activated complement 
proteins. If MC proliferation and homeostasis in the tissues is not properly regulated, 
it can lead to a myeloproliferative disorder known as mastocytosis, where an 
abnormal accumulation of pathogenic MCs can be observed in various organs such as 
skin, liver, spleen, lymph nodes and most commonly the bone marrow. The symptoms 
of the disease are caused by the release of MC mediators in the tissues, resulting in a 
progressive loss of function on the organ involved. This disorder can have a clinical 
course variably ranging from asymptomatic to highly aggressive and devastating, and 
understanding the molecular basis that regulate MC differentiation and function in 
normal as well as diseased conditions may lead to new treatments of MC-related 
disases39-42. 
NF-kB is a family of transcription factors involved in the regulation of many 
biological processes such as inflammation and innate immune responses122. 
Dysregulated NF-kB activation can have important outcomes in both allergy and 
tumor transformation. For example, mice that lack the NF-kB p50 subunit are unable 
to mount airway eosinophilic inflammation due to the inability to produce IL-4, IL-5 
and IL-13, and to a defect in the polarization of Th2 lymphocytes119. 
Here, we investigated whether NF-kB p50 may have a role in regulating MC 
proliferation, differentiation, overall homeostasis in the tissues and activation, as it 
could improve our understanding of the molecular mechanisms at the basis of MC-
related diseases such as asthma, allergy and mastocytosis. We provide evidence that 
p50KO MCs showed increased survival upon withdrawal of essential cytokines, 
which may explain the increased percentage of MCs observed in the tissues of p50-
deleted animals. We also show that the underlying mechanism for such increased 
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survival involved increased expression of pro-survival factors such as Bcl2 and A1, as 
well as reduced expression of pro-apoptotic factors such as Bax and miR-146a. The 
latter in particular acted in this context as a modulator of NF-kB signalling by 
targeting TRAF6 and reducing MC survival.  
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Material and Methods 
Cell cultures and stimulation 
Bone marrow-derived MCs (BMMCs) from C57Bl/6 mice and p50KO mice123 
(6-8 weeks old) were differentiated in vitro by culturing total bone marrow cells in 
IMDM medium containing 10% FBS, 2mM L-glutamine, 0.1mM non essential amino 
acids, 50 µM β-mercaptoethanol, antibiotics and 50% WEHI-3 conditioned 
supernatant as a source of IL-3. WEHI-3 conditioned supernatant was prepared 
exactly as described124. Cell differentiation was assessed by surface staining for FcεRI 
and Kit receptor and by toluidine blue staining as described124. Briefly, 5x105 
BMMCs were resuspended in PBS and cytospun on glass slides at 300-500rpm for 3-
5min, after which they were stained for 5min at RT with a solution of 0.1% basic 
toluidine blue. Toluidine blue stains nuclei and cells other than MCs in pale blue, 
while MCs show a characteristically purple cytoplasm full of dark purple granules. 
For acute activation, MCs were stimulated with 1.5 µg/ml IgE-antiDNP (clone 
SPE7, Sigma), 0.2 µg/ml DNP-HSA (Sigma) for different times, or with 20-100 
µg/ml of LPS, depending of the experimental conditions. In some specific cases, 
indicated in the text, cells were stimulated with 20nM PMA  and 2 µM ionomycin. 
 
Plasmids 
 The control lentiviral vectors were previously described and expressed either a 
synthetic hairpin against the luciferase gene (shLuc) or a non-targeting hairpin (NT) 
or GFP alone125. The 394bp PCR fragment encompassing the pre-miR-146a hairpin 
plus 150bp of surrounding genomic sequence was obtained from a BAC clone and 
cloned using standard cloning techniques. Figure I and II show a schematic 
representation of the vectors used throughout this study. Overall, the plasmids used 
were the following: 
 
Packaging vectors: 
1) psPAX2 (Addgene plasmid 12260): this is the packaging vector containing the 
CAG promoter (a combination of chicken beta-actin promoter and CMV enhancer) 
driving the expression of packaging proteins Gag and Pol. 
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2) pMD2G (Addgene plasmid 12259): this vector expresses the envelope protein 
–G of vesicular stomatitis virus (VSV-G), which has a high stability and confers 
broad tropism to the virus. 
 
Transfer vectors:  
1) pAPM-shLuc: this is a control vector in which the expression of the reporter 
gene (puromycin resistance) is driven by the spleen focus-forming virus promoter 
(SFFVp). An shRNA hairpin directed against an irrelevant gene (luciferase) is cloned 
downstream the reporter gene and it is expressed in the context of the miR-30 
surrounding genomic sequences126. We also used a version of this vector (pAGM-
shLuc) that contains GFP instead of the puromycin resistance as a reporter gene. 
 
 
 
Figure I: schematic representation of the pAPM-shLuc vector 
 
2) pAPM-miR146a: this vector is identical to pAPM-shLuc except that the miR-
146a murine genomic sequence is cloned downstream the reporter gene.  
 
 
 
 
Figure II: schematic representation of the pAPM-miR146a vector 
 
HEK 293T cells transfection and transductions of BMMCs 
A transfection of three plasmids (two packaging and one transfer vector) was 
used to generate recombinant viral particles. The detailed method is described in ref 
124. Briefly, the following cocktail was prepared in Opti-MEM: 5µg of pMD2G, 
15µg psPAX and 20µg of lentiviral vector. After addition of 90 µl of 1mg/ml 
polyethylenimine pH 7.6 (Polyscience, Inc), the solution was incubated for 10min at 
RT and then added to the cells. Medium was replaced 12-16h after transfection and 
viral particle-containing supernatant was collected 24 and 48h later. Viral particles 
SFFVp  PUROR miR30 miR30 
 SFFVp PUROR 
1
miR146a 
2
 miR146a 
Sh-luc 
miR146a 
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were concentrated by ultra centrifugation on a sucrose gradient (4°C, 2h at 24’300 
rpm) in a Beckman Coulter Optima LE-80 K ultracentrifuge and SW-32-Ti buckets 
rotor. 
1x106 BMMCs were transduced with lentiviral particles produced as described 
above at a multiplicity of infection (MOI = Transduction Units/cell) of about 100. The 
transduction efficiency of MCs under these conditions is usually around 50%. After 
transduction cells were either selected with 2µg/ml puromycin for 2 days or sorted for 
GFP expression, depending on the reporter used.  
 
RNA extraction and RT-PCR 
 Total RNA was extracted using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions. To analyse miRNA expression, qRT-PCR was performed 
using a miRNA reverse transcription kit and TaqMan miRNA assays from Applied 
Biosystems, following exactly the manufacturer’s instructions. To analyse Bcl2 
family member expression, total RNA (1µg) was reverse transcribed using the iScript 
kit (Bio-Rad), before PCR amplification with the primers listed below. β-actin was 
used as an endogenous control. 
Bcl2 = FW  5’-TTCGCAGCGATGTCCAGTCAGCT 
   RV  5’-TGAAGAGTTCTTCCACCACCGT 
A1 = FW 5’-GATTGCCCTGGATGTATGTGCTTA 
   RV   5’-AGCCATCTTCCCAACCTCCATTC 
Bcl-XL= FW 5’-CAGTGCCATCAATGGCAACCCATC 
    RV 5’-CGCAGTTCAAACTCATCGCCTGC 
BAX =   FW 5’-ACTGGACAGCAATATGGAGCTG 
   RV  5’-CCCAGTTGAAGTTGCCATCAG 
 
Degranulation assay 
 5x104 BMMCs were resuspended in 50µL OptiMEM, 1% FBS and stimulated 
for 1h with either PMA and ionomycin or IgE-antiDNP and DNP-HSA. The 
supernatant was collected and the cell pellet was lysed in 50µL of 0.5% Triton-X100 
in OptiMEM, 1% FBS. The β-hexosaminidase substrate (4-nitrophenyl N-acetyl-β-D-
 84 
glucosaminidate (Sigma)) was then added to both the cell lysates and supernatants 
(50µL of 3.8mM solution). After incubation for 2h at 37°C, the reaction was stopped 
with 90µL glycine 0.2M, pH 10.7, and the absorbance was read at 405nm. The 
percentage of degranulation was calculated as the ratio between the absorbance of 
supernatants and the total absorbance of supernatants and cell lysates127. 
 
Thymidine incorporation assay 
1x105 BMMCs were stimulated as described above for 24h, and in the last 16 
h of incubation, 1 µCi/ml [3H]thymidine (GE Healthcare) was added. Cells were then 
collected with a BUCHER (BIOTEC) and levels of thymidine incorporation evaluated 
with a scintillation beta-counter (MicroBeta TRULUX 1450-021). 
Intracellular cytokine staining 
1x106 BMMCs were stimulated with either PMA and ionomycin, IgE and 
antigen complexes or LPS for 3h. In the last 2 hours of incubation, 10µg/ml brefeldin-
A was added to the cultures. The cells were fixed for 10min with 4% 
paraformaldehyde at RT and permeabilized in 0.5% saponin/ 1% BSA. After a short 
pre-incubation with 0.5µg/µl of FcBlock (eBioscience) cells were stained with 
directly conjugated anti-cytokine fluorescent antibodies (eBioscience) for 30min at 
RT, prior washing and FACS analysis.  
 
Analysis of apoptosis 
For cell death analysis, cells were washed extensively to remove all IL-3 and/ 
or SCF from the culture medium and were either left resting or were stimulated with 
IgE and antigen. Apoptosis was evaluated at different time points using the Annexin-
V-PE apoptosis kit (BD-Pharmingen) following the manufacturer’s instructions. 
 
Adoptive transfer, peritoneal lavages, and passive cutaneous anaphylaxis 
For adoptive transfer experiments, BMMCs were differentiated from C57Bl/6 
and p50KO mice as described above and injected either intradermally (i.d.) (106 
cells/mouse) in the ear pinna or in the peritoneal cavity (i.p.) of mice lacking MCs 
(C57Bl/6Kit W-sh/W-sh from Jackson Laboratory)8. Tissue reconstitution was allowed to 
proceed for 4 weeks for i.d. injections and 6 weeks for i.p. injections. 
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For passive cutaneous anaphylaxis reactions, four weeks after i.d. 
reconstitution, transferred MCs were sensitized by intradermal injection in the ear 
pinna of IgE-antiDNP (1.5 µg/ml), and than challenged 24h later with intravenous 
injection of 250 µg/ml DNP-HSA and 5mg/ml Evans-blue in 250µl PBS to assess 
extravasation. Mice were sacrificed 30min after challenge and the blue ear intensity 
(measuring extravasation and therefore the extent of MC activation) was analysed by 
spectrophotometer (OD=600) after extraction from the tissues by incubation in 
formamide at 63°C O/N. Presence of MCs in the reconstituted ears was assessed by 
embedding the tissues in paraffin and performing toluidine-blue staining on the tissue 
slides, which were then manually counted at the microscope for the presence of MCs. 
Peritoneal lavages of either WT C57Bl/6 mice, p50KO mice or C57Bl/6Kit W-
sh/W-sh mice reconstituted with in vitro differentiated WT or p50KO MCs, were 
performed by injecting 2-3mL of PBS in the peritoneal cavity of the animal and 
recovering as much liquid as possible after extensive washing. The total number of 
recovered cells was assessed by manual counting and was normalized to the volume 
recovered, while percentage of MCs was evaluated by surface staining and FACS 
analysis for cells expressing Kit and FcεRIα. 
 
Western Blots and Immunofluorescence staining 
Total protein extracts for Western blot were prepared by direct lysis of the 
cells in Laemmli sample buffer and boiling for 10min. Samples were run on 12% 
SDS-polyacrylamide gels and immune-detection was performed with NF-kB p50 
antibodies (NLS, sc-114, Santa Cruz Biotechnologies), TRAF6 H-274 antibodies (sc-
7221, Santa Cruz Biotechnologies) and β-Tubulin H-235 antibodies (Santa Cruz 
Biotechnologies) as a loading control. Quantification was performed by ImageQuant 
LAS 4000.  
Tissue slides of paraffin-embedded organs from WT and p50KO mice were 
kindly provided by Antonio Sica, Istituto Clinico Humanitas (Rozzano, Italy), de-
paraffinized in xylol and rehydrated with decreasing concentrations of ethanol. 
Antigen retrieval was performed with an antigen retrieval solution (pH 6.1, Dako) for 
30 min at 95°C. After blocking with serum–free blocking agent (Dako) for 10 min at 
RT, tissue sections were incubated over-night with 2µg anti-MC tryptase (FL-275, 
Santa Cruz Biotechnologies). After extensive washes, slides were then incubated for 
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30 min with an anti-rabbit AlexaFluor 594 secondary antibody (Invitrogen) and 
mounted with a DAPI-containing mounting medium. Images were captured with 
Nixon Eclipse E800 and analyse with the Openlab software (Improvision).  
 
Hematopoietic stem cell differentiation 
Bone marrow was harvested by flushing the femurs and tibias from young 
adult mice (4 to 8 weeks). Murine hematopoietic stem cells (HSCs) were enriched by 
FACS-sorting Lin- Kit+ ScaI+ cells and plated in 96-wells plate by limiting dilution 
(1 and 5 cells/well) in the presence of IL3. After three weeks the surviving colonies 
were counted and analysed for the expression of the following surface markers: 
FcεRIα, Kit, Mac-1 and Gr-1, in ordere to assess MC, macrophage and granulocyte 
differentiation.  
 
Statistical analysis 
 Results are expressed as a mean with the standard deviation. Comparisons 
were made using the unpaired t-test and the GraphPad Prism Software. 
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Results 
- MCs lacking p50 can be differentiated in vitro and are morphologically similar 
to control cells. 
To assess whether MCs could differentiate normally even in the absence of 
p50, bone marrow from p50KO and control animals was cultured in the presence of 
IL-3 and/or SCF for at least 3 weeks (Figure 1A). During differentiation (between 
week 2 and 3) we observed a slightly reduced percentage of differentiated cells in 
cultures from p50KO bone marrow compared to controls, however at the end of the 
differentiation period (between week 3 and 4), p50KO MCs were homogenously 
differentiated and looked phenotypically normal. Specifically, p50KO and WT MCs 
expressed similar levels of FcεRI and Kit (Figure 1B, top), as assessed by surface 
staining, and showed comparable morphology and presence of cytoplasmic granules 
upon toluidine blue staining (Figure 1B, bottom). To assess proliferation, we 
performed a thymidine incorporation assay in resting and stimulated conditions, and 
found that p50KO MCs proliferated similarly to the controls also in response to IgE 
crosslinking, which normally stimulates MC proliferation (Figure 2A). Having 
established that p50KO cells could differentiate and proliferate normally even in 
response to antigen, we evaluated their ability to perform their effector functions 
(degranulation, cytokine production) in response to different stimuli, such as PMA 
and ionomycin, IgE-Ag complexes and LPS. To assess the extent of MC 
degranulation, we measured the release of β-hexosaminidase, an assay widely used to 
characterize cellular components and mechanisms involved in stimulated exocytosis, 
including those initiated by crosslinking of IgE receptors on MCs. As expected, since 
this is not supposed to be an NF-kB-dependent process, p50KO MCs degranulated 
normally in response to either IgE crosslinking or PMA and ionomycin stimulation 
(Figure 2B). We therefore investigated more specifically possible effects on NF-kB-
dependent genes in cells lacking p50. In fact, NF-kB regulates the expression of 
several hundred genes, including IL-13, TNF-α and IL-6, all cytokines produced at 
high levels by activated MCs128. We therefore stimulated WT and p50KO cells with 
either LPS or IgE crosslinking, and assessed expression of IL-6, TNF-α and IL-13 by 
intracellular cytokine staining (Figure 2C). MCs lacking p50 showed a modest 
reduction in cytokine production in response to both LPS and IgE-Ag complexes. 
This reduction was statistically significant for IL-13, which is the cytokine necessary 
 88 
and sufficient for asthmatic responses in models of experimental asthma129.  While 
this defect in IL-13 production in the absence of p50 may contribute to the asthma 
resistant phenotype observed in p50KO animals119, it is however rather modest and 
probably not sufficient to explain the complete lack of airway hyper-resistance and 
eosinophilia of these mice, which therefore remains predominantly Th2-dependent119. 
 
- MCs lacking p50 showed a marked increase in their ability to survive apoptosis 
in response to withdrawal of essential cytokines 
NF-kBp50 is also implicated in cell survival130/131. Overexpression of p50 has 
been observed in a number of human cancer including non-small cell lung carcinoma, 
colon cancer, prostate cancer, breast cancer, bone cancer and brain cancer98-100. The 
rearrangement of p50 gene, however, has been identified only in certain acute 
lymphoblastic leukemias122. We therefore investigated whether p50KO MC are 
significantly affected in their ability to survive in response to IgE crosslinking and/ or 
withdrawal of essential cytokines. In order to do this, MCs cultured in the presence of 
IL-3 or IL-3 and SCF were extensively washed to remove the survival cytokines and 
then cultured in the absence of IL-3 or IL-3 and SCF for several days, with of without 
concomitant stimulation with IgE-Ag complexes. Indeed, IgE crosslinking has been 
shown to be an important survival factor for MCs, by favouring induction of pro-
survival factors such as A1132. Cell death was assessed daily by Annexin-V staining, 
and in all conditions tested p50KO cells showed consistently an increased ability to 
survive in response to withdrawal of essential cytokines compared to the controls 
(Figure 3A-B). As expected, stimulation with IgE partially rescued the cell death of 
control cells, but once again, this effect was even more pronounced in the absence of 
p50 (Figure 3C). NF-kB has been detected in most cell types, and specific NF-kB 
binding sites have been identified in promoters and enhancers of a big number of 
inducible genes involved in cell death, including Bcl-2, A1 and Bcl-xL133. In 
particular, Bcl-2 is a known regulator of IL-3 withdrawal-dependent apoptosis in 
MCs134, while A1 is a specific regulator of IgE-dependent survival in MCs132. We 
therefore investigated whether Bcl-2, A1 and other pro- and anti-apoptotic genes may 
be involved in the observed increased survival of p50KO MCs. To this end p50KO 
MCs and control cells were either left resting or were stimulated for 24h with IgE and 
antigen or LPS, after which total RNA was extracted and a qRT-PCR was performed 
to assess levels of expression of pro- and anti-apoptotic gene candidates.  
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Interestingly, both Bcl-2 and A1 were upregulated in cells lacking p50. Such 
up-regulation was already present at basal levels, but it became even more evident 
upon stimulation with IgE-DNP or LPS (Figure 4A-B). Another pro-survival factor, 
Bcl-XL, was slightly reduced (about 18%) in p50KO cells (Figure 4C), while the 
pro-apoptotic gene Bax was downregulated (Figure 4D). Since Bcl-2 and especially 
A1 were already shown to be involved in regulating MC survival132, it is likely that 
the overall net increase of pro-survival factors is at the basis of the observed enhanced 
survival of p50KO cells. Our data therefore show that p50KO cells are able to survive 
much better in response to a variety of stimuli, and that such enhanced survival is 
likely due to a profound alteration in the balance between pro- and anti-apoptotic 
factors, with the latter being overall favoured. 
 
-MiR146a regulates mast cells survival 
Since miRNAs are known to be involved in the regulation of a variety of cell 
functions, and p50KO cells showed altered cytokine production and survival in 
response to stimulation, we assessed whether miRNAs might also be involved in these 
processes. We assessed in particular expression of two miRNAs (miR-146a and miR-
221) that we already knew to be inducible in MCs and to be dependent on NF-kB 
activation121 .To assess whether miRNA expression was altered in the absence of p50, 
p50KO and control MCs were either left resting or were stimulated with PMA and 
ionomycin for 24h, after which total RNA was extracted and levels of miR-146a and 
miR-221 were assessed by qRT-PCR. Levels of miR-27a were also measured as a 
control of a miRNA that should not change in MCs in response to stimulation. 
Strikingly, p50KO MCs showed strongly reduced expression of miR-146a, but not of 
miR-221 or miR-27a, in response to PMA and ionomycin stimulation (Figure 5A). 
Interestingly, in the absence of p50, MCs were unable to induce miR-146a expression 
in all conditions tested, including IgE-Ag or LPS stimulation for various time points 
(Figure 5B-C), indicating that p50 is indeed absolutely required for the expression of 
this miRNA. In contrast, expression of miR-221, also known to be inducible upon 
MC-stimulation in a NF-kB-dependent manner121, was comparable between p50KO 
cells and controls, indicating that for miR-221, but not miR-146a expression, the lack 
of p50 can be compensated by the presence of other NF-kB subunits. 
Since p50KO cells are completely unable to induce miR-146a expression, and it is 
known that miR-146a is itself a regulator of NF-kB activation83, we asked whether at 
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least part of the phenotype observed in MCs in the absence of p50 could be due to the 
inability of these cells to induce miR-146a expression. Therefore, we forced 
expression of miR-146a by lentiviral transduction of WT and p50KO MCs. 
Importantly, we did not overexpress miR-146a, but rather achieved physiological 
levels of expression that were comparable or lower to the levels of endogenous 
expression induced by the cells upon stimulation (compare Figures 6A and figure 
5A and 5C). To assess whether our lentivirally-derived miR-146a was also 
biologically functional, we assessed levels of expression of the known miR-146a 
target, TRAF683. In order to do this, p50KO MCs and controls were transduced with 
either a control vector (shLuc, expressing an irrelevant hairpin), or miR-146a. After 
selection of the transduced cells, cells were lysed and TRAF6 expression evaluated by 
Western blot (Figure 6B). Such analysis showed a significant decrease in TRAF6 
expression whenever miR-146a was expressed, in both p50KO and control cells. We 
therefore assessed whether miR-146a expression led to altered survival in MCs, 
somehow mimicking a general reduction in NF-kB activation. Cell death was assessed 
in cells expressing miR-146a by Annexin-V staining, and in these conditions MCs 
transduced with miR-146a showed consistently an increased ability to survive 
compared to the controls, even when cultured in full medium, supplemented with all 
survival factors (Figure 6C). Interestingly, forced miR-146a expression led to a 
modest reduction of Bcl-2 expression in p50KO cells, indicating that although miR-
146a works in the same pathway as p50, forced miR-146a expression is not sufficient 
to completely compensate and revert the phenotype induced by the lack of p50 
(Figure 6D). Along the same line, we did not observe any particular effect of miR-
146a on IL-6 and TNFα expression, cytokines that were also modestly altered, even 
by the absence of p50 (Figure 6E).  
 
- MCs can be tolerized regardless of p50 expression.  
MiR-146a is known to regulate LPS-tolerance in macrophages135. Since we 
found that p50KO cells cannot induce miR-146a in response to LPS, we assessed 
whether p50KO MCs were impaired in their responses to sequential stimulations with 
LPS. In order to do this, p50KO and control cells were either left unstimulated 
(‘medium’ sample, M/M), treated with LPS for 3h (‘stimulation’ conditions), which 
was then replaced by normal culture medium (L/M), treated with LPS for 20h (also, a 
stimulation condition, M/L), or treated repeatedly with LPS (‘tolerance’ conditions) 
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4h+20h (L/L) or even 3h+24h+48h (L/L/L). The expression of IL-6 and TNF-α was 
assessed by intracellular cytokine staining (Figure 7A), while in a parallel experiment 
the expression of miR-146a was evaluated by qRT-PCR (Figure 7B).  
Interestingly, MCs lacking p50 showed a reduction in cytokine production in response 
to acute LPS stimulation while they became unresponsive to subsequent stimulations 
with LPS similarly to control cells. This result indicates that p50KO MCs have 
reduced activation in response to LPS but similar tolerance ability. Moreover, in the 
absence of p50, MCs were unable to induce miR-146a expression also upon multiple 
stimulations, indicating not only that p50 is absolutely required for the expression of 
this miRNA even in tolerized condition, but also that in these cells miR-146a is not 
required for LPS unresponsiveness (Figure 7B). 
 
- Immunofluorescence analysis shows elevated numbers of MCs in the tissues of 
p50KO mice 
To assess whether the increased survival observed in p50KO MCs in vitro 
might have an effect also in the normal homeostasis of MCs in vivo, we investigated 
the numbers of MCs in the tissues and peritoneal cavity of mice lacking p50. 
Peritoneal lavages of WT and p50KO mice were performed and total cell numbers 
and percentages of MCs were assessed by surface staining and FACS analysis of 
FcεRIα+ Kit+ cells. The number of MCs recovered from the peritoneal cavity in the 
absence of p50 was significantly augmented compared to control animals (Figure 
8A). A similar increase in the percentage of MCs was also observed in the intestinal 
tissues of p50KO animals, as assessed by immunofluorescence staining using two 
different MC markers (tryptase and Kit) and blind counting (Figure 8B). These 
results indicate that there is an overall increase of the number of MCs in the tissues of 
p50KO animals, without however any alterations in the homing properties of these 
cells. Indeed, MCs were found in all tissues and compartments where they are 
normally found also in control animals, but not in organs, like the spleen or liver, 
where MCs are not usually found (not shown).  
We hypothesized that such increase in MC numbers could be due to the 
enhanced survival of p50KO MCs in the tissues. To test whether there was a cell-
intrinsic ability of p50KO cells to repopulate tissues in higher numbers, we performed 
adoptive transfer experiments of in vitro differentiated p50KO MCs and control cells 
into MC-deficient recipient mice (C57Bl/6 KitW-sh/W-sh). Adoptive transfer and MC 
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reconstitution was performed either intradermally in the ear pinna (Figure 9A-C) or 
in the peritoneal cavity (Figure 9D). First, we performed passive cutaneous 
anaphylaxis experiments in which MCs in the ear were sensitized with IgE and then 
challenged with antigen in the presence of Evans blue dye to measure extravasation 
induced by the release of vasoactive mediators upon MCs degranulation. As expected 
since p50KO MCs also degranulated normally in vitro (as shown in figure 2B), in 
vivo p50KO MCs responded to IgE activation to levels comparable to controls 
(Figure 9A and B). Reconstitution of the ear pinna with MCs was confirmed by 
toluidine blue staining of paraffin-embedded ear sections (Figure 9C). Manual 
counting of MCs in ear sections, as well as FACS analysis of MC reconstitution of the 
peritoneal cavity (Figure 9C and figure 9D respectively), showed that p50KO MCs 
were able to reconstitute the tissues at levels that were similar or just slightly lower 
compared to control cells. However, in adoptive transfer experiments, in vitro 
differentiated MCs did not repopulate tissues at a higher percentage compared to WT 
cells, and therefore did not recapitulate in a cell-autonomous manner the observation 
that in the tissues of p50KO animals there is a significant increase of MCs. This could 
be due to the fact that the adoptive transfer of fully differentiated, resting cells does 
not activate the NF-kB pathway and we were therefore unable to observe any 
difference between WT and KO cells. It is also possible that in an in-vivo situation 
where IgE are present, there is less of the difference between the ability of WT and 
KO cells to survive, as we could show in in vitro experiments in cells stimulated with 
IgE-Ag complexes (Figure 3C).  
One other possibility would also be that in vivo there is an increased 
differentiation to MCs from p50KO hematopoietic progenitors that leads to an 
unbalanced homeostasis of MCs with increased numbers in the tissues. To evaluate 
the latter possibility we set up an in vitro differentiation system in which the fraction 
of murine bone marrow containing hematopoietic stem cells (HSCs) was enriched by 
FACS-sorting of Lin-Kit+ ScaI+ cells. These cells were then plated in 96-well plates 
at one- or five-cells/ well, and allowed to differentiate in MC conditions (presence of 
IL-3) for three weeks. After this time total surviving colonies were counted and 
analysed for the expression of FcεRIα, Kit, Mac-1 and Gr-1, to assess percentages of 
colonies that contained MCs (FcεRIα+ Kit+), granulocytes (Gr-1+) and macrophages 
(Mac-1+). As shown in Figure 10, p50KO and WT HSCs were comparable in their 
ability to give rise to MCs and other types of myeloid cells, when assessed as 
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percentage of specific colonies over the total. However, when we counted the overall 
number of myeloid colonies that were able to grow from p50KO HSC cells gave rise 
to 1,9-fold more colonies indicating an increased ability of p50KO HSC to 
differentiate to myeloid cells. 
Overall, our findings indicate that p50 acts both at the level of HSCs to favour 
myelopoiesis and also in a cell-autonomous manner in differentiated MCs to favour 
survival especially in response to withdrawal of essential cytokines and in response to 
antigenic stimulation. This novel molecular network comprising NF-kB p50 and miR-
146a and regulating MC survival and tissue homeostasis may have important 
implications for our understanding of the physiologic MC expansion and activation 
occurring during responses to helminths or allergens, and possibly in MC hyper-
proliferative disorders such as systemic mastocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 95 
Discussion 
 NF-kB is involved in regulating many aspects of cellular activity, in stress, 
injury and especially in pathways of the immune response. Known inducers of NF-kB 
activity are highly variable and include, among others, TNFα, interleukin 1-beta (IL-
1β), LPS136/137. Moreover, NF-kB is involved in many aspects of cell growth, 
differentiation and proliferation via the induction of other transcription factors such as 
c-myc, ras and p53137.  
Here, we found that in the absence of one specific NF-kB family member, 
p50, MCs showed an increased ability to survive in response to a variety of signals.  
The underlying mechanism for such increased survival involved increased expression 
of pro-survival factors such as Bcl2 and A1, as well as reduced expression of pro-
apoptotic factors such as Bax and miR-146a, which in this context acted as a pro-
apoptotic factor and as a modulator of NF-kB signalling by targeting TRAF6. 
Activation of NF-kB must be a tightly regulated event. In normal cells, NF-kB 
becomes activated only after the appropriate stimuli, and upregulates the transcription 
of its target genes. However, regulatory mechanisms must be in place to return NF-kB 
to its inactive state. NF-kB activation is therefore an inducible and transient process. 
 In Figure 11 we propose a model for the role of miR-146a and NF-kB p50 in 
regulating MC survival and activation. In MCs, NF-kB activation can occur as a result 
of FcεRI crosslinking or TLR4 engagement. In normal conditions this leads to nuclear 
translocation of p65-p50 heterodimers that activate transcription of both anti-
apoptotic factors (such as Bcl2 and A1) as well as of pri-miR-146a, which helps 
shutting down NF-kB activation in a negative feedback loop (panel A). Our data 
showed that in the absence of p50 not only some survival factors are strongly 
upregulated (Bcl-2 and A1 predominantly), but also the negative feedback of NF-kB 
activation is lost, as miR-146a cannot be expressed (panel B). The fact that in the 
context of NF-kB activation and MC survival miR-146a acts as a pro-apoptotic factor 
is highlighted by the finding that forced expression of miR-146a (therefore artificially 
increasing the negative part of the network) led to increased cell death (panel C). 
What remains to be investigated is the mechanism by which p50 may act as a 
positive regulator of some genes (including miR-146a, for which p50 is essential), and 
as a negative regulator of other genes (namely Bcl-2 and A1, whose expression is 
increased in both basal and activated conditions). One possible explanation could rely 
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on a difference in the binding activity of NF-kB at the promoters of these specific 
genes: our current working hypothesis is that p50 homodimers may negatively 
regulate expression of Bcl-2 and A1 in resting conditions, which is overcome by other 
activating heterodimers upon activation. MiR-146a expression on the other hand, 
remains exquisitely dependent on p50 in all conditions. 
Therefore, further experiments will be necessary to assess the molecular 
mechanism responsible for the pro-survival effect observed in a p50 KO background. 
The difficult task of elucidating the exact mechanisms of action of p50 may be due to 
this key transcription factor’s ability to act as both a transcriptional repressor when 
homodimerized and a transcriptional activator when heterodimerized with p65. 
Indeed, negative regulation of genes by p50 homodimers has been reported to 
reduce expression of TNFα by tolerant macrophages138. Interestingly, macrophages 
from p50KO mice were resistant to tolerance induced by LPS 138, and overexpression 
of p50 in the presence of constant amounts of p65 inhibited LPS-induced transcription 
of the TNF-α promoter, thus mimicking LPS-induced tolerance130/140. LPS-induced 
tolerance in human monocytes is also associated with a predominance of p50-p50 
homodimers binding to the TNF-α promoter, resulting in reduced TNF-α production 
140/141. Moreover, it is knows that different NF-kB binding sites can have different 
binding affinities for the different family members homo- and heterodimers141.  
Finally, our preliminary data on hematopoietic differentiation from p50KO 
and C57Bl/6 bone marrow-derived HSCs showed a comparable ability to generate 
MCs and other types of myeloid cells in terms of relative percentages. In other words, 
the percentage of MC colonies over the total number of colonies observed was similar 
in the p50KO and in control cells. However, p50KO HSCs were able to produce 1.9- 
fold more myeloid colonies compared to the control, suggesting that in these mice 
myeloid differentiation may be overall increased, a hypothesis that we will continue 
to investigate in future experiments.  
Although still completely speculative, an interesting aspect of our findings is 
also related to aging. Indeed, the activation of NF-kB signaling is also associated with 
the aging process142. Cellular aging involves a progressive accumulation of damaged 
and defective cellular components, which cause a decline in physiological function of 
tissues and body fitness. Interestingly, aging cells show an increased resistance to 
apoptotic stimuli and increased Bcl2 expression143. Moreover, old mice show altered 
HSCs differentiation with increased myelopoiesis142. Since these phenotypes are 
 97 
similar to the ones we observed in p50KO mice, it is tempting to speculate that the 
absence of p50 may also lead the cells towards a premature aging program. This 
aspect will be the topic of future work.  
In conclusion, our findings indicate that p50 acts both at the level of HSCs to 
favour myelopoiesis and also in a cell-autonomous manner in differentiated MCs to 
decrease cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
Figure Legends 
 
Figure 1: MCs can be differentiated from murine bone marrow even in 
the absence of p50 A) BMMCs were cultured in presence of IL-3 with or without 
addition of SCF (10ng/ml) and the percentages of FcεRIα+ Kit+ cells (differentiated 
MCs) was assessed weekly. Each dot represents one independent experiment. B) (Top 
panel) Surface staining of fully differentiated MCs, showing comparable expression 
of FcεRIα and Kit between WT and p50KO cells. (Bottom panel) Toluidine blue 
staining of cytospins of differentiated WT and p50KO MCs, showing overall similar 
morphology and similar content of cytoplasmic granules. 
 
Figure 2: p50KO MCs responses to a variety of stimuli. A) The ability of 
MCs to proliferate at steady state and in response to stimulation was assessed by 
thymidine incorporation assay. p50KO and control BMMCs were either left resting or 
were stimulated for 24h with IgE-Ag complexes or LPS prior addition of 3H-
thymidine. Shown is one representative experiment out of three B) To assess MC 
degranulation in response to acute stimulation, BMMCs were either left untreated or 
were stimulated with IgE-Ag complexes or LPS for 1h prior measurement of β-N-
acetylhexosaminidase release in degranulation assay. Shown is one representative 
experiment out of three. C) To assess cytokine production, cells were stimulated with 
IgE-Ag complexes or LPS for 5-6h and the productions of IL-6, TNF- α and IL-13 
was analysed by intracellular cytokine staining. Each dot in the graphs represents one 
independent experiment. 
 
Figure 3: BMMCs lacking p50 showed a marked increase in their ability 
to survive apoptosis in response to withdrawal of essential cytokines. A-B) 
BMMCs were cultured with IL-3 or IL3+SCF prior removal of IL-3 or SCF for 4 and 
6 days. Cell death analysis was performed by Annexin-V staining. The graph in panel 
A) shows the mean of four independent experiments, while panel B) is representative 
of at least two experiments. C) Same experiment as in panel A, except that cells were 
either left unstimulated or were stimulated with IgE and antigen at the time of initial 
IL-3 withdrawal. Shown is one representative experiment out of at least two.  
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Figure 4: Expression levels of some pro- and anti-apoptotic NF-kB 
depending genes. p50KO MCs and control cells were either left resting or were 
stimulated for 24h with IgE-Ag complexes or LPS. Total RNA was extracted and a 
qRT-PCR was performed to assess the expression levels of the pro- and anti-apoptotic 
gene candidates Bcl2, A1, Bcl-XL and BAX. Shown is one representative experiment 
out of at least four for Bcl2, A1 and BAX, and at least three for Bcl-XL.  
 
Figure 5: MiR-146a is not expressed in p50KO MCs. A) Differentiated 
BMMCs were either left resting or were stimulated with PMA and ionomycin (P+I) 
prior analysis of the expression of three different miRNAs (miR-146a, miR-221 and 
miR27a) by qRT-PCR. SnoRNA 202 was used as endogenous control. Shown is one 
representative experiment out of three. B) WT and p50KO BMMCs were stimulated 
for the indicated times with IgE-Ag complexes, and expression levels of miR-146a 
were assessed by qRT-PCR. Shown is one representative experiment out of at least 
three. C) Same as in B) except that cells were stimulated with LPS and analysed at 
different time points.  
 
Figure 6: MiR-146a regulates MCs survival. A) WT BMMCs were 
transduced with lentiviral vectors pAPM-shLUC (as a control) and pAPM-miR146a. 
MiR-146a expression level in transduced cells was assessed by qRT-PCR. B) TRAF6 
expression levels in WT and p50KO BMMCs transduced with pAPM-shLUC and 
pAPM-miR146a were analysed by Western blot. β-tubulin was used as loading 
control and quantification was performed by LAS 4000. Representative of two 
independent experiments. C) BMMCs transduced as in A) were analysed for levels of 
apoptosis by annexin-V staining. D) Total RNA from BMMCs transduced as in A) 
was extracted and levels of Bcl-2 expression were assessed by qRT-PCR. β-actin was 
used as endogenous control. Shown is one representative experiment out of three. E) 
BMMCs transduced as in A) were stimulated with LPS and intracellular cytokine 
staining was performed to assess expression of the indicated cytokines. Each dot 
represents one independent experiment. 
 
Figure 7: Tolerization of BMMCs upon LPS stimulation and expression 
level of miR-146a A) WT and p50KO BMMCs were either left unstimulated 
(medium only, M/M), treated with LPS for 3h (L/M), treated with LPS for 20h (M/L), 
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treated repeatedly with LPS for 3h+20h (L/L) or for 3h+20h+24h (L/L/L). After 
stimulation an intracellular cytokine staining was performed to assess expression of 
the indicated cytokines. Representative of at least four independent experiments B) 
WT and p50KO BMMCs were treated as in A) and the expression level of miR-146a 
was assesses by qRT-PCR.  
 
Figure 8: Peritoneal lavage and immunofluorescence analysis show 
elevated numbers of MCs in the tissues of p50KO mice. A) Peritoneal lavage was 
performed on WT and p50KO animals, and the resulting cells were analysed for Kit 
and FcεRIα expression by surface staining. The top graph shows one representative 
staining, while the compiled results of several mice are plotted in the bottom graph. 
At least 7 animals per group were analysed. B) Immunofluorescence staining using 
two different MC markers (tryptase or Kit) and blind counting on intestinal tissues of 
p50KO animals and WT (top). At least 10 fields per tissue were observed and counted 
blindly (the operator counting the cells was not aware of the type of sample, which 
was coded). The percentage of tryptase + or Kit+ cells are plotted in a histogram chart 
(bottom). 
 
Figure 9: p50KO MCs are able to reconstitute the tissues similarly to the 
controls. BMMCs were differentiated from C57Bl/6 and p50KO mice and injected 
either intradermally (i.d.) in the ear pinna or in the peritoneal cavity (i.p.) of 
C57Bl/6Kit W-sh/W-sh mice. A) Passive cutaneous anaphylaxis. After 4 weeks of i.d. 
reconstitution of MCs in the ear pinna, mice were sensitized with i.d. injections of 
IgE-anti-DNP and challenged intravenously 24h later with DNP-HSA together with 
Evans blue dye to measure extravasation. Blue color appeared only in the presence of 
activated MCs. The ‘empty’ ear received no MC injection and didn’t become blue, 
while the control, WT and p50KO ear all became blue as an index of MC activation. 
B) Compiled results of passive cutaneous anaphylaxis experiments in WT and p50KO 
ears. Blue ear intensity was analysed by spectrophotometer (OD=600). Each dot 
represents one ear. C) Effective ear reconstitution was evaluated by embedding in 
paraffin ‘empty’ (C57Bl/6Kit W-sh/W-sh) ears and ears reconstituted with p50KO or WT 
(not shown) MCs. Staining of paraffin-embedded ears was performed by toluidine 
blue. Shown is one representative experiment. MCs present in reconstituted ear stain 
purple (arrows) as compared to other cell types that stain blue. Imaging was 
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performed with a Nikon Eclipse E800 microscope. D) C57Bl/6Kit W-sh/W-sh mice were 
reconstituted i.p. with in vitro differentiated WT or p50KO MCs. Six weeks after i.p. 
injections, peritoneal lavages were performed and the percentage of MCs was 
evaluated by Kit and FcεRIα surface staining. Each dot in the graph represents one 
individual mouse. 
 
Figure 10: p50KO animal shows increased myeloid differentiation 
activity. Lin- Kit+ ScaI+ cells (enriched in HSCs) from bone marrow of WT and 
p50KO animals were plated in 96-wells plate at 1 or 5 cells/well in the presence of 
IL3. After three weeks the surviving colonies were counted and analyzed for the 
expression of the following surface markers: FcεRIα, Kit, Mac-1 and Gr-1. The 
overall number of colonies (compared to the number of seeded wells) was 1.9-times 
higher in p50KO cells compared to WT. Individual colonies were analyzed for the 
presence of MCs (FcεRIα+ Kit+), macrophages (Mac-1+, Kit-, FcεRIα-, Gr-1-), 
granulocytes (Gr-1+, Mac-1-, Kit-, FcεRIα-). Plotted are the percentages of colonies 
over the total that contained either MCs alone (MC only), macrophages alone (Mac 
only), or mixed colonies (mixed). 
 
Figure 11: Summary of the role of p50 and miR-146a in NF-kB activation 
pathways. Hypothesis on the role of miR-146a, pro/anti survival factors and NF-
kBp50 subunit in regulating MC survival. A) In normal conditions, upon cell 
stimulation NF-kB enters the nucleus where it activates the expression of specific 
genes, leading to a physiological response. B) In the absence of p50, the upregulation 
of pro-survival genes (A1 and Bcl2) together with the impaired expression of the 
negative regulator miR-146a leads to increased survival. C) Forced expression of the 
negative regulator miR-146a leads to reduced activity of the entire pathway with 
increased cell death in WT cells, slight reduction of Bcl-2 expression levels, and 
partial compensation for the lack of p50.  
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Figure 6 : miR-146a and cell death 
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Figure 7: tolerization of BMMCs 
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Figure 10: BMMCs hematopoiesis 
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Chapter 3 
 
“MiR146a influences human T cell expansion and memory 
formation, but does not alter Th1/Th2 balance or cell death“ 
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Summary  
The development and propagation of an adaptive immune response to an 
invading pathogen is a highly orchestrated process that involves the precise regulation 
of cytokine expression, as well as the formation of an immunological memory. MiR-
146a is a known regulator of the immune system, with established roles in the 
regulation of both innate and adaptive immunity. However, little is known about its 
role in primary human T cells, and the role of miRNAs in the establishment of a 
memory phenotype is heavily under-investigated. Here, we found that miR-146a was 
expressed at high levels in the memory T cell compartment in both human and mouse. 
Importantly, expression of miR-146a in primary human T cells favored cell expansion 
in response to TCR triggering and reduced CCR7 expression, while showing no 
significant effect on cytokine production or cell death, pointing towards a role for this 
miRNA in regulating memory formation.  	
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Introduction 
Memory T cells can be broadly separated into central memory (TCM) that 
express the chemokine receptor CCR7 and recirculate through lymphoid organs, and 
effector memory (TEM) that lack CCR7 and preferentially home to non-lymphoid 
tissues
50
. Despite intense investigation, the requirements for the acquisition and 
maintenance of the memory phenotype have yet to be completely elucidated. MiR-
146a is a well-known regulator of the immune system
144
: it has an established role in 
regulating NF-kB activation and tolerance in innate immunity
83
, it acts as an 
oncosuppressor, and it modulates T regulatory (Treg) cell functions
87/89
. However, the 
role of miR-146a (and miRNAs in general) in the establishment of immunological 
memory remains almost completely unexplored. Here, we found that miR146a was 
expressed at high levels in the human memory compartment. Although expression of 
miR-146a in primary human T cells determined no significant effect on cytokine 
production and Fas-mediated cell death, miR-146a expression lead to increased 
expansion in response to TCR stimulation as well as to reduced expression of CCR7, 
pointing towards a role for this miRNA in human T cell activation and memory 
formation.  
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Material and methods 
Human T cell cultures 
Primary human T cells (CD4+ CD45RA– CD25– CD8–) were purified from 
peripheral blood and expanded as described145. After initial experiments, TH1 
(CCR6– CCR4– CXCR3+), TH2 (CCR6– CCR4+ CXCR3–) or TH17 (CCR6+ 
CCR4+ CXCR3–) subsets were used interchangeably as they gave identical results. 
Cells were stimulated with immobilized anti-CD3 TR66 (1-10µg/mL) and anti-CD28 
(2µg/mL), and expanded in medium containing 500U/mL rhIL-2. 
 
Mouse T cell cultures.  
Naïve CD4+ or CD8+ T cells were purified using beads (Dynal or Miltenyi 
Biotec) from spleen and lymph nodes of OT-II or C57Bl/6 mice, followed by sorting 
for CD62Lhi and CD44lo naïve cells. Cells were then activated with plate-bound anti-
CD3 (0.25µg/mL) and anti-CD28 (1µg/mL) for 48h in IMDM medium supplemented 
with 10% FBS, 1% penicillin-streptomycin, non-essential aminoacids, L-glutamine, 
50 µM β- mercaptoethanol and rhIL-2 (20U/mL; Peprotech). Cells were cultured in 
Th1/Th2 skewing conditions exactly as described88. Naïve, TEM and TCM cells were 
obtained ex-vivo from the spleen and draining lymph nodes of C57Bl/6 mice 
challenged sub-cutaneously with CFA/OVA. Cells were collected two weeks after 
challenge and they were sorted in the different subsets based on the expression of 
CD4, CD8, CD62L, CD44 and CD127. All animal studies were performed in 
accordance with the Swiss Federal Veterinary Office guidelines and were approved 
by the Dipartimento della Sanita’ e della Socialita’. 
 
Plasmids 
The control lentiviral vectors were previously described and expressed either a 
synthetic hairpin against the luciferase gene (shLuc) or a non-targeting hairpin (NT) 
or GFP alone125. The 394bp PCR fragment encompassing the pre-miR-146a hairpin 
plus ~150bp of surrounding genomic sequence was obtained from a BAC clone and 
cloned using standard cloning techniques. The TRAF6-luciferase reporter vector was 
generated by cloning in the pGL3-promoter vector 1439bp of the 3’UTR of murine 
TRAF6 (RefSeq NM_009424) encompassing 3 predicted miR-146 binding sites (as 
predicted by TargetScan73/74, http://www.targetscan.org) downstream a luciferase 
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reporter vector, using standard cloning-techniques. 
 
Transductions 
Lentiviral particles were produced exactly as described124 and added to 
primary T cell cultures with a multiplicity of infection of ~60. Jurkat T cells were 
transduced exactly as for primary human T cells, except that the vector used to 
express miR-146a contained the puromycin resistance gene (rather than GFP), and 
cells were therefore selected by culturing for several days in 10µg/mL puromycin. 
 
Intracellular cytokine staining.  
Cells were stimulated for 5h with 20nM PMA and 2µM ionomycin, with 
addition of brefeldin-A (10µg/mL, Sigma) for the last 2h prior permeabilization and 
staining146. 
 
qRT-PCR 
Total RNA was extracted using TRIzol reagent (Invitrogen). First-strand 
synthesis and qPCR were performed using a miRNA first-strand synthesis kit and 
TaqMan assays from Applied Biosystems. 
 
Apoptosis 
For death receptor-mediated apoptosis, 20ng/mL of anti-Fas antibody 
(BioLegend) were added to the cultures for ~18h. Levels of apoptosis were assessed 
by Annexin-V staining (BD Pharmingen). 
 
Luciferase reporter assays 
Jurkat cells were transiently transfected with 100ng of TK-Renilla plasmid 
(Promega), and 1µg luciferase reporter plasmid. Cells were transfected at room 
temperature by electroporation in serum-free medium with pulses at 270V, 960µF. 
Twenty-four hours after transfection, cells were stimulated with 2µM ionomycin and 
20nM PMA. Eighteen hours after stimulation, cells were harvested, and cell extracts 
were assayed for luciferase and Renilla activity using an automated luminometer and 
a dual-luciferase reporter assay system (Promega) following manifacturer’s 
instructions. Luciferase data were normalized to Renilla readings. Primary murine T 
cells were transiently transfected with the Amaxa nucleofactor with 100nM dsRNA 
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oligonucleotides and program X-01. 
 
Northern blots 
Northern blots were performed exactly as described88. Briefly, total RNA 
(25µg) was separated on 12–15% denaturing 8M urea-polyacrylamide gels in 0.5x 
Trisborate- EDTA (TBE) buffer. RNA was transferred on a Nytran SuPerCharge 
membrane (Schleicher & Schuell Microscience) via wet transfer in 0.5x TBE buffer at 
4°C, followed by cross-linking to the membrane in a UV Stratalinker (Stratagene). 
Membrane hybridization was performed overnight at 39°C with radiolabeled DNA-
oligo probes (complementary to the mature miRNA sequence as reported in the 
miRBase database58). Membranes were washed at 37°C, three times for 10min with 
2x SSC/0.1% SDS and once for 5min with 0.1x SSC/0.1% SDS. Band intensities 
were quantified using a PhosphorImager and Image-Quant 5.0 software (Molecular 
Dynamics). 
 
Cell cycle analysis 
DNA content in cycling cells was assessed by propidium iodide staining. 
Briefly, 1.106 cells were fixed in 70% ethanol for 45min on ice, followed by 
incubation for 30min at 37°C with 100µg/mL RNaseA and 40µg/mL propidium 
iodide. Cells were analyzed at the FACS immediately after staining. 
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Results 
 
- MiR-146a is consistently elevated in the CD4 and CD8 memory compartment in 
both human and mouse. 
Despite the growing importance of miR-146a in various immune processes, its 
role in human T cell function and in the establishment of immunological memory is 
still almost completely unexplored. Here, we found that expression of miR-146a was 
consistently elevated in the CD4 and CD8 memory compartment in both human and 
mouse (respectively Figure 1A and B). Increased miR-146a expression was observed 
in both TEM and TCM, although TEM cells showed consistently slightly elevated 
expression (Figure 1A and B), indicating that this miRNA may have a role in 
regulating T cell activation and/ or in the establishment of immunological memory. 
Indeed, miR-146a expression also increased upon acute stimulation of both human 
and mouse cells (Figure 1A right and B right).  
 
- Primary human T cells expressing miR-146a did not show alteration in Fas-
mediated cell death.  
In accordance with published data84, ectopic expression of miR-146a in Jurkat 
cells led to a mild reduction in Fas-mediated cell death (Figure 2A). To have this 
result, an artificial overexpression of miR-146a in Jurkat cells was performed with a 
lentiviral vector expressing both a puromycin reporter and miR-146a or a control 
vector. (Figure 2B Top). Moreover a northern blotting was assessed to proof the 
efficiency of the transduction, checking on the miR-146a expression levels in resting 
and stimulated cells. (Figure 2B Bottom). After a positive selection with puromycin, 
the levels of miR-146a were assessed (Figure 2C). Interestingly, we did not see any 
effect in proliferation in Jurkat cells (Figure 2D) or in T cells at early time-points 
after stimulation. To further investigate the role of miR-146a specifically in human 
lymphocytes, cells were transduced with a lentiviral vector expressing both a GFP 
reporter and miR-146a or a control vector (Figure 3A). After sorting, levels of miR-
146a expression were assessed by qRT-PCR (Figure 3B), and resulted to be overall 
comparable to the physiological levels of endogenous overexpression observed in 
human and mouse lymphocytes upon TCR stimulation (Figure 1A and B). However, 
we found that primary human cells expressing miR-146a did not show any significant 
 125 
alteration in Fas-mediated cell death (Figure 4A), with levels of CD95 that also 
remained comparable between miR-146a expressing cells and controls (Figure 4B). 
Such discrepancy in cell death could be due to the fact that while in Jurkat cells 
activation-induced cell death (AICD) was shown to be completely cell autonomous, 
primary T cells undergo AICD only if they can make contact with their activated 
neighbors, resulting in ‘fratricide’ rather than ‘suicide’146-148. Moreover, we observe 
no significant effect of miR-146a on IL-2, IFN-γ or IL-4 cytokine production (Figure 
5A and data not shown). 
 
- MiR-146a could have a role in regulating human T cell responses and memory 
formation possibly though the modulation of CCR7 and TRAF6. 
Interestingly, as we showed in figure 2D, we did not see any effect in 
proliferation in Jurkat cells or in T cells at early time-points after stimulation but 
human T cells expressing miR-146a showed increased expansion upon TCR 
stimulation (Figure 5B). Specifically, cell expansion was initially similar between 
miR-146a-expressing and control cells (up to ~day 3-4 after stimulation), but miR-
146a-expressing cells were able to sustain proliferation for longer times after TCR 
stimulation. This effect was especially evident in the absence of exogenous IL-2, and 
it was independent of anti-CD3 concentration (Figure 5B and data not shown). TCR 
stimulation of unsorted populations containing both transduced (GFP+) and un-
transduced (GFP–) cells, led to a steady increase of the percentage of GFP+ cells in 
miR-146a-expressing cells, but not in control cells, further indicating that this miRNA 
could act directly in response to TCR stimulation to favor cell expansion (Figure 6A). 
Ruled out the fact that cytokine production was largely unaffected by miR-146a 
expression in all the conditions tested, the possibility that miR-146a-expressing cells 
could sustain their own proliferation through increased IL-2 production. Of note, the 
IL-2 signal strength has been shown to contribute to the differentiation of CD8+ 
effector and central memory T cells in the mouse149. Along the same line, in our 
culture conditions, the absence of IL-2 evidentiated a TEM-like phenotype, with 
inability to sustain CCR7 expression and cell expansion for long time after TCR 
stimulation (Figure 6B). Interestingly, miR-146a expression determined a reduction 
of CCR7 expression in all condition tested meaning that not only miR-146a 
contributes to cell expansion upon stimulation, but it may also modulate the 
establishment of a TEM-like memory phenotype (with reduced CCR7 expression) in 
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primary human T cells (Figure 6C) as well as in naïve CD4+ T cells (Figure 6D, left 
panel). Of note, it was shown that mice with a T-cell-specific deletion of TRAF6 
mounted robust CD8 effector responses, but had a profound defect in their ability to 
generate memory cells150. Interestingly, Fas-mediated apoptosis in TRAF-KO T cells 
was normal, and cells showed increased proliferation in response to TCR 
stimulation151. Indeed, in reporter assay experiments the 3’untranslated region (UTR) 
of Traf6 was efficiently targeted by miR-146a in human naïve T cells (Figure 6D 
middle and right panel respectively) as well as in Jurkat cells and in primary murine 
Th2 cells (Figure 7). These data point towards a role for miR-146a in regulating 
human T cell responses and memory formation possibly though the modulation of a 
number of targets including TRAF6. 
 
- Human Th1 and Th2 cells express similar levels of miR-146a, meaning that it is 
probably not implicated in Th1/Th2 polarization. 
Since we originally reported that miR-146a was differentially expressed 
between Th1 and Th2 murine lymphocytes88, we evaluated a possible role for this 
miRNA in lymphocytes polarization by analyzing its expression in human T cell 
subsets. Surprisingly, human Th1 and Th2 cells expressed similar levels of this 
miRNA (Figure 8A-B), indicating that miR-146a is probably not implicated in 
Th1/Th2 polarization, which in fact appears to be normal in mice lacking miR-146a89. 
To identify new relevant miRNA candidates that may be important in human T cell 
polarization we performed miRNA arrays on highly purified T cell subsets from 
peripheral blood (Zielinski, Sallusto and Monticelli, unpublished). Confirming our 
own data, there was no significant difference in miR-146a expression in primary 
human Th1, Th2 and Th17 cells. However, this miRNA turned out to be expressed at 
very high levels in Tregs, as it has been already shown for the mouse89, suggesting a 
possible role for miR-146a in regulating Treg functions also in human.  
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Discussion 
Memory cells are characterized by the ability to quickly expand and respond 
upon secondary exposure to their cognate antigen. Two phenotypic subpopulations of 
TM cells have been identified based on the expression of different surface markers: 
TEM and TCM.  
MiR-146a is a known regulator of the immune system, with established roles 
in the regulation of both innate and adaptive immunity. Recently it has been found 
that NF-kB and c-ETS binding sites are essential for the induction of miR-146a 
transcription upon TCR stimulation in T cells83. Moreover, in a Jurkat T cell line, 
miR-146a was shown to regulate activation-induced cell death (AICD) through 
modulation of FADD expression84. In human T cells, miR-146a is expressed at low 
levels in naïve T lymphocytes while it is abundantly expressed in memory T cells88 as 
well as in Treg89 and it is induced upon TCR stimulation, consistent with its 
expression being dependent on NF-kB induction84. In Treg cells, miRNA ensures 
their suppressor function by maintaining a normal activation of transcription factors89.  
In this chapter we showed that expression of miR-146a was consistently 
elevated in the CD4 and CD8 memory compartment in both human and mouse, 
meaning that this miRNA may have a role in regulating T cell activation and/ or in the 
establishment of immunological memory compartment. Moreover we found that miR-
146a-expressing cells were able to sustain proliferation for longer times after TCR 
stimulation. This effect was especially evident in the absence of exogenous IL-2. 
While IL-2 does not significantly contribute to the initial cycling of antigen stimulated 
T cells, as signals generated through TCR stimulation are sufficient for initial 
activation, it is nevertheless necessary for the survival of activated cells and the 
successful generation of effector and memory responses152. Of note, the IL-2 signal 
strength has been shown to contribute to the differentiation of CD8+ effector and 
central memory T cells in the mouse149. Interestingly, miR-146a expression 
determined a reduction of CCR7 expression in all condition, with or without 
exogenous IL-2, meaning that miR-146a contributes to cell expansion upon 
stimulation and also modulate the establishment of a TEM-like memory phenotype in 
primary human T cells. Such effect on the human primary T cells is unlikely to be 
exerted directly on CCR7 as this molecule is not a direct target for this miRNA73, and 
it is therefore probably mediated by other miR-146a targets such as TRAF6-IRAK1 
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and STAT183/89/144. 
In summary, we showed that in human primary T cells (and possibly mouse T 
cells as well) a general role for this miRNA, independent on the T cell subset, appears 
to be the regulation of cell expansion upon TCR engagement, potentially also 
influencing the generation of the memory compartment. Although our effect was too 
modest to allow a full biochemical investigation of the targets, the importance of the 
data shown here relies on the identification of a new possible role for a miRNA in the 
establishment of human T cell memory, and on the identification of other miRNAs 
that may be relevant in human T cell polarization.  
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Figures Legends 
 
Figure 1. Memory T cells express high levels of miR-146a. A) (Left panel) 
Primary human T cells were sorted from peripheral blood as follows: naïve: CD4+ 
CD8– CD25– CD45RA+ CCR7+; TEM: CD4+ CD8– CD25– CD45RA– CCR7–; 
TCM: CD4+ CD8– CD25–CD45RA– CCR7+. Cells were lysed in Trizol immediately 
after sorting and miR-146a expression was assessed by qRT-PCR. (Right panel) 
resting primary human CD4+ cells were either immediately lysed in Trizol or were 
stimulated with plate-bound anti-CD3 and anti- CD28 for 3 and 6 days prior analysis 
of miR-146a expression by qRT-PCR. B) (Left and middle panel) C57Bl/6 mice 
were challenged sub-cutaneously with CFA-OVA. Four days after challenge effector 
cells were sorted from peripheral lymph nodes as CD4+ (or CD8+) CD62Llo CD44hi 
CD127–, while memory cells were sorted from spleen and lymph nodes two weeks 
after challenge. TEM cells were sorted as CD4+ (or CD8+) CD62Llo CD44hi CD127+, 
while TCM cells were CD4+ (or CD8+) CD62Lhi CD44hi CD127+. Naïve T cells were 
sorted as CD4+ (or CD8+) CD62Lhi CD44lo CD127–. Cells were lysed in Trizol 
immediately after sorting for RNA extraction and miR-146a levels were assessed by 
TaqMan qRT-PCR. Each bar in the graph is a pool of two mice, and the graph is 
representative of four independent experiments. (Right panel) Naïve CD8+ T cells 
were isolated from the spleen and lymph nodes of C57Bl/6 mice and were stimulated 
for 2 days with plate-bound anti-CD3 and anti-CD28 and further expanded in the 
presence of 10-100U/mL IL-2. At day 5, cells were either left resting or were 
restimulated with PMA and ionomycin for 6h prior RNA extraction and TaqMan 
analysis to assess miR-146a expression. 
 
Figure 2. MiR-146a overexpression in Jurkat T cells led to a mild 
reduction in cell death. A) Jurkat cells transduced with the lentiviral vectors 
(schematically represented on B top) were selected with puromycin prior treatment 
with 20ng/mL anti-Fas antibody for 24-48h. Cell death was assessed by annexin V 
staining. Shown is the mean of 4 independent experiments, normalized in each case to 
the level of cell death in the control cells. B) Cells as in A) were stimulated with PMA 
and ionomycin (P+I) for 24h and RNA was extracted. The control vector used 
expressed an irrelevant hairpin directed against luciferase (ctrl-shLuc). MiR-146a 
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expression was assessed by Northern blot. As a control, the same blot was hybridized 
with a probe corresponding to the mature product from the luciferase shRNA. A probe 
against an Arg-tRNA was used as loading control. Differently from primary T cells, 
unstimulated Jurkat cells expressed undetectable levels of miR-146a. C) Same as in 
A), except that the control vector used expressed a non-targeting hairpin (NT) and that 
miR-146a expression was assessed by qRT-PCR. D) Cells as in figure A) were 
stained with propidium iodide for DNA content and cell cycle analysis. 
 
Figure 3. Forced miR-146a expression does not influence Fas-mediated 
cell death or CD95 expression. A) Top: schematic of the lentiviral vectors used 
throughout this study. Bottom: Primary human T cells transduced with the indicated 
vector were sorted for GFP expression 2-5 days after transduction. Shown are cells 
obtained after sorting in one representative experiment. B) Primary human T cells 
transduced with the indicated vectors were lysed in TRIzol to determine miR-146a 
expression by qRT-PCR. Shown is one representative experiment.  
 
Figure 4: Primary human cells expressing miR-146a did not show 
alteration in Fas-mediated cell death. A) Primary human T cells of different subsets 
(mostly Th1 and Th2) were transduced with the indicated lentiviral particles and were 
either left untreated of were treated over-night with 20ng/mL of an anti-Fas antibody. 
Shown is the mean of 10 independent experiments. B) Primary human T cells were 
transduced with the indicated vectors, and CD95 expression was assessed by surface 
staining at different days after transduction. Shown is one representative experiment 
out of three. 
 
Figure 5: MiR-146a expression enhances human T cell expansion A) 
Primary human T cells transduced with either a miR-146a- or control-expressing 
vector were stimulated with PMA and ionomycin for 5h prior intracellular cytokine 
staining to assess expression of IL-2 and IFN-γ. The staining is representative of tens 
of experiments. B) Primary human T cells transduced with either a miR-146a- or 
control-expressing vector were stimulated for 48h on plate-bound anti-CD3 and anti-
CD28 in the presence or absence of 500U/mL IL-2. Cell number was assessed daily 
and plotted as fold expansion. The left panel shows one representative experiment 
while the right panel shows the mean result of four experiments (fold expansion at 
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day 6 only).  
 
Figure 6: MiR-146a expression determined a reduction of CCR7 
expression. A) Cells were treated as in figure 5A except that they were not sorted 
after transduction and were left as a mixture of GFP+ and GFP– (untransduced) 
throughout the experiment. B) Primary human T cells were either left resting or were 
stimulated with plate-bound anti-CD3 and anti-CD28 for 48h in the presence or 
absence of exogenous IL-2, after which the expression of CD45, CD25, CD62L and 
CCR7 was assessed daily. Stimulated cells were homogenously CD45RA– CD25+. 
Shown is one representative FACS-plot of resting or day 3 and day 5-stimulated cells. 
C) Primary human T cells transduced with either a miR-146a- or control-expressing 
vector were sorted and lysed in Trizol prior analysis of CCR7 mRNA expression by 
qRT-PCR. Shown is one representative experiment out of three. D) Naïve T cells 
were sorted from peripheral blood as follows: CD4+ CD8– CD25– CD45RA+ 
CCR7+ and transduced as figure 3A. After 48h from the transduction, cells were 
stimulated with plate-bound anti-CD3 and anti-CD28 for 48h in the presence or 
absence of exogenous IL-2, and after 5 days of stimulation, the expression of CCR7 
(left panel), TRAF 6 (middle panel) and miR-146a (right panel) was assessed by q-
RT –PCR. 
 
Figure 7: TRAF6 is a target of miR-146a in JKT cells and in murine Th2 
cells. Top: Jurkat cells were transduced with the lentiviral vectors. After puromycin 
selection, cells were electroporated with a Traf6-UTR luciferase reporter vector, and 
luciferase levels were assessed 36h later. Shown is the mean of three independent 
experiments. Bottom: Primary murine Th2 cells were differentiated in vitro for 5 days 
prior transfection with Amaxa. 2.5x106 cells were transfected with 1-3µg Traf6-UTR 
reporter plasmid, 0.5µg TK Renilla, 100nM double-stranded oligonucleotides (miR-
21 was used as an irrelevant miRNA control). Luciferase assay was performed 24h 
after transfection. Shown is the mean of two independent experiments, with levels of 
‘mock’ transfected cells (no double-stranded (ds) RNA) set to 100 and used as a 
reference.  
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Figure 8: Human Th1 and Th2 cells express similar levels of miR-146a. A) 
Naïve CD4+ T cells were isolated from the spleen and lymph nodes of C57Bl/6 mice 
and were differentiated in vitro to Th1 and Th2 T cell subset by stimulating them for 2 
days with plate-bound anti-CD3 and anti-CD28 in the presence of IL-12 and anti-IL-4 
antibody (Th1 conditions), or IL-4 and anti-IL-12 and anti-IFNg antibodies (Th2 
conditions). Cells were then expanded until day 5 in media containing 20U/mL IL-2. 
At day 5, cells were either left resting or were restimulated with PMA and ionomycin 
for 6h prior RNA extraction and TaqMan analysis to assess miR-146a expression 
(top) and intracellular cytokine staining to verify polarization (bottom). SnoRNA202 
was used as endogenous control. B) MiR-146a expression in human Th1 and Th2 
clones was assessed by TaqMan qRT-PCR (top). RNU48 was used as endogenous 
control. Clones were characterized by the expression of surface markers and by the 
expression of IFN-g and IL-4 (bottom). Th1 cells were CD4+ CD8– CD45RA– 
CD25– CCR5+ CRTh2–, and Th2 cells were CD4+ CD8– CD45RA– CD25– CCR5– 
CRTh2+. In some experiments, Th1 cells were also sorted as CD4+ CD8– CD45RA– 
CD25– CXCR3+ CCR6– CCR4–, and Th2 cells as CD4+ CD8– CD45RA– CD25– 
CXCR3– CCR6– CCR4+. Both of these sorting protocols gave similar results in 
terms of enrichment of specific cytokine-producing subsets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
A) 
0!
1!
2!
3!
4!
5!
6!
resting! d3! d6!
αCD3 + αCD28!
TEM! TCM!naïve !
1!
2!
3!
0!
ex-vivo!
m
iR
-1
46
a 
/ R
NU
48
 !
m
iR
-1
46
a 
/ s
no
RN
A2
02
!
0.0!
0.5!
1.0!
1.5!
2.0!
2.5! ex-vivo !
CD4+!
Naïve! TEM! TCM!
0!
2!
4!
6!
8!
10!
12!
14!
16!
Naïve! Teff! TEM! TCM!
ex-vivo !
CD8+!
m
iR
-1
46
a 
/ s
no
RN
A2
02
 !
m
iR
-1
46
a 
/ s
no
RN
A2
02
!
0!
2!
4!
6!
8!
10!
12!
14!
naive!
Day 6!
P+I!
CD8+!
Day 2!
unst.!
αCD3/αCD28!
m
iR
-1
46
a 
/ R
NU
48
 !
Figure 1: miR-146a in human and mouse T cells 
Figure 2: miR-146a overexpression in JKT cells 
and cell death 
-     P+I       -      P+I !
miR-146a!
pre-miR-146!
miR-146!
Luc!
Arg-tRNA!
ctrl-shLuc!
B) 
A) 
PuroR!
miR!
SFFVp!
0!
1!
2!
3!
4!
5!
6!
7!
8!
9!
10!
ctrl-NT! miR-146a!
m
iR
-1
46
a 
ex
pr
es
sio
n 
(to
 R
NU
48
)!
0.01!
C) 
0!
20!
40!
60!
80!
100!
120!
ctrl-NT! miR-146a!R
ela
tiv
e 
%
 o
f a
nn
ex
inV
+ 
ce
lls
!
JURKAT 
# 
Ce
lls
!
0! 200! 400! 600! 800! 1000!
0!
200!
400!
600!
800!
1000!
14.0!
23.1!
ctrl-shLuc!
0! 200! 400! 600! 800! 1000!
0!
200!
400!
600!
800!
1000!
61.8!
13.2!
23.4!
miR-146a!
FL2-Area!
61.0!
G1! S! G2!
D) 
B)!
0!
2!
4!
6!
8!
10!
12!
ctrl! miR-146a!
m
iR
-1
46
a 
/ R
NU
48
 !
10!0! 10!1! 10!2! 10!3! 10!4!
0!
200!
400!
600!
800!
1000!
98.8!
10!0! 10!1! 10!2! 10!3! 10!4!
0!
200!
400!
600!
800!
1000!
93.3!
10!0! 10!1! 10!2! 10!3! 10!4!
0!
200!
400!
600!
800!
1000!
0.02!
A) 
GFP!
miR!
EF1α!
untransd.! GFP ctrl! miR-146a!
SS
C!
GFP!
Figure 3: miR-146a overexpression in Human T 
cells 
A) 
%
 o
f M
ax
!
0! 102! 103! 104! 105!
CD95!
0!
20!
40!
60!
80!
100! neg!
ctrl!
miR-146a!
B) 
ctrl! ctrl!miR-146a! miR-146a!
untreated! anti-FAS Ab!
%
 A
nn
ex
inV
+ 
ce
lls
!
Figure 4: miR-146a and Fas-mediated cell death 
A) 
IF
N-
γ!
ctrl! miR-146a!
B) 
0!
2!
4!
6!
8!
10!
12!
14!
16!
18!
20!
3! 4! 5! 6!days!
fo
ld 
ex
pa
ns
ion
!
miR-146a! + IL-2!
no IL-2!
ctrl!
miR-146a!
ctrl!
0 10 3 10 4 10 5 
0 
10 3 
10 4
10 5
0 10 3 10 4 10 5
0 
10 3
10 4 
10 5 
1.70!
22.3!62.8!
13.2! 1.60!
25.3!58.2!
14.9!
fo
ld 
ex
pa
ns
ion
 a
t d
ay
 5
 !
ctrl miR-146a ctrl miR-146a 
+ IL-2 no IL-2 
(p<0.05)!*!
Figure 5: MiR-146a favors human T cell 
expansion 
IL-2!
CC
R7
 / 
18
S 
RN
A!
0.0!
0.2!
0.4!
0.6!
0.8!
1.0!
1.2!
1.4!
ctrl! miR-146a!
Figure 6: CCR7 expression  
B) 
C) 
CC
R7
 / 
18
S 
RN
A!
CCR7!
0 10 2 10 3 10 4 10 5 0 
20 40 
60 80 
100 resting!
+ IL-2!
no IL-2!
0 10 2 10 3 10 4 10 5 0 
20 40 
60 80 
100 
%
 o
f M
ax
!
day 3! day 5!
0!
2!
4!
6!
8!
10!
12!
14!
16!
0! 3! 5!
days!
resting!
+ IL-2!
no IL-2!
days!
%
 G
FP
+ 
ce
lls
!
miR-146a!
ctrl!
A) 
TRAF6 in naïve T cells D5
CT
R
mi
R-
14
6a
0.0
0.5
1.0
1.5
TR
A
F6
 e
xp
re
ss
io
n
re
l a
t iv
e 
to
 1
8 S
miR-146a in naïve T cells D5
CT
R
mi
R-
14
6a
0
1
2
3
4
5
m
iR
-1
46
a 
ex
pr
es
s i
o n
re
la
ti v
e  
t o
 R
N
U
 4
8
D) 
CCR7 naïve T cells D5
CT
R
mi
R-
14
6a
0.0
0.5
1.0
1.5
2.0
C
C
R
7 
ex
pr
es
si
on
re
la
tiv
e 
to
 1
8S
ctrl!
shLuc!
!
miR-146a!
ctrl!
NT!
Jurkat!
0!
20!
40!
60!
80!
100!
120!
140!
Lu
cif
er
as
e 
un
its
 (r
ela
tiv
e 
to
 R
en
illa
)!
0!
20!
40!
60!
80!
100!
no dsRNA!
ds !
miR-146!
ds !
miR-21!
Primary Th2 lymphocytes!
Figure 7: TRAF6 is a target of miR-146a in JTK 
and primary murine Th2 cells 
IL-4!
IF
N-
γ!
0!
2!
4!
6!
8!
10!
12!
Th1! Th2!
unstim!
P+I 6h!
m
iR
-1
46
a 
/ s
no
RN
A2
02
!
10!0 10!1 10!2 10!3 10!4!10!0
10!1!10!
2
10!310!
4
89.3!1.6!
0.1!
Th1!
10!0 10!1 10!2 10!3! 10!410!0
10!110!
2
10!3!10!
4
2.3! 5.0!
42.6!
Th2!
A) 
0.0!
0.5!
1.0!
1.5!
Clone !
6!
Clone !
8!
Th1!
Clone !
4!
Clone !
14!
Th2!
IL-4!
IF
N-
γ!
100! 101! 102! 103! 104!
100!
101!
102!
103!
104!
42.6! 2.8!
4.4!
Clone 6!
100! 101! 102! 103! 104!
100!
101!
102!
103!
104!
0.7! 0.4!
56.4!
Clone 4!
B) 
m
iR
-1
46
a 
/ R
NU
48
!
Figure 8: miRNA in Human T cells 
 141 
 
Chapter 4 
 
“MiR146a in  immunity and disease” 
 
 
SAGE-Hindawi Access to Research
Molecular Biology International
Volume 2011, Article ID 437301, 7 pages
doi:10.4061/2011/437301
Review Article
MiR-146a in Immunity and Disease
Nicole Rusca and Silvia Monticelli
Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
Correspondence should be addressed to Silvia Monticelli, silvia.monticelli@irb.unisi.ch
Received 17 December 2010; Accepted 17 February 2011
Academic Editor: Alessandro Desideri
Copyright © 2011 N. Rusca and S. Monticelli. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
MicroRNAs (miRNAs) are regulatory molecules able to influence all aspects of the biology of a cell. They have been associated with
diseases such as cancer, viral infections, and autoimmune diseases, and in recent years, they also emerged as important regulators
of immune responses. MiR-146a in particular is rapidly gaining importance as a modulator of differentiation and function of
cells of the innate as well as adaptive immunity. Given its importance in regulating key cellular functions, it is not surprising that
miR-146a expression was also found dysregulated in different types of tumors. In this paper, we summarize recent progress in
understanding the role of miR-146a in innate and adaptive immune responses, as well as in disease.
1. Introduction
MicroRNAs (miRNAs) represent a pervasive feature of all
cells, as they regulate large fractions of the cell’s tran-
scriptome. So far, 672 mouse miRNAs and 1048 human
miRNAs have been described in the miRBase database
(http://www.mirbase.org/, release Sept. 2010) with each
miRNA potentially regulating the expression of hundreds of
target genes, highlighting the extent of this form of regulation
[1]. Whereas some miRNAs are widely expressed, others
exhibit only limited developmental stage-, tissue-, or cell
type-specific patterns [2]. Similar to any other mammalian
cell type, cells of the immune system rely on miRNAs to
regulate lineage commitment, proliferation, migration, and
differentiation. Inmost cases, these activities are orchestrated
by both ubiquitously expressed and cell type-specific miRNA
species [3–7]. The importance of miRNAs in regulating
differentiation and function of immune cells is underlined
by the phenotypical perturbations that occur when miRNA
expression is altered. Given the emerging roles of miRNAs in
modulating immune responses, it is likely that any dysreg-
ulation of miRNA expression may contribute to the patho-
genesis of autoimmune diseases, chronic inflammation, and
malignancies. Indeed, several human diseases have now
been associated with dysregulated miRNA expression, and
miRNAs have been shown to function both as oncogenes and
tumor suppressor genes [8, 9]. MiR-146a has been recently
shown to be an important modulator of differentiation and
function of cells of innate as well as adaptive immunity.
Here, we summarize recent progress in understanding the
role of miR-146a in immune responses and in disease (see
also Table 1).
2. What Are MicroRNAs?
MiRNAs are small (20–25 nucleotides), noncoding RNA
molecules involved in posttranscriptional gene regulation.
They derive from primary transcripts (pri-miRNA) that
are processed into hairpin precursors (pre-miRNAs) within
the nucleus of the cell by the Microprocessor complex,
which includes the RNAseIII enzyme Drosha. Pre-miRNAs
are translocated into the cytoplasm and processed by Dicer
into their mature form (for a recent review see [25]). An
exception to this rule is represented by the less abundant
“mirtrons”, that bypass Drosha and are processed only by
Dicer [26]. Mature miRNAs loaded onto the RNA-induced
silencing complex (RISC) recognize sites located mostly
in the 3′ untranslated region (3′ UTR) of target mRNAs
through canonical base-pairing between the seed sequence
of the miRNA (nucleotides 2–8 at its 5′ end) and its
complementary sequence in the target mRNA. This leads to
a block in translation with or without destabilization and
degradation of the targeted mRNA. MiRNAs modulate a
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Table 1: Summary of the described roles for miR-146a in immune responses and disease, with indicated references and known targets.
Ref. Expression/Function Targets
Mouse
[5] Differential expression in Th1/Th2 cells
[10] Impaired Treg function in mice lacking miR-146a STAT1
[11] Provided protection from bacteria induced epithelial damage in neonates IRAK1
Human
[12] Attenuated TLR4 signaling in monocytes IRAK1, TRAF6
[13] Regulated activation induced cell death and IL-2 expression in Jurkat T cells FADD
[14] Contributed to the establishment of endotoxin tolerance in monocytes IRAK1, TRAF6
[15] Desensitized Langerhans cells to inappropriate TLR signaling
[16] Negatively regulated inflammatory response in lung epithelial cells
[17] Controlled megakaryopoiesis CXCR4
[18] Reduced migration and invasion capacity of breast cancer cells IRAK1, TRAF6
[19] Promoted cell proliferation in cervical cancer
[20] Tumor suppressor in hormone-refractory prostate cancer ROCK1
[21] Suppressed invasion of pancreatic cancer cells EGFR, IRAK1
[22] SNP in pre-miR-146a predisposes to papillary thyroid carcinoma
Viruses
[23] Promoted VSV replication in macrophages IRAK1, IRAK2, TRAF6
[24] EBV-encoded LMP1 induced cellular miR-146a expression
broad range of gene expression patterns during development
and homeostasis, as well as in pathogenesis of disease.
Most miRNAs are transcribed by RNA polymerase II, and
their upstream regulatory regions contain canonical core
promoters and enhancers, regulated by transcription factors.
The importance of miRNA biogenesis as a whole in the
immune system is clearly highlighted by the fact that
conditional ablation of Dicer or other miRNA processing
factors resulted in a profound block of both B- and T-cell
development [27–30]. Moreover, deletion or overexpression
of certain individual miRNAs also led to a severe impairment
of the development and/or function of cells of the immune
system [31–38]. Some miRNAs, like miR-146, are expressed
as a family that shares the same seed sequence, but is encoded
by different loci in the genome. Indeed, the miR-146a gene
is located on mouse chromosome 11, while miR-146b is
located on chromosome 19 (chromosomes 5 and 10, resp.,
in human). The mature sequences for miR-146a and miR-
146b differ by only two nucleotides. Nevertheless, since
they share the same seed sequence they should in principle
recognize the same targets [39].While in some cell types (like
monocytes) these miRNAs appear to have similar functions
[12], in other cases, like in regulatory T (Treg) cells [10],
only miR-146a, but not miR-146b, was shown to be highly
expressed. While it is still unclear if these two miRNAs
have redundant and/or separate functions, the majority of
the published work focuses mostly on miR-146a, which is
therefore the miRNA we will be mainly referring to in this
paper.
3. MiR-146a in Adaptive Immune Responses
Adaptive immune responses are vital for the efficient eradi-
cation of infectious agents, although dysregulated responses
might also lead to autoimmune and chronic inflammatory
diseases. The development and propagation of an adaptive
immune response specific for an invading pathogen is
a highly orchestrated process that involves the activation
and proliferation of immune cells and their subsequent
migration to sites of inflammation. The first indication that
miRNAs were involved in regulating differentiation of cells
in the immune system came from a study from Chen and
colleagues that identified miR-181 as a miRNA specifically
expressed in hematopoietic cells [31]. Its ectopic expression
in hematopoietic progenitors led to an increased fraction
of B-lineage cells in both in vitro differentiation assays and
mousemodels. Following this pioneering work, many studies
identified miRNAs as crucial components of the molecular
circuitry that controls differentiation and functions of cells
of the immune system.
Upon encounter with the antigen, naı¨ve CD4+ T-
cells give rise to T-cell subsets (Th1, Th2, Th17, Tregs, T
follicular helper and probably others) with functions that are
tailored to their respective roles in host defence [40]. Initial
expression profiling studies identified miRNAs specifically
expressed in different T-cell subsets and stages of differen-
tiation [5–7]. T-cell-specific deletions of Dicer revealed a
requirement for the miRNA pathway in the development
of T cells [27, 29], as well as for differentiation of effector
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T-cell subsets. Indeed, T cells lacking Dicer showed increased
differentiation to the Th1 subset with a correspondingly
reduced polarization to Th2 [29]. Adding to the complexity
of gene regulatory networks, proliferating T cells express
genes with shorter 3′ UTRs than those expressed in resting T
cells, making these mRNAs less susceptible to regulation by
miRNAs due to the loss of miRNA binding sites [41]. Finally,
individual miRNAs were also shown to play important
roles in T-cell differentiation and function. For example,
miR-181a, which is upregulated during T-cell development,
was shown to enhance T-cell receptor (TCR) signalling
strength by directly targeting a number of protein phos-
phatases [32], while mice lacking miR-155 showed an altered
Th1/Th2 polarization with a bias towards Th2, indicating
that miR-155 promotes differentiation towards Th1 cells
[35].
As for the role of miR-146a in T cells, by analyzing the
expression of miRNAs in highly purified subsets of cells of
the immune system, we showed that miR-146a is one of
the very few miRNAs differentially expressed between Th1
and Th2 cells in the mouse, suggesting that it might be
involved in fate determination of these cells [5]. Recent work
performed in miR-146a-deficient mice showed an increase
in the percentage of INFγ-producing T-cell subset in the
absence of miR-146a [10]. In human T cells, miR-146a is
expressed at low levels in naı¨ve T lymphocytes while it is
abundantly expressed in memory T cells and it is induced
upon TCR stimulation, consistent with its expression being
dependent on NF-κB induction [12, 13]. Indeed, NF-κB
and c-ETS-binding sites were shown to be required for the
induction of miR-146a transcription in human T cells, and
such induction potentially modulated cell death in these
cells by targeting FADD and by impairing both AP-1 activity
and IL-2 production [13]. Treg cells constitute a specialized
T-cell subset able to maintain immune homeostasis by
limiting the inflammatory responses, and their suppressive
function is indispensable for immune homeostasis and
survival of higher organisms. Recently, Lu and colleagues
reported that miR-146a is among the miRNAs prevalently
expressed in Treg cells and showed that it is critical for
Treg functions. Indeed, deficiency of miR-146a resulted in
increased numbers but impaired function of Treg cells and
as a consequence, breakdown of immunological tolerance
with massive lymphocyte activation, and tissue infiltration in
several organs [10]. The immune-mediated lesions induced
by the lack of miR-146a in Tregs were dependent on INFγ
and Stat1.
4. MiR-146 in Innate Immunity and
Nonimmune Systems
Cells of the innate immune system, such as granulocytes,
natural killer (NK) cells, monocytes, and macrophages,
provide an important first line of defense for the organism
against invading pathogens.MiRNAs have been implicated in
both the development and functions of innate immune cells.
For example, the macrophage inflammatory response to
infection involves the upregulation of several miRNAs, such
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Figure 1: MiR-146a negatively regulates signal transduction path-
ways leading to NF-κB activation. Upon activation of a cell surface
receptor such as TLR4, a molecular cascade including TRAF6
and IRAK1 leads to IκBα phosphorylation and degradation and
to NF-κB activation and nuclear translocation [12, 42]. NF-κB
activation induces transcription of many genes, including pri-miR-
146a. Once translocated to the cytoplasm and loaded onto the
RISC complex, mature miR-146a contributes to attenuate receptor
signaling through the downmodulation of IRAK1 and TRAF6.
as miR-155, miR-146, miR-147, miR-21, and miR-9 [12, 43–
46]. Several studies linked miR-146a expression to NF-κB
signaling within the innate immune system (Figure 1) and
were initiated by a study showing that miR-146a is quickly
induced upon activation of human monocytes [12]. In this
study, miR-146a was found to be inducible upon stimulation
with LPS in a NF-κB-dependent manner, and to target the
TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-
associated kinase 1 (IRAK1) genes. These genes encode two
key adapter molecules downstream of cytokine and Toll-
like receptors (TLR), pointing towards a role for miR-146a
in controlling signaling from these receptors through a
negative feedback regulatory loop involving downregulation
of TRAF6 and IRAK1 [12]. It was also suggested that
miR-146a contributes to the establishment of endotoxin
tolerance in monocytes and to the regulation of TNFα
production [14]. In this context, miR-146a would therefore
act as a tuning mechanism to prevent an overstimulated
inflammatory state. In human Langerhans cells (LCs), miR-
146a was found to be constitutively expressed at high levels,
as compared to interstitial dendritic cells (intDCs) [15].
In these cells, high miR-146a expression was induced by
the transcription factor PU.1 in response to TGF-β1, a key
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signal for epidermal LC differentiation, and while it did
not influence myelopoiesis or DC subset differentiation, the
authors suggested that constitutively high miR-146a expres-
sion may represent a novel mechanism to desensitize LCs
to inappropriate TLR signaling at epithelial surfaces through
decreased NF-κB signal strength downstream of the receptor
[15].
Somewhat differently from the studies mentioned above,
a study performed in human lung alveolar epithelial cells
showed a rapid, time- and concentration-dependent increase
in miR-146a upon stimulation with IL-1β [16]. Such in-
creased miR-146a expression negatively regulated the release
of the proinflammatory chemokines IL-8 and RANTES in
a way that did not seem to involve IRAK1 and TRAF6,
highlighting how the role of miRNAs can be exquisitely
cell type-specific. MiR-146a was also shown to have an
important role in normal epithelial functions: specifically,
miR-146a-mediated downregulation of IRAK1 was sufficient
to induce innate immune tolerance and provide protec-
tion from bacteria-induced epithelial damage in neonates
[11].
A molecular cascade involving miR-146a, the miR-146a
negative regulator PLZF, and the miR-146a target CXCR4
was also shown to be active during megakaryopoiesis [17].
This regulatory pathway involved enhanced expression of
PLZF, which in turn inhibited miR-146a transcription. The
resulting downmodulation of miR-146a caused an increase
in CXCR4 expression, which is necessary for megakary-
ocytes differentiation and maturation. As a result, miR-
146a overexpression, as well as PLZF or CXCR4 silencing,
impaired megakaryocytic proliferation, differentiation, and
maturation, as well as colony formation [17].
5. MiR-146a and Viruses
Various layers of negative regulators are used by immune cells
to avoid uncontrolled immune responses when facing viral
invasion, and such regulatory mechanisms can also be used
by viruses in order to escape immune surveillance. A role
for miR-146a was discovered in the regulation of vesicular
stomatitis virus (VSV) infection [23]. In macrophages, VSV
infection upregulated miR-146a expression in a RIG-I/NF-
κB-dependent manner. Elevated miR-146a expression led
to negative regulation of the production of VSV-triggered
type I IFN through downregulation of TRAF6, IRAK1, and
IRAK2, thus promoting VSV replication in macrophages
[23]. The authors proposed a model in which VSV infection
is first sensed by RIG-I, which in turn initiates type I IFN
production against VSV infection. At the same time, VSV
infection upregulates miR-146a expression, which inhibits
innate antiviral immune response by impairing RIG-I signal-
ing.
The Epstein-Barr virus (EBV) infects over 90% of the
human population worldwide. EBV infection can result in a
number of malignancies, including Burkitt’s and Hodgkin’s
lymphomas. LMP1 (latent membrane protein 1) is the major
oncoprotein of EBV, able to activate transcription factors
such as NF-κB and AP-1, and thus to manipulate host
cellular processes that regulate cell proliferation, migration,
and apoptosis. Through its ability to activate transcription
factors, LMP1 also induces expression of cellular miRNAs,
most notably miR-146a, which therefore could contribute to
cellular immortalization and tumorigenesis in the context of
EBV infection [24].
6. MiR-146 and Cancer
Cancer is the result of a complex multistep process that
involves the accumulation of sequential alterations in several
genes, including those encoding miRNAs [8, 9]. Since
miRNAs participate in keeping the balance of gene regulatory
networks that determine the fate of a cell, their dysregulation
potentially weakens this balance, thereby contributing to
oncogenesis and cancer progression. Indeed, miRNA profil-
ing has uncovered significantly altered miRNA expression in
many types of cancer [8].
Initial evidences on the possible involvement of miR-
146a in cancer came from a study showing that miR-146a was
upregulated in papillary thyroid carcinoma (PTC) samples
compared with unaffected thyroid tissue. Interestingly, a set
of five miRNAs, including miR-221, miR-222, and miR-
146, was sufficient to distinguish unequivocally between
PTC and normal thyroid [47]. Similarly to the observations
performed in immunologic settings, overexpression of miR-
146a/b in the highly metastatic human breast cancer cell
line MDA-MB-231 significantly downregulated expression
of IRAK1 and TRAF6, negatively regulating NF-κB activity
[18]. Functionally, this resulted in markedly impaired inva-
sion and migration capacity relative to control cells. These
findings implicated miR-146 not only as a negative regulator
of constitutive NF-κB activity in breast cancer cells, but
also suggested that modulating miR-146 levels might have
therapeutic potential to suppress breast cancer metastases.
Along the same line, miR-146a was among the miRNAs
found upregulated in cervical cancer tissues compared to
normal cervix [19]. When introduced into cell lines, miR-
146a promoted cell proliferation. Although the molecular
mechanism underlying such increased proliferation remains
to be investigated, these observations potentially implicate
miR-146a in cervical carcinogenesis. In another type of
cancer, the hormone-refractory prostate carcinoma (HRPC),
miR-146a levels were diminished compared to androgen-
sensitive noncancerous epithelium [20]. In this context,miR-
146a acted as a tumor suppressor, reducing levels of its
target ROCK1, one of the key kinases involved in HRPC
transformation. Accordingly, forced miR-146a expression
reduced ROCK1 protein levels, cell proliferation, invasion,
and metastasis to human bone marrow endothelial cell
monolayers. Similarly, miR-146a was lower in pancreatic
cancer cells compared with normal human pancreatic
cells [21]. Re-expression of miR146a inhibited the invasive
capacity of pancreatic cancer cells with downregulation
of EGFR (epidermal growth factor receptor) and IRAK-
1. Finally, a recent study showed that the treatment of
bone marrow-derived mesenchymal stem cells (MSCs) with
Molecular Biology International 5
diazoxide (DZ) markedly increased the expression of miR-
146a and promoted cell survival. Moreover the down-
regulation of miR-146a expression by antisense inhibitors
eliminated the DZ-induced cytoprotective effects. This result
suggested a critical role of miR-146a in MSC survival
[48].
7. Polymorphisms and Posttranscriptional
Modifications
Polymorphisms affecting miRNA expression, maturation, or
mRNA recognition may also become important determi-
nants for increased tumor risk. Indeed, a genetic variant in
the 3′ UTR of the KIT oncogene was recently described, that
resulted in a mismatch in the seed region of miR-221 and
correlated with increased risk of melanoma [49]. As for miR-
146a, a single nucleotide polymorphism (rs2910164; G/C)
was found on the passenger strand of pre-miR-146a [22]. The
rarer C allele decreased nuclear pri-miR-146a processing,
reducing levels of pre-miR-146a and mature miR-146a and
unblocking expression of its target genes, including TRAF6
and IRAK1. In an association study of PTC patients, the
germ-line GC heterozygous state was associated with an
increased risk of acquiring PTC, while both homozygous
states (GG and CC) were protective. Importantly, this
polymorphism was also found to undergo somatic mutation
in PTC tumor tissue [22], underlying the need for more
studies on polymorphisms, both on the miRNAs themselves
as well as on the binding sites in their targets as, based on
the studies mentioned above, they can clearly contribute to
cancer progression.
Along the same line, point mutations in either a miRNA
or its targets may dramatically alter miRNA expression
and/or functionality, respectively. Even in normal, nondis-
eased conditions, specific adenosine residues of certain
miRNA precursors can be edited by adenosine deaminase
acting on RNA enzymes (ADAR) [50]. The resulting A →
I conversions replace A-U Watson-Crick pairs with I : U
wobble pairs in the double-stranded RNA, altering miRNA
processing. For example, editing of pri-miR-142, expressed
in hematopoietic tissues, resulted in suppression of its
processing by Drosha and consequently in its degradation
[50]. Interestingly, interferons induce the upregulation of
ADAR1 [51], thus raising the possibility that mutations
introduced by ADAR in the pri-miRNAs might lead to
alteration of miRNA expression and/or target recognition
during inflammation [52].
8. miR-146: A Role as Biomarker?
A biomarker is a measurable indicator of a biological state,
either normal or pathological, with or without pharmacolog-
ical treatments [53]. Ideal biomarkers should be detectable
with high sensitivity and specificity, should have high
predictive power, and should be accessible in a noninvasive
manner. The data accumulated on miRNA expression in
tumors demonstrate that miRNAs are indeed promising
candidates to distinguish between different tumors and
different subtypes of tumors, as well as to predict their
clinical behavior [53]. Large miRNA expression studies have
supported the role of miRNAs as either prognostic and/or
diagnostic markers in various types of cancer (for a detailed
review see [8]). These studies generally showed that the
miRNA profiles reflected the developmental lineage and
the differentiation status of tumors, and that such miRNA
signatures enabled the tumor samples to be grouped on the
basis of their tissue of origin. Such profiling studies will
become a useful tool to identify miRNA signatures that are
associated with a particular diagnosis or probable outcome
of a disease.
As mentioned above, a good biomarker should also
be easily accessible; the ability to detect clinically relevant
miRNAs in the plasma or serum of patients raises therefore
a lot of interest, particularly since serum miRNAs appear
to exist in a stable and protected form, possibly within
exosome-like particles [53, 54]. Moreover, the levels of
miRNAs in serum were shown to be stable, reproducible,
and consistent among individuals of the same species
[55]. While more studies need to be performed on the
role that miR-146a specifically might have as a biomarker,
there is little doubt that miRNA detection in serum or
PBMCs could provide a convenient and noninvasive measure
for diagnosis and monitoring of many different types of
disease.
9. Concluding Remarks
The discovery of miRNAs has revealed a new layer of
regulation of gene expression with a profound impact on
many biological systems. Studies in recent years have shown
that miRNAs have a unique expression profile in cells of the
innate and adaptive immune system and have crucial roles
in the regulation of both cell development and function.
Moreover, it is becoming widely accepted that miRNAs can
function both as oncogenes or tumor suppressors in an
expanding number of tumors and cell types. There is now
increasing evidence to suggest that miR-146a is involved in
the regulation of the adaptive as well as innate immune
response, and that miR-146a can be an important player in
regulating tumor progression. However, more work remains
to be done to fully understand its role and mechanism
of action in normal and pathologic conditions, so that
expression of this miRNA can potentially be exploited as a
new point of entry for therapy. With the identification of a
vast number of miRNAs each carrying a long list of putative
targets, the challenge is now to understand the details of their
biological functions.
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Conclusions 
 
While it is clear that miRNAs regulate many different cellular processes, 
understanding the details of the functions of individual miRNAs remains challenging.  
A difficult aspect of dealing with miRNAs is that each miRNA has many potential targets 
with disparate functions, with no means to decide a priori which is the most meaningful and 
therefore worthy of experimental validation. Moreover, the degree of target down-regulation 
is typically less than 50%123/165 and understanding which fraction of the miRNA-target 
interaction is actually relevant for a biological response remains a challenging task. 
  
Here we found that miR-221 and miR-146a are activation-induced miRNAs 
important in regulating MCs activation and survival. Specifically miR-221 regulates basic 
cellular functions such as the actin cytoskeleton, as weel as stimulation dependent 
mechanisms, such as cytokine production and degranulation. 
 
Moreover miR_146a regulated MC survival in a cell-intrinsic manner in a regulatory 
network with NF-kB p50. 
 
Finally we showed that miR-146a had also an important role in regulating human T 
lymphocytes activation and expansion and possibly memory formation. 
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